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Cancer immunotherapy using chimeric antigen receptor (CAR) T-cells has 
shown exceptional promise in the treatment of patients with refractory B-cell 
malignancy.  In this approach, patient-derived peripheral blood T-cells are 
engineered to express a cell surface receptor, which confers specificity for a 
tumour-associated (TA) antigen. Mucin-1 (MUC1) is a large transmembrane 
glycoprotein that is overexpressed in 90% of breast cancers. A further 
important characteristic of this mucin is the fact that it is under-glycosylated in 
cancer cells. This holds the potential for CAR T-cell mediated targeting of 
MUC1 epitopes in tumour-cells which are not exposed in normal cells. 
Antibodies such as TAB004 and HMFG2 are considered to bind preferentially 
to TA-MUC1. The aim of this PhD project was the development of a CAR T-
cell approach for MUC1-positive breast cancer. Herein, the anti-tumour 
potential of a novel 2nd generation MUC1-specific CAR, named TAB28z, has 
been investigated. The binding domain of this CAR is derived from the 
TAB004 anti-MUC1 antibody. TAB28z is being compared with two other 
previously developed MUC1-specific CARs, H28z and HDF28z, both of which 
are derived from the HMFG2 antibody. TAB28z CAR T-cells demonstrated 
significant anti-tumour activity against MUC1-positive breast cancer cell lines 
in the in vitro setting. Nevertheless, it became apparent throughout this project 
that MUC1 expressed on activated T-cells is detected by both HMFG2-based 
and TAB004-based CAR T-cells during the T-cell expansion period. This 
background recognition resulted in tonic signalling by CARs, which was 
accompanied by constitutive production of IFN-γ, CAR T-cell enrichment, 
reduced T-cell expansion and a trend towards upregulation of T-cell activation 
and exhaustion markers. Despite these observations, the activity of the three 
MUC1-specific signalling CARs was investigated in two different breast 
cancer xenograft models. No significant anti-tumour responses were 
observed in either of the two models, which could possibly be attributed to the 
effects of tonic signalling. 
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1.1 Breast Cancer 
1.1.1 Epidemiology 
Breast cancer is the most common malignancy in women, with 1.77 
millions cases per year, and the second most diagnosed type of cancer 
worldwide, following lung cancer1,2. One in eight women will develop breast 
cancer during their lifetime. Additionally, breast cancer is the leading cause of 
cancer death in females in both developed and less developed countries, with 
521,900 deaths reported worldwide in 20121. Men can also develop breast 
cancer, accounting for 1% of all cases.  
 
Figure 1.1: Breast cancer incidence and mortality in UK (2014). A) Twenty most common 
cancers in both males and females. B) Twenty most common cancer types responsible for 
cancer-associated deaths. Adapted from Cancer Research UK Statistics 
(http://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality/common-
cancers-compared#heading-Zero). 
In the United Kingdom, breast cancer is the most common cancer in 
both women and men combined, accounting for the 15% of all cancer cases, 
and is the third leading cause of cancer deaths (8%) (Figure 1.1)3,4. Although 
B)A) . . 
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incidence has increased over time, mortality rates have declined substantially, 
with a 32% decrease since the early 1970s5. This is mainly attributed to the 
improvement of treatment options and to early detection5. 
1.1.2 Risk factors 
Breast cancer is strongly associated with age with 48% of cases 
occurring at age 65 and above (Figure 1.2)6.  
 
Figure 1.2: Breast cancer incidence in relation to age at diagnosis in females in UK (2014). 
Adapted from Cancer Research UK Statistics (http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-in-
situ#heading-One), accessed 20th August 2017).  
Other risks factors have been linked to the development of the disease, 
including hormonal factors, lifestyle and environmental factors and genetic 
predisposition. These are summarised in  and have been reviewed by S. 
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Singletary7. The factors mentioned in the table below affect the risk of disease 
presentation at varying levels. For example, environmental and hormonal 
factors have a moderate influence with ~1.0-2.0 relative risk7. In contrast, 
BRCA1 and BRCA2 mutation are reported to substantially increase the risk 




Table 1.1: Risk factors associated with breast cancer. 
Risk factor Risk group/comments 
Age Risk increases with age. 
Race/ethnicity9,10 
White women are at increased risk in 
comparison with women from other race groups, 
such as Hispanic and African American. 
Reproductive factors  
Age of menopause11 Increased risk if occurs after the age of 55. 
Age of menarche12 Increased risk if occurs before the age of 12. 
Pregnancy13 Nulliparous women are in higher risk. 
Age of first full-term 
pregnancy13,14 
Increased risk in women who gave birth ³30 
years of age. 
Oophorectomy12 Decreased risk in premenopausal women. 
Lifestyle and 
environmental factors  
Alcohol 
consumption15 
Increased risk related to excessive 
consumption. 
Body mass index 
(BMI)16,17 
Increased risk in postmenopausal women with 
high BMI; protective in premenopausal women. 
Radiation 
exposure18,19 
Increased risk, especially in females treated in 
younger age. Latency period for cancer 
presentation is >30 years. 





Increased risk in current or recently ceased 
users after 5 years or more of use. 
Contraceptive pill23 
Increased risk associated with medium and 
high-dose oestrogen contraceptives. 
Progesterone-based contraceptives also 
increase the risk. There are two types of 
progestin-based contraceptive pills. The 
estrane-type showed higher risk related to 
cumulative dose. By contrast, increased risk 
associated with gonane-based contraceptives 
did not correlate with dose. 
Previous presentation 
of hyperplasia24 or 
breast cancer 
Increased risk. 
Family History25 Increased risk if a first or/and second degree relative have had breast cancer. 
Genetic mutations8 
(e.g BRCA1, BRCA2) 
Increased risk. The relative risk (RR) for BRCA1 
carriers is >30 fold at age <40 years old and 14-
fild for individuals age >60. The RR for BRCA2-
mutation carriers is 11-fold at all age groups. 
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1.1.3 Histological and molecular classification 
Historically, breast cancer was considered as a single disease with 
distinct histological and morphological characteristics. Traditionally, 
classification of breast cancer types into subgroups was mainly based on the 
clinico-pathological characteristics of the disease such as histological type, 
involvement of lymph nodes, histological grade or presence of metastatic 
disease26. Predictive markers were also extensively used for the classification 
and selection of treatment, including the expression of oestrogen (ER) and 
progesterone (PR) receptors (for endocrine therapy), and HER-2 
overexpression (for treatment with trastuzumab)26.  
Most of the attempts at histological-based classification of breast 
cancer have failed due to the fact that breast cancer is comprised by areas 
with distinct morphological characteristics27. This heterogeneity in breast 
carcinomas has been well documented by the World Health Organisation 
(WHO)28. The WHO has identified at least 38 different breast cancer types 
and subtypes, including 20 types of breast cancer and 18 special types28. Of 
all documented types, invasive ductal carcinoma of no special type (IDC-NST) 
appears to be the most commonly reported type (40-75%), while invasive 
lobular carcinoma accounts for 5-15% of all cases28. 
In recent years, with the advent of high throughput technologies, there 
has been a breakthrough in the understanding of the biology of breast cancer. 
Microarray-based studies that allow gene expression analysis revealed that 
breast cancer should not be considered as a single disease with various 
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subtypes but rather as a number of different diseases that affect the same 
anatomical side29,30.  
Perou et al. published the first study that provided a molecular 
classification of breast cancer based on gene expression patterns31. The first 
key observation was that ER-positive and ER-negative breast cancers are 
highly distinct tumours based on their gene expression profiles. Moreover, 
extensive work has revealed the presence of four different molecular subtypes 
of breast cancer, named as luminal (luminal A, B and C), HER-2 positive, 
basal-like and normal breast-like (intrinsic subtype classification)31–34. This 
molecular classification is of major clinical importance as each of these 
subtypes are reported to have different prognosis, incidence and response to 
treatment32,34–38. 
 
Figure 1.3: Molecular classification of breast cancer. 85 samples were used for the gene 
expression analysis. These included 78 malignant tumours, three benign tumours and four 
normal tissues. The tumour samples were divided into five (or six) subtypes based on 
differences in gene expression. The cluster dendrogram  is showing the five (six) subtypes of 
tumours. basal-like – red; ERBB2+ – pink; normal breast-like – green; luminal subtype C - light 
blue; luminal subtype B – orange; luminal subtype A - dark blue. Adapted from Sorlie et. al 
(2001)32. 
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As depicted in Figure 1.3, the distinct molecular types of breast cancer 
are split into two major branches, the ER-low to negative branch (basal-like, 
ErbB2+, normal-like) and the ER-positive tumour types (luminal). The basal-
like category is characterised by shorter overall survival and includes triple-
negative breast cancer (ER-ve PR-ve HER-2-ve), which tends to be more 
aggressive than the other breast cancer types32,34,39,40. Additionally, this 
category includes cancers that carry a BRCA1 mutation34. The HER-2 
category is characterized by amplification of the ErbB2 gene while the normal-
like category exhibits higher expression of genes expressed in non-epithelial 
cells. The luminal category is divided into three different subtypes. The luminal 
A subtype occurs at the highest frequency (50-60%) and is characterised by 
high expression of ER and good prognosis. Subtypes B and C present 
moderate to low ER expression but once again may be distinguished based 
on their unique gene expression profiles 32.  
Gene expression technology has also been used for the development 
of prognostic signatures which help to predict the outcome of the disease in 
individual patients and to distinguish which patients could benefit from 
endocrine or cytotoxic treatment. The most well-known platforms are the 
Oncotype DX and MammaPrint and both are considered useful tools in the 
clinic40–42. Notably, a study was conducted which compared the five most 
popular prognostic platforms: Oncotype DX, MammaPrint, intrinsic subtype 
classification, wound-response model and the two-gene ratio model43. Based 
on this study, all of the platforms (with the exception of the two-gene ratio 
model) showed agreement in the outcome predictions for individual patients43.  
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1.1.4 Treatment strategies 
1.1.4.1 National Institute for Health and Care Excellence (NICE) 
recommendations 
According to the recommendations of the National Institute for Health 
and Care Excellence (NICE), the standard treatment for breast cancer differs 
for early and advanced disease44,45. In both cases, the treatment plan offered 
to each patient may include one or a combination of the following: surgery, 
chemotherapy, radiotherapy, endocrine therapy and biological therapy. 
Different combinations of these modalities of treatment may be used in the 
generation of a treatment plan for an individual breast cancer patient, 
depending on the tumour’s clinico-pathological and molecular 
characteristics44,45. 
The diagnosis of breast cancer is generally based on clinical 
assessment followed by mammography, ultrasound imaging of the axilla, core 
biopsy and/or fine needle aspiration cytology44,45. In the case where the 
ultrasound reveals abnormal lymph nodes, then an ultrasound-guided needle 
biopsy may be performed in order to stage disease44,45. The most common 
technique of ultra-guided needle biopsy is sentinel lymph node biopsy (SLNB). 
This technique is based on the fact that tumour cells spread to the lymph 
nodes through the lymphatic system46,47. The sentinel lymph node is the first 
node which is infiltrated by tumour cells46,47. To perform SLNB, a radioactive 
element and/or a blue dye are injected in the breast near the tumour. These 
travel to the sentinel node via the lymphatic vessels which allows for the 
localisation of the sentinel node48,47. Afterwards, a gamma probe is used in 
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order to detect the radioactive nodes48,49. It is noteworthy that there can be 
more than one sentinel node. Lymph nodes that are radioactive or stained 
with the blue dye are excised and analysed for tumour cell infiltration50.   
Treatment of patients usually includes surgery, which can be either 
breast conserving or mastectomy. In breast conserving surgery, a tissue 
excision with minimum 2 mm radial margin is recommended44,45. In the case 
of patients with invasive breast cancer, the excised tissues are characterised 
for ER and HER-2 status. Additionally, an axillary lymph node dissection is 
performed in patients where the sentinel lymph node biopsy has previously 
revealed the presence of infiltrating tumour cells44,45. 
Breast cancer patients often also undergo neoadjuvant (administered 
before surgery) or adjuvant cytotoxic chemotherapy (administered after 
surgery)44,45. Usually a combination of two to three different drugs are used 
for chemotherapy treatment. Following surgery, patients with early invasive 
breast cancer are offered radiotherapy to the breast44,45. Patients with high 
risk of recurrence undergo radiotherapy targeted to the chest wall. 
Additionally, patient with positive lymph nodes are being offered additional 
radiotherapy to the axilla or to supraclavicular fossa44,45. If a patient undergoes 
chemotherapy after surgery, then the radiotherapy takes place post 
chemotherapy. Additionally, patients with HER-2-positive breast cancer can 
receive biological treatment, e.g trastuzumab44,45. 
The above treatments can be used in combination with endocrine 
therapy for ER+ve and/or PR+ve tumours. The agents usually used for this 
purpose include tamoxifen and aromatase inhibitors, such as letrozole, 
anastrozole and exemestane44,45. Tamoxifen is usually given to pre-
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menopausal women while aromatase inhibitors are generally prescribed for 
post-menopausal women44,45. Tamoxifen acts as binding competitor of 
oestrogen to oestrogen receptor while aromatase inhibitors prevent the 
production of oestrogen44,45. 
1.1.4.2 Targeting DNA-repair mechanisms 
In parallel with studies related to the molecular characterization of 
breast cancer, there have been many advances in the understanding of 
signalling pathways that are involved in tumour formation. This research has 
led to the emergence of several new targeted therapies for breast cancer in 
recent years. The hallmarks of tumour development include uncontrolled cell 
proliferation, genomic instability, cell metabolic changes and induction of 
angiogenesis51. Genetic instability is responsible for the generation of random 
mutations which cause either loss or gain of gene function. One well-known 
example is the inactivation of the BRCA1 or BRCA2 genes, both of which are 
normally involved in DNA repair. Inactivation of these genes leads to the 
accumulation of mutations in breast cells52. Germ-line mutations of these 
genes are associated with inherited predisposition to breast and ovarian 
cancer53.  
The enzyme, poly [ADP-ribose] polymerase 1 (PARP1) is also involved 
in the repair of DNA-single strand breaks. Inhibitors of PARP1 (PARPi) have 
been developed as a form of targeted therapy and they function by blocking 
the DNA repair mechanism of malignant cells which eventually causes the 
apoptosis of these cells54.  PARP inhibitors appear to be particularly effective 
in patients carrying mutant BRCA1 and/or BRCA2 genes55–58. This has been 
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reported to be due to a synthetic lethal interaction54,59. Synthetic lethality, first 
described by Dobzhansky in 1946, is the phenomenon where a defect in a 
single gene does not result in significant cell damage60,61. Nevertheless, a 
defect in two distinct but complementary genes significantly increases cell 
damage60.  
1.1.4.3 Targeting tyrosine kinase receptors 
A second important example stems from the fact that uncontrolled 
proliferation of breast cancer cells may be caused by signalling of tyrosine 
kinase receptors. The most representative example is HER-2 (ErbB2) which 
belongs to the human epidermal growth factor receptor (HER) family. Patients 
with HER-2 overexpression have poorer prognosis and they respond less well 
to standard treatment62,63. Many monoclonal antibodies have been produced 
and approved by the Food and Drug Administration (FDA) for treatment of 
HER-2 positive breast cancer. Trastuzumab (Herceptin) was the first such 
agent and even though it showed significant activity, a limited duration of 
response is frequently observed due to acquired resistance to the drug64. 
These observations led to the development of other HER-2 targeted therapies 
- either single or double targeting approaches64. These include antibody drug 
conjugates and tyrosine kinase inhibitors (TKIs). 
Trastuzumab emtansine (T-DM1, Kadcylaä) is a HER-2 specific 
antibody drug conjugate which has been generated by conjugating 
trastuzumab with the DM1 cytotoxic agent65. It has been shown to have anti-
tumour activity against both trastuzumab-resistant and lapatinib-resistant 
tumour cells, both in vitro and in vivo65,66. The potential of trastuzumab 
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emtansine as a monotherapy for HER-2 amplified breast cancer was 
confirmed in a recent Phase III clinical trial67.  In that study, 991 breast cancer 
patients who have been previously treated with trastuzumab and taxane-
based drug received either T-DM1 or lapatinib plus capecitabine67. Patients 
who received T-DM1 achieved significantly prolonged progression-free 
survival (PFS), with 9.6 months median PFS versus 6.4 months in patients 
treated with lapatinib plus capecitabine67. These results led to the approval of 
Trastuzumab emtansine by the FDA for the treatment of patients with 
metastatic HER-2 positive breast cancer and who have been previously been 
treated with trastuzumab and taxane-based drug68. 
Lapatinib (Tykerb) is an orally administered small molecule inhibitor 
with dual specificity for epidermal growth factor receptor (EGFR) and HER-
269. As with other TKIs, it functions by blocking auto-phosphorylation of the 
intracellular signalling domain of tyrosine kinases, thus preventing the 
activation of downstream signalling pathways69,70. Lapatinib is the only FDA-
approved TKI for breast cancer. It was initially approved in 2007 to be used in 
combination with capecitabine (Xeloda) for the treatment of HER-2-positive 
breast cancer patients who have previously been treated with anthracycline, 
taxane, and trastuzumab-based drugs71. The approval was based on the 
results of a Phase III randomised clinical trial in which patients received 
capecitabine alone or in combination with lapatinib72. The combination of the 
two drugs resulted in a delay in disease progression, with median time-to-
progression (TTP) of 27.1 weeks versus 18.6 weeks for patients treated with 
capecitabine alone72. Additionally, lapatinib was approved by FDA in 2010 as 
combination therapy with letrozole as first-line treatment of ER-positive and 
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HER-2-positive breast cancer71. The approval of lapatinib with letrozole was 
based on results showing that the PFS of patients who received the 
combination of two drugs was 8.3 months compared to 3 months for letrozole 
alone 73.   
Monoclonal antibodies have also been produced in order to target 
vascular endothelial growth factor (VEGF), which is involved in the process of 
angiogenesis. Bevacizumab was initially proved to significantly improve the 
PFS of breast cancer patients when combined with chemotherapy74. These 
results led to the approval of bevacizumab by FDA in 2008 as a first-line 
treatment for patients with metastatic HER-2–positive breast cancer75. 
Nevertheless, additional studies did not confirm these findings76,77. For this 
reason, FDA re-considered its decision and eventually decided in 2011 to 
withdraw the recommendation of this drug for the treatment of metastatic 
breast cancer78.  
1.1.4.4 Immune checkpoint inhibitors 
Other immunotherapeutic strategies are under investigation for the 
treatment of breast cancer. These include immune checkpoint inhibitors and 
chimeric antigen receptor (CAR) T-cells.  
Different studies have shown expression of program death ligand-1 (PD-
L1) in breast cancer clinical samples, indicating the rationale for its blockade 
with checkpoint inhibitors79–83. Interestingly, higher PD-L1 expression was 
observed in triple negative cell lines (TNBC) and in tumour samples with a 
triple negative phenotype82,83. PD-L1 and PD-L2 are ligands for the PD-1 
immune checkpoint receptor, which is a negative-regulator of T-cell function. 
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The efficacy of either PD-L1 or PD-1 checkpoint inhibitors is being 
investigated in various clinical trials for patients with TNBC or hormone-
positive breast cancer84–87. One example is the KEYNOTE-012 phase 1b trial, 
in which the activity of pembrolizumab, a PD-1 inhibitor, has been 
investigated88. In this study, patients with advanced, PD-L1-positive TNBC 
received pembrolizumab as monotherapy. The results were promising, with 
an 18.5% overall response rate88. Based on the results of this study, a Phase 
II clinical trial is currently ongoing (NCT02447003)89. 
Another negative regulator of T-cell activation is the cytotoxic T-
lymphocyte–associated antigen 4 (CTLA-4). CTLA-4 is expressed on 
activated T-cells and provides a negative regulatory signal upon interaction 
with its ligands, CD80 and CD86, thus inhibiting T-cell activation. A variety of 
checkpoint inhibitors specific for CTLA-4 have been generated and some of 
these are being investigated in clinical trials for the management of breast 
cancer. In a Phase I clinical trial, 26 women with advanced breast cancer were 
treated with tremelimumab, an anti-CTLA-4 monoclonal antibody, in 
combination with hormonal therapy (exemestane)90. Although no complete 
responses were observed, 42% of the patients presented stable disease for ³ 
12 weeks90. Additionally, the combination of two distinct immune checkpoint 
inhibitors as potential treatment strategy for breast cancer is currently being 
investigated. In a single-arm Phase II clinical trial, patients with HER-2-
negative metastatic breast cancer are being treated with tremelimumab in 
combination with durvalumab (MEDI4736)91. This clinical trial is currently 
ongoing (NCT02536794)91. 
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1.1.4.5 Chimeric antigen receptor (CAR) T-cells 
Chimeric antigen receptor (CAR) T-cell immunotherapy is a strategy 
whereby T-cells are engineered to express a synthetic receptor with specificity 
for an antigen expressed on the tumour cell surface. This immunotherapeutic 
strategy in analysed in depth in section 1.1.4.5. Numerous clinical trials are 
currently on-going in patients with breast cancer and these are listed in Table 
1.292. Antigens that are being targeted with CAR T-cells in these clinical trials 
include mesothelin, carcinoembryonic antigen (CEA), receptor tyrosine 
kinase-like orphan receptor 1 (ROR1), MUC1, HER-2 and CD133. However, 
no results are available as yet in regard to their efficacy or safety in breast 
cancer patients.  
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Table 1.2: Clinical trials investigating the efficacy and safety of chimeric antigen receptor 
(CAR) T-cells in breast cancer patients. The information provided in this table has been 
acquired from http://clinicaltrials.gov (accessed 24th September 2017)92. 
Antigen 
Targeted Phase Institution Identifier 
HER-2 I/II Fuda Cancer Hospital, Guangzhou NCT02547961 
EpCAM I Sichuan University NCT02915445 
Mesothelin I Memorial Sloan Kettering Cancer Center NCT02792114 
cMET Early I University of Pennsylvania NCT03060356 
CEA I Southwest Hospital, China NCT02349724 
CD70 I/II National Cancer Institute (NCI) NCT02830724 
ROR1 I 
Fred Hutchinson Cancer 
Research Center, 














Southwest Hospital of 
Third Millitary Medical 
University 
NCT02713984 
Mesothelin I Chinese PLA General Hospital NCT02580747 
CD133 I Chinese PLA General Hospital NCT02541370 
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1.2 Mucin-1 (MUC1) as a target 
The concept of targeted cancer therapies is based in the hypothesis that 
tumour cells have a distinct antigen expression profile, when compared to 
healthy cell types. An ideal target is considered to be an antigen (or a pattern 
of antigens) that is both overexpressed and exclusively present in the tumour 
cells but not in normal tissues. In addition, an antigen could be considered as 
a good target if it is immunogenic. Nevertheless, very few antigens are known 
to have these characteristics, allowing their classification as tumour 
associated antigens (TAAs). One of these TAAs is mucin-1 (MUC1), for the 
reasons that are explained in this section. 
1.2.1 Mucins 
Epithelial cells are found in various organs and tissues, such as in the 
gastrointestinal (GI) tract, the respiratory system, the liver, pancreas and the 
eye93. The epithelial lining of these tissues requires continuous protection due 
to the critical and dynamic functions that they are involved with (e.g. gas 
exchange, digestion and absorption of nutrients, lubrication of ocular surface 
etc) 93. The contribution of mucins in this protection is vital as they cover the 
surface of epithelial cells with a mucosal gel-barrier93. Additionally, mucins 
“sense” changes in the external microenvironment and transmit this 
information to epithelial cells, leading to various cellular responses such as an 
increase in cell proliferation94. 
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Mucins are glycoproteins characterized by high molecular weight and 
a large degree of glycosylation. In total, 21 different mucins have been 
identified with distinct tissue localization patterns (MUC1-MUC21). Mucins 
share a number of common characteristics such as the presence of a large 
extracellular domain that contains tandemly repeated elements. In addition, 
these molecules are typically rich in serine and threonine residues, allowing 
them to undergo extensive O-linked glycosylation95. Mucins can be classified 
into two categories, namely: secreted (e.g. MUC2, MUC5B, MUCB5C, MUC6, 
MUC19, MUC7, MUC20) and transmembrane types (e.g. MUC1, MUC3A, 
MUC3B, MUC4, MUC12, MUC13, MUC16 MUC17, MUC22). Both types of 
mucins have a major role in the protection of epithelial surfaces. The secreted 
mucins form a physical barrier through the formation of a mucus gel while the 
transmembrane mucins contribute to this barrier through their O-glycosylated 
ectodomain94. 
Secreted mucins can be further subdivided into gel-forming (MUC2, 
MUC5B, MUCB5C, MUC6, MUC19) and non-gel forming subtypes (MUC7, 
MUC20). While in the endoplasmic reticulum (ER), gel-forming mucins 
undergo homodimerisation through the formation of inter-molecular disulphide 
bonds96. These bonds are created between the amino and/or carboxyl termini 
of monomeric mucins in cysteine-rich domains97. Mucin homodimers undergo 
O-linked glycosylation in the Golgi apparatus and they connect further to each 
other, leading to the creation of multimeric chains96,98. These multimeric 
mucins are packed into granules and are transported to the surface of the 
epithelial cells99,100. Upon exocytosis, the granules are dispersed and the 
mucus gel is formed99,100. The ability of mucins to create homodimers is 
 39 
responsible for the viscous properties of the mucus. Transmembrane mucins 
will be considered in the next section in the context of MUC1. 
1.2.2 MUC1 in healthy tissues 
1.2.2.1 MUC1: a membrane-tethered glycoprotein 
The most extensively studied transmembrane mucin is MUC1 (also 
known as episialin, PEM, EMA, ECM, DF3 antigen and H23 antigen)101.  
MUC1 is a heavily glycosylated glycoprotein with its extracellular domain 
extending up to 200-500nm from the cell surface. MUC1 has been shown to 
be expressed in epithelial cells present in a variety of organs and tissues 
including lung, pancreas, oesophagus, duodenum, colon, kidney, seminal 
vesicle, prostate, cervix and endometrium and, to a lesser extent, in 
haematopoietic cells102(Figure 1.4). 
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Figure 1.4: Protein expression of MUC1 in 44 different tissues types. The colour-coding 
scheme is based on common functional features of the tissues listed. Endocrine tissues, dark 
purple; bone marrow & immune cells, grey; lung, yellow; light purple, liver & gallbladder; 
pancreas, green; gastrointestinal track, dark blue; kidney & urinary bladder, dark orange; male 
tissues, light blue; female tissue, pink; skin, light orange. From the Human Protein Atlas 
(http://www.proteinatlas.org/ENSG00000185499-MUC1/tissue, accessed 5th September 
2017).  
1.2.2.2 Structure of MUC1 
MUC1 is normally translated as a single polypeptide which undergoes 
auto-cleavage following translation to yield two subunits: the MUC1 N-terminal 
subunit (MUC1-N) and the MUC1 C-terminal subunit (MUC1-C). The two 
subunits remain attached to each other through non-covalent bonds103. The 
MUC1-N domain contains the variable number tandem repeats (VNTR) region 
and the SEA (sperm protein, enterokinase and agrin) domain (Figure 1.5). The 
SEA domain contains the GSVVV motif in which the auto-cleavage occurs104.  
 41 
 
Figure 1.5: MUC1 structure as expressed in normal cells. The MUC1 glycoprotein is initially 
translated as a single polypeptide which then undergoes autocleavage, leading to the 
formation of an heterodimeric complex. This complex is comprised of the MUC1-N and the 
MUC1-C domains. The MUC1-N domain consists of the signal peptide, the VNTR region and 
the SEA domain. The VNTR region contains serine and threonine residues which become O-
glycosylated. Different MUC1 glycoforms exist, depending on the type of the O-glycans 
present (e.g. core-1 glycans, core-2 glycans etc). The MUC1-C domain consists of the 
extracellular domain, the transmembrane region and the cytoplasmic tail. The latter delivers 
stress signals associated with cell proliferation and growth in order to restore the epithelium, 
in case of damage. In normal epithelial cells, MUC1 is localized on the apical membrane while 
various growth factors and tyrosine kinase receptors are localized on the basolateral surface. 
Owing to genetic polymorphism, the VNTR region contains 25-125 
repeats of a 20 amino acid sequence, mainly comprised of proline, serine and 
threonine residues. Serine and threonine residues serve as a scaffold for the 
attachment of O-glycans105,106. In addition to O-glycosylation, N-glycosylation 
is also observed at five asparagine residues which are present in the MUC1 
heterodimer. Four of these residues are situated in the VNTR region and one 
in the SEA domain107. The molecular mass of MUC1 varies between 200 and 
500kDA, depending on the extent of glycosylation and the number of tandem 
repeats present95,108.  
N-glycosylation occurs in the ER post auto-cleavage of MUC1 and is 
characterised by the addition of mannose-rich glycans to asparagine residues. 
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This glycosylation reaction is accomplished by N-acetylgalactose 
aminyltransferase (GalNAcT). The MUC1 heterodimer is then transferred to 
the Golgi apparatus where the N-glycans are further processed. In parallel, 
step by step O-glycolysation occurs. During this process, galactose, fucose, 
N-acetylgalactosamine (GalNAc) and/or sialic acid are attached to the 
hydroxyl group of a serine or threonine residue. The process of O-
glycosylation will be further explained in section 1.2.3.2. An immature form of 
protein is released at the cell surface which is then re-internalised and re-
surfaces through multiple cycles. Ultimately, a mature, fully sialylated protein 
is generated and is transported to the cell membrane109. The addition of a 
sialyl-residue is the last step in O-glycosylation. 
The MUC1-C subunit consists of an extracellular domain (ECD-58 aa), 
transmembrane domain (TM-28 aa) and a cytoplasmic tail (CT-72 aa). Under 
normal conditions, MUC1 is expressed as heterodimeric molecule. In 
conditions of cellular stress or in malignancy, production of pro-inflammatory 
cytokines such as interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α), 
lead to dissociation of the MUC1-C/MUC1-N complex and release of the 
MUC1-N domain from the MUC1-C (Figure 1.6). This process, known as 
‘shedding’, is catalysed by enzymes with sheddase activity, such as tumour 
necrosis factor-α enzyme (TACE/ADAM17) and membrane-type matrix 
metalloproteases (MT-MMP)110,111. The MUC1-C domain, and in particular the 
cytoplasmic tail (CT) is responsible for promoting cell growth and survival 
signalling, enabling the repair of the epithelial layer when this is damaged. 
Further studies have demonstrated that this domain has a key role in 
tumourigenesis (reviewed by Donald W. Kufe)112–115. 
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Figure 1.6: MUC1 shedding. In malignant or stressed cells, the MUC1-N domain is cleaved 
from MUC-C and is released into the bloodstream. Consequently, serum MUC1 measurement 
may be used as a biomarker to monitor disease status in breast cancer and pancreatic cancer 
patients (e.g. the CA15.3 test – see section 1.2.4). 
1.2.2.3 Functions of MUC1 
As MUC1 belongs to the family of mucins, its function involves the 
lubrication of epithelial cells and physical protection of epithelial cells from 
pathogens. In keeping with this, it has been shown that MUC1-deficient mice 
are more prone to bacterial infections, such as conjunctivitis and bacterial 
infections of the gastrointestinal tract116,117. Furthermore, MUC1-null mice 
develop chronic inflammation and infection of the lower reproductive tract 
caused by bacteria normally present in the flora118. It has been suggested that 
bacteria attach to the glycosylated chains of mucins, hindering their ability to 
penetrate tissues. Upon bacterial infection and in cell stress conditions, 
MUC1-CT becomes phosphorylated and regulates signalling pathways 
related to cell apoptosis and proliferation119. This process will be considered 
further in section 1.2.3.3. On the other hand, overexpressed and under-
glycosylated MUC1 can drive chronic inflammation, such as inflammatory 
bowel disease (IBD), by recruiting cells of the innate immune system, such as 
dendritic cells and macrophages (see section 1.2.3 for details in MUC1 






expression seems to be mediated by the production of pro-inflammatory 
cytokines upon initial inflammation120. 
MUC1 is also characterized by anti-adhesion properties, an effect that 
is attributed to steric hindrance caused by its large extracellular domain121,122. 
In relation to this, it has been reported that downregulation of MUC1 
expression in uterine epithelial cells (UEC) is essential for embryonic 
implantation123.  
The role of MUC1 in tumourigenesis as well as its interaction with 
immune compartments is described in the section 1.2.3.3. 
1.2.3 MUC1 in cancer 
1.2.3.1 Overexpression 
MUC1 has been found to be overexpressed in 90% of breast cancers 
but also in other epithelial adenocarcinomas (e.g. ovarian, lung, pancreas, 
gastrointestinal tract) and in some haematological malignancies (e.g. multiple 
myeloma, B-cell lymphoma and acute myeloid leukaemia)124–129. The gene 
encoding for MUC1 is located in chromosome 1 (long arm-q, position 21). Its 
expression is regulated both at the transcriptional and post-transcriptional 
level. Interestingly, the long arm in chromosome 1 has been reported to be 
commonly altered in breast cancer130. In accordance with this, overexpression 
of MUC1 has been related to gene amplification, leading to an increase in both 
mRNA and protein levels131,132. Additionally, the MUC1 gene promoter 
contains binding sites for multiple transcription factors133. An example is the 
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transcriptional regulation of MUC1 by IFN-γ and TNF-α as these cytokines 
signal through nuclear factor kappa B (NF-κB) and signal transducer and 
activator of transcription (STAT) transcription factors134. 
Post-transcriptional regulation of MUC1 can also result in its 
overexpression. One well-known post-transcriptional regulatory mechanism 
of gene expression involves microRNAs (miRNAs). These molecules 
decrease RNA expression by causing mRNA degradation or by inhibiting 
translation. Expression of miR-125b has been found to be decreased in breast 
cancers135. Additionally, miR-125b has been shown to have a binding site at 
the 3’UTR of MUC1136. Consequently, it was suggested that downregulation 
of miR-125b in breast cancer might contribute to MUC1 overexpression as a 
result of dysregulated translation of MUC1136. 
Epigenetic modifications have also been associated with regulation of 
MUC1 expression. It has been reported that demethylation of CpG islands 
and demethylation and acetylation of histone 3 lysine 9 (H3-K9) in the 5′ 
flanking region of the MUC1 promoter can lead to elevated MUC1 
expression137. 
1.2.3.2 Aberrant glycosylation 
A typical characteristic of tumour-associated MUC1 (TA-MUC1) is that 
it is aberrantly glycosylated and in particular is under-glycosylated138. This 
leads to the exposure of protein epitopes that are not normally accessible in 
normal, heavily glycosylated, MUC1 molecules.  
The first step in the process of O-glycosylation is the addition of GalNAc 
to serine and threonine residues within the peptide chain by a GalNAc 
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transferase (Figure 1.7). This modification creates a classical tumour antigen 
known as the Tn antigen, which can have two fates. First, the chain may be 
further elongated through addition of galactose by core 1 β1,3-galactose 
transferase (core 1 β1,3-Gal T). This reaction generates the core 1 glycan, 
which is also referred to as the T antigen. Alternatively, chain elongation may 
be terminated by addition of sialic acid by the α6-sialyltransferase (ST6GalNAc 
I), to create the STn antigen. Similarly, the T antigen can either be sialylated 
(to give ST antigen) or glycosylated further in order to form the core 2 
elongated glycans. Addition of sialic acid to T antigen is performed by α3-
sialyltransferase (ST3Gal I). Core 2 glycans are created by adding N-acetyl 
glucosamine (GlcNAc) to core 1 glycan by core 2 β1,6-N-acetyl glucosamine 
transferase (β1,6-C2GnT I). The chain can be further elongated until a sialic 
acid is added to the last glycan.  
 47 
 
Figure 1.7: O-glycosylation. The process of O-glycosylation is initiated via the addition of the 
first monosaccharide, GalNAc, to serine and/or threonine residues of the peptide chain. The 
resulting glycan is known as Tn antigen and the addition of GalNAc is performed by the 
GalNAc trasnferases. The Tn antigen can be further glycosylated with the addition of 
galactose, a process that is mediated by the β1,3 Gal T enzyme. This reaction generates the 
T antigen. Alternatively, the elongation of Tn antigen can be terminated by the addition of 
sialic acid by the ST6GalNAC 1 sialic acid trasferase. The sialylated Tn antigen is known as 
STn antigen. In a similar manner, T antigen can be either further elongated or sialylated. In 
the case of chain elongation, GlcNAc is added to T antigen by C2GnT1 trasferase, which 
results in the formation of core 2 glycan. Alternatively, sialic acid can be added by ST3Gal1, 
thus forming the ST antigen. The core 2 glycan can be further elongation by the addtion of 
GlcNAc and Gal. GalNAc – N-acetylogalactosamine; GlcNAc – N-acetyloglucosamine; Gal – 
galactose; β1,3 Gal T – β1,3-galactose transferase; ST6GalNAc I – α6-sialyltransferase; 
ST3Gal I – α3-sialyltransferase; β1,6 C2GnT I - β1,6 N-acetyl glucosamine transferase. 
Under normal conditions, MUC1 expressed by healthy cells is mainly 
covered with extensively elongated and branched core 2 glycans. By contrast, 
malignant cells are characterized by reduction of core 2 glycans and a 
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associated with changes in the expression of a number of 
glycosyltransferases. One key change is the frequent downregulation in 
tumour cells of the core 2 transferase, β1,6 C2GnT1, which results in 
accumulation of core 1 glycans139. This is accompanied by early termination 
of chain elongation due to increased sialylation. Sialylation is mediated by 
enzymes such as ST3Gal-I, the expression of which is commonly increased in 
breast carcinomas140. It has been hypothesised that ST3Gal-I competes with 
β1,6 C2GnT1 for the same substrate (T antigen), thus resulting in increased 
expression of sialyl-T antigen by tumour cells138,141.  
In addition to the above, it has also been shown that under-glycosylated 
MUC1 demonstrates increased intracellular accumulation in comparison with 
heavily glycosylated MUC1142. It has been suggested that this increased 
accumulation is caused by enhanced clathrin-mediated endocytosis, not 
linked to increased MUC1 degradation142. 
1.2.3.3 Cell signalling and tumourigenesis 
As previously mentioned, MUC1 is normally localised on the apical 
surface of epithelial cells143. By contrast, stressed or malignant cells 
demonstrate a loss of the apical-basal epithelial polarity (Figure 1.8). As a 
result, MUC1 and a number of growth factors and tyrosine kinase receptors 
(RTKs) which are normally positioned on the basal-lateral side of the epithelial 
cells become re-distributed across the entire surface of the cell112. The 
constitutive interaction between MUC1-C and a number of RTKs leads to 
MUC1-associated continuous activation of various signalling pathways that 
are involved in cell growth, proliferation and survival102,112.  
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Figure 1.8: Distribution of MUC1 in cancer cells. In cancer or stressed cells, MUC1 is 
overexpressed and underglycosylated. In addition, a loss of cell polarity is observed that leads 
to the relocalisation of MUC1 and RTKs all over the cell surface. This results in constitutive 
interaction of the MUC1-C domain with these receptors, which in turn plays a critical role in 
cancer progression. 
One typical example is the interaction of MUC1 with the epidermal 
growth factor receptor (EGFR). The N-glycosylation of an asparagine residue 
(Asn-36) present in the extracellular domain (ED) of MUC1 transforms the 
residue into a binding site for galectin-3. Galectin-3 will then function as an 
extracellular bridge between MUC1-C and EGFR thus allowing their 
interaction144. Interaction of MUC1 with EGFR has been reported to cause 
blockade of the EGFR degradation and increase in EGFR nuclear localization, 
thus resulting in enhanced activation of the cell cycle regulator cyclin D1 and 
myb-related protein B (MYBL2)145,146.  
Additionally, it has been reported that MUC1 mediates cell proliferation 
and enhances tumourigenesis via its interaction with the platelet-derived 
growth factor-A (PDGFA)147. According to the suggested mechanism, MUC1-
CT interacts with hypoxia inducible factor-α (HIF1-α), leading to its 
translocation to the nucleus. HIF1-α then drives the expression and secretion 




invasion through the activation Ras-Raf-MEK-ERK and phosphatidylinositol-
3-kinase (PI3K) pathways respectively. In parallel, it has been shown that 
MUC1-CT interacts with β-catenin and the complex is then transported into 
the nucleus. This nuclear re-localisation appears to be dependent in part upon 
PDGFA secretion147. 
MUC1-C is further involved in the activation of the Ras-Raf-MEK-ERK 
pathway148. It has been suggested that MUC1-CT contains a YTPN site that 
becomes phosphorylated. Upon phosphorylation, growth factor receptor-
bound protein 2 (Grb2) binds to phosphorylated MUC1-CT domain. The 
complex then binds to son of sevenless (Sos) protein through the SH3 domain 
of Grb2, which result in activation of the Ras-Raf-MEK-ERK signalling 
pathway148. 
Further work has demonstrated that hypoxia drives MUC1 
overexpression which in turn promotes angiogenesis through formation of 
endothelial cell tubes149. In particular, it has been suggested that hypoxia-
induced MUC1 overexpression leads to the translocation and accumulation of 
MUC1-CT into the nucleus. Nucleus-located MUC1-CT drives the expression 
of connective tissue growth factor (CTGF) by binding to the promoter of CTGF. 
Additionally, MUC1 induces the expression of other factors which promote 
angiogenesis, such as vascular endothelial growth factor-A (VEGFA) and 
platelet-derived growth factor B (PDGFB)149. 
Another suggested mechanism by which MUC1 may contribute to 
tumourigenesis is via its interaction with the Wnt signalling pathway114. Under 
normal conditions, the phosphorylation of β-catenin is promoted by glycogen 
synthase kinase 3β (GSK3β). Phosphorylated β-catenin is then recognised by 
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the β-TrCP (β-transducin repeat containing) domain of the E3 ubiquitin ligase, 
leading to its degradation. Increased accumulation of β-catenin has been 
reported upon downregulation of GSK3β. In malignant cells, the MUC1-CT 
domain interacts directly with β-catenin114. This interaction results in the 
blockage of GSK3β-mediated phosphorylation of β-catenin and thus to the 
stabilisation of β-catenin. Accumulation of β-catenin results in the transcription 
of Wnt target genes, such as cyclin-D1, thus promoting increased cell 
proliferation and tumourigenesis114. 
In another setting, Beatson et al. have reported that tumour-associated 
(TA)-MUC1 contributes to the formation of the tumour microenvironment150.  
In this study, it has been shown that a TA-MUC1 glycoform, MUC1-ST, binds 
to myeloid cells, such as macrophages and primary monocytes through 
Siglec-9150. Binding of MUC1-ST to primary monocytes induced the 
production of several factors related to promotion of inflammation and tumour 
progression. These include angiogenesis-promoting factors such as 
plasminogen-activator inhibitor (PAI-1) and interleukin (IL)-8, inflammatory 
cytokines such as IL-6 and monocyte- and neutrophil-recruiting factors such 
as C-X-C motif chemokine ligand 5 (CXCL5), CXCL1, chemokine (C-C motif) 
ligand 2 (CCL2) and CCL3. Additionally, the interaction of MUC1-ST with 
monocytes induced their differentiation to tumour-associated macrophages 
(TAM)150. This was accompanied by increased expression of indoleamine-
pyrrole 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). Both 
molecules have been previously associated with inhibition of proliferation and 
functionality of T-cells. Binding of MUC1 to Siglec-9 induced increase in 
calcium flux and activation of the Ras-Raf-MEK-ERK signalling pathway150.  
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1.2.4 MUC1 and clinical applications 
Measurement of tumour-associated MUC1 has various clinical 
applications in diagnosis, the prediction of disease prognosis and in 
therapeutic intervention. Overexpression of MUC1 is associated with 
advanced tumours and poorer prognosis, particularly in colorectal and 
pancreatic carcinomas151,152. By contrast, in breast cancer, immune-
histological studies have revealed that increased MUC1 expression is linked 
with more differentiated cells and better prognosis. Nevertheless, aberrantly 
localised MUC1 in the cytoplasm of malignant cells or in the non-apical 
surface is associated with worse prognosis153. In addition, MUC1 expression 
can inhibit the effects of tamoxifen in breast cancer patients. This is related to 
the fact that MUC1-C interacts with the oestrogen receptor and antagonises 
the binding of tamoxifen to the receptor154. 
MUC1 is also used as a disease biomarker for both breast and 
pancreatic cancer. As already mentioned, MUC1-N subunit is shed and 
released into the circulation of cancer patients. Different biomarker tests have 
been developed which are based on the detection of carbohydrate antigens 
15-3 and 19-9 (CA 15-3, CA 19-9), both of which are glyco-epitopes of 
MUC1155,156. The CA 15-3 test was used for the detection of breast cancer 
metastasis and disease recurrences in breast cancer patients, even though it 
was not significantly successful in detecting early-stage disease155.  The 
detection of CA 19-9 antigen is mainly used for the detection and management 
of pancreatic cancer107. In a study published in 2012, it was reported that 
MUC1 is a robust biomarker for predicting overall survival in pancreatic cancer 
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patients as MUC1 overexpression is associated with worse prognosis in these 
patients157. Nevertheless, the utility of these two biomarkers is generally 
confined to the monitoring of response to treatment107. As previously 
mentioned, release of MUC1-N domain is observed not only in malignant cells 
but also in stressed cells, a fact that could result in false-positive results. 
1.2.5 MUC1-specific immunotherapy 
The concept of immunotherapy is based on the idea of specifically 
targeting tumour-associated antigens in order to elicit antigen-specific 
immune responses. MUC1 has long been considered as an attractive 
immunotherapeutic target due to its overexpression and its aberrant 
glycosylation in malignant cells, in addition to its involvement in tumour 
pathogenesis158.  
In 1989, Barnd et al. were the first to show that tumour-associated (TA) 
MUC1 is immunogenic and capable of inducing specific immune 
responses159. Importantly, they were able to isolate MUC1-specific cytotoxic 
lymphocytes (CTLs) from breast and pancreatic cancer patients159,160. It 
should be noted however that despite the presence of TA-MUC1, antigen-
specific cytotoxic T-cells (CTLs) fail to efficiently eliminate the tumour cells161.  
Different MUC1-specific immunotherapeutic strategies have been 
developed over the last three decades and have been investigated in the 
clinical setting in order to boost the cellular immune response against TA-
MUC1. These include the development of MUC1-specific therapeutic peptide 
vaccines, monoclonal antibodies and chimeric antigen receptor (CAR) T-cells.   
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1.2.5.1 Therapeutic cancer vaccines 
The mechanism of action of a cancer therapeutic vaccine is the 
generation of an antigen-specific immune response162. This includes the 
expansion of specific CTLs and the production of antigen-specific antibodies 
by B-cells162. Over the last few decades, a wide variety of MUC1 vaccines 
have been developed which have been recently reviewed by Hossain et al.163. 
The first developed MUC1 vaccines included peptide epitopes from the VNTR 
region of MUC1. These antigenic moieties were usually conjugated to a carrier 
molecule such as Keyhole Limpet Haemocyanin (KLH) or bovine serum 
albumin (BSA), and were co-delivered with adjuvants such as the attenuated 
mycobacteria, Bacille de Calmette et Guérin (BCG)163. These approaches 
aimed to increase the immunogenicity of the peptide vaccine, leading to more 
potent immune responses164,165. Another strong immunogenic carrier that has 
gained popularity is tetanus toxoid (TT)166. A number of studies have also 
shown that MUC1 vaccines conjugated with TT were able to produce strong 
immune response in mice166,167.  
Other interesting approaches have been developed in order to increase 
the efficacy of MUC1-peptide vaccines. Apostolopoulos et al.  developed a 
MUC1-vaccine coupled with mannan in oxidized conditions (M-FP vaccine)168. 
The aim of this approach was to increase the efficacy of the vaccine by 
targeting mannose receptors that are expressed in antigen-presenting cells 
(APCs), such as macrophages and dendritic cells, resulting in increased 
antigen presentation and generation of more potent immune responses169. 
The efficacy of the M-FP vaccine was evaluated in a pilot Phase III clinical trial 
(ISRCTN71711835), in which 31 breast-cancer patients with early-stage 
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disease (stage II) were treated either with the M-FP vaccine (16 patients) or 
with placebo (15 patients). Based on the results obtained from long term (10-
12 years) follow-up, the M-FP vaccine significantly decreased the disease 
recurrence rate. Specifically, only two out of 16 patients treated with M-FP 
presented recurrent disease while nine of 15 patients treated with placebo 
developed tumour recurrence170,171. However, others have further tested the 
efficacy of M-FP in clinical trials and no significant survival benefit was 
shown172. 
Another promising approach entailed the development of the L-BLP25 
vaccine (Stimuvaxâ-Tecemotide)173. This vaccine consists of a 25-amino acid 
MUC1 peptide from the VNTR region, which is encapsulated in a liposomal 
formulation173. This approach could potentially facilitate the delivery of the 
peptide to APCs and thereby enhance MHC-peptide presentation. A Phase III 
clinical trial (START trial) was conducted in order to investigate if Stimuvax 
had any benefit for patients with stage III non-small cell lung cancer (NSCLC), 
when given as a maintenance treatment post chemoradiation174. No overall 
survival benefit was reported; nevertheless, it appeared that Stimuvax had 
notable benefit in Caucasian patients treated previously with concurrent 
chemoradiotherapy. The latter was not observed in patients treated with 
sequential chemoradiation. Merck decided to discontinue the further 
development of Stimuvax after the results of the EMR 63325-009 trial failed 
to show any benefit for any of the patients’ subgroups175. This Phase I/II trial 
was conducted in Japanese patients with stage III unresectable NSCLC. The 
authors suggested that the differences in the outcome of the START and EMR 
63325-009 trials could potentially be related to the fact that the latter trial was 
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underpowered (smaller number of patients) and due to genetic differences 
between Japanese and Caucasian patients158,175. 
More recently, another MUC1 vaccine named as TG4010 has shown 
promising efficacy in various clinical trials176. These data are summarised by 
Arriole et al. in a recent review publication177. TG4010 is a recombinant viral 
vector which carries the sequences of both full-length MUC1 and of the 
immune-stimulating cytokine, IL-2. The viral vector is derived from the 
modified virus of Ankara (MVA). This vaccinia viral strain is significantly 
attenuated, but nevertheless has retained its immunogenicity. Based on 
results from these clinical trials, TG4010 in combination with chemotherapy 
seems to significantly improve the progression free survival of NSCLC 
patients. Nevertheless, a robust biomarker is being actively sought in order to 
predict the subgroup of patients that could benefit the most from this 
treatment177.  
Another notable approach has been developed by the research group 
of O. Finn. In this approach, MUC1-specific antibodies were isolated from 
healthy individuals who were treated in a prophylactic setting with a MUC1-
peptide vaccine178. The trial was the first in which a cancer vaccine specific 
for a tumour-associated antigen was administered to individuals that have not 
been diagnosed with malignancy. The vaccine proved to be highly 
immunogenic. Consequently, the authors suggest that the induced MUC1-
specific antibodies could prove beneficial in antibody-based therapy 
approaches or for the development of chimeric antigen receptors178. 
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1.2.5.2 MUC1-specific antibody-based therapy 
Monoclonal antibody-based cancer therapy has shown exceptional 
promise in recent years, as best exemplified by trastuzumab, which is used 
for the treatment of HER-2-positive breast cancer and some other tumours. 
The efficacy of antibody-based therapy relies on the ability of monoclonal 
antibodies to block the targeted protein and to recruit immune effector 
functions, such as complement- and antibody-dependent cell-mediated 
cytotoxicity (ADCC)179. Numerous MUC1-specific antibodies have been 
developed in recent decades and a few of these have been tested clinically.  
The efficacy of a fully humanized HMFG1 antibody, named as AS1402, 
was evaluated in Phase I and Phase II clinical trials. In the Phase II clinical 
trial, patients with locally advanced or metastatic breast cancer were treated 
with AS1402 alone or in combination with an aromatase inhibitor named 
letrozole180. However, the study was stopped early due to worsening of 
disease progression.  
Additionally, MUC1-specific monoclonal antibody conjugates have 
been developed. In 1993, Hird et al. developed an HMFG1 antibody 
conjugated with the Yttrium-90 (90Y) radio-isotope181. This conjugated 
antibody had the property to bind preferentially to MUC1-expressing tumour 
cells and eliminate them through the release of radiation from 90Y181. 
Promising results led to a Phase III clinical trial in 447 women with epithelial 
ovarian cancer who had previously been treated with surgery and 
chemotherapy. Patients received a single intraperitoneal dose of 90Y-
HMFG1182. However, no improvement in the overall survival or in the disease-
free survival rate was observed. Nevertheless, there were significantly lower 
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intraperitoneal recurrences in the patients treated with the 90Y-HMFG1 and 
significantly higher appearance of extraperitoneal tumours182,183.  
Another conjugated MUC1-specific monoclonal antibody is 
clivatuzumab tetraxetan, which is derived from a humanised version of the 
PAM4 monoclonal antibody184. PAM4 specifically targets pancreatic cancer 
cells by binding to TA-MUC1 and is additionally labelled with 90Y. The efficacy 
of this radiolabelled antibody was evaluated in a Phase I clinical trial in which 
untreated patients with stage III/IV pancreatic adenocarcinoma received a 
single or repeated cycles of 90Y-PAM4 in combination with low-dose 
gemcitabine. The results showed modest anti-tumour activity with 16% of 
patients achieving partial response and 44% showing stable disease184. 
Over the course of these studies, it became apparent that the 
development of an effective MUC1-specific antibody therapy was potentially 
hindered by circulating MUC1 in the serum of cancer patients, thus preventing 
effective drug delivery to tumour cells and the generation of ADCC185.  
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1.3 Cancer Immunotherapy 
1.3.1 Overview 
The immune system is a fundamental defence mechanism of the 
human body. In recent decades, there has been enormous progress in our 
understanding of the human immune system and its close inter-relationship to 
cancer. Although considerable evidence indicates that immune surveillance 
of cancer occurs, it is apparent that T-cells generally do not create immune 
responses potent enough to eliminate established tumours. Different 
mechanisms have been proposed which are responsible for this incapability. 
For example, it has been suggested that cancer cells can “hide” from immune 
cells by down-regulation of tumour-specific antigens or of MHC molecules186–
190. In addition, tumours have an increased content of immunosuppressive 
cytokines (e.g. IL-10 and transforming growth factor (TGF)-β) as well as 
increased concentration of suppressive cell populations such as regulatory T-
cells (Tregs), M2 polarised macrophages (TAM) and myeloid derived 
suppressor cells (MDSC) (reviewed by Hanahan and Weinberg191)192–195. 
Three fundamentally different immunotherapeutic approaches have 
been developed that have in common the harnessing of the immune system 
against cancer. Examples of these different strategies have already been 
mentioned in previous sections. The first category includes the administration 
of cancer vaccines that aim to boost the immune responses against an 
immunogenic tumour antigen (e.g. MUC1 vaccines). Another category 
consists of the production and use of monoclonal antibodies (mAbs) which 
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block overexpressed proteins such as ErbB dimers. A major antibody 
application involves immune checkpoint blockade (ICB). The third category 
includes various adoptive T-cell immunotherapeutic strategies that have been 
developed (see section 1.3.3). 
1.3.2 Immune checkpoint blockade 
The concept of immune checkpoint blockade is based on the idea of 
counteracting tumour-mediated inhibition of immune responses. T-cell 
activation is positively or negatively regulated by the interaction of co-
stimulatory or co-inhibitory ligands with their receptors. Co-inhibitory ligands 
are commonly expressed on tumour cells or immunosuppressive subtypes of 
dendritic cells or macrophages.  A variety of monoclonal antibodies have been 
generated which inhibit the effect of these negative regulatory signals. Most 
clinically relevant immune checkpoint inhibitors are targeted against CTLA-4 
and PD-1, which are expressed on T-cells, and PD-L1 which is expressed on 
tumour cells. Ipilimumab (Yervoy), an anti-CTLA-4 antibody has shown 
promising results in clinical trials for the treatment of patients with metastatic 
melanoma196,197. These positive results led to its approval by the FDA for the 
treatment of melanoma patients with metastatic or unresectable disease in 
2011198. In 2015, FDA approved ipilimumab for the treatment of patients post-
surgery that are in high-risk for disease recurrence199. Additionally, two anti-
PD-1 antibodies, namely pembrolizumab (Keytruda) and nivolumab (Opdivo), 
have been approved for the treatment of different advanced malignancies, 
including melanoma, head and neck squamous cell carcinoma, non-small cell 
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lung cancer, classical Hodgkin’s lymphoma, non-squamous non-small lung 
cancer and urothelial carcinoma200,201. In May 2017, pembrolizumab was also 
approved for the treatment of patients with any type of metastatic or 
unresectable solid malignancy which is characterized by microsatellite 
instability-high (MSI-H) or mismatch repair deficiency (dMMR)202. 
1.3.3 Adoptive T-cell therapy 
 Adoptive T-cell therapy (ACT) is the most recently developed 
immunotherapeutic strategy and it includes the adoptive transfer of either 
autologous or allogeneic T-cells into cancer patients. The pioneer of adoptive 
T-cell therapy is Steven Rosenberg who developed T-cell immunotherapy 
using tumour-infiltrating lymphocytes (TILs). In this approach, patient’s TIL 
cells are isolated from an excised tumour mass, expanded ex-vivo in culture 
with IL-2 and then re-injected back to the patient after conditioning with either 
chemotherapy or radiotherapy. The first promising results came in 1988 when 
60% of melanoma patients achieved tumour regression after injection of 
TILs203. Nevertheless, this approach is not applicable in many other tumour 
types as it is very difficult to detect tumour-specific T-cells or to expand TIL 
cells.  
In an attempt to broaden the tumour types in which ACT is applicable, 
other strategies were developed which became feasible with improved 
efficiency of gene transfer technology. In these derivative approaches, 
patient-derived T-cells are re-directed against tumour cells by introduction of 
genetically encoded receptors.  The redirection is achieved by expressing on 
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the T-cell surface either an antigen specific T-cell receptor (TCR) or chimeric 
antigen receptor (CAR). Conventional ab T-cell receptors recognise 
processed peptide antigen, presented in a HLA-dependent manner. By 
contrast, chimeric antigen receptors are artificial fusion molecules that 
recognise native cell surface targets in an antibody-like manner. Chimeric 
antigen receptor technology is described in further detail in section 1.3.4. 
Exemplifying the former approach, a variety of TCRs with different 
antigenic specificities have been developed and tested in numerous clinical 
trials204. The efficacy results derived from some early-phase clinical trials are 
promising. In 2015, it was reported that NY-ESO-specific TCR engineered T-
cells demonstrated promiscuous clinical responses, including 50% response 
rate in multiple myeloma patients and 91% in synovial sarcoma205. 
Despite the promising results, this approach may be complicated by 
occurrence of “on target, off tumour” toxicity. These toxicities result from the 
fact that the expression of the targeted antigen is not restricted to tumour cells 
but is also present in some normal tissues. In a trial in patients with metastatic 
melanoma, patients were treated either with engineered TCR T-cells specific 
for either the melanoma-associated antigen recognized by T cells (MART-1) 
or the glycoprotein 100 (gp100)206.  Objective tumour regressions were 
observed in 30% and 19% of patients respectively. Responses were 
accompanied by on target off tumour toxicity to skin, ears and eyes, due to 
the presence of melanocytes in these tissues206.  In another clinical trial, anti-
MAGE (melanoma associated antigen) A3/A9/A12 TCR-engineered T-cells 
were administrated to nine patients with melanoma, synovial sarcoma or 
oesophageal cancer207. Five patients achieved tumour regression. 
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Nevertheless, three of the patients developed altered mental status which 
proved fatal in two cases. These neurological toxicities were associated with 
physiological expression of MAGE A12 in the brain which was recognised by 
the TCR engineered T-cells, leading to neuronal cell destruction207. 
1.3.4 Chimeric Antigen Receptors 
In the last decade, CAR engineered T-cells have shown exceptional 
promise in the treatment of patients with refractory B-cell malignancy208–211. 
The concept of the chimeric antigen receptors was first introduced in 1989 by 
Eshhar and colleagues who created chimeric T-cell receptors212,213. These 
fusion molecules were combining the specificity of monoclonal antibodies with 
the cytolytic activity of T-cells. In this concept, they have replaced the TCR’s 
antigen binding domain by that of a mAb; thus the T-cells attacked and 
destroyed the tumour cells as a result of recognition of surface antigens in an 
MHC independent manner212,213. The fact that the CAR T-cells can recognise 
tumour-antigen in non-MHC restricted manner is an important advantage over 
TCR engineered T-cells, since the latter are MHC-restricted.  
1.3.4.1 CAR structure  
 A CAR molecule is comprised from three domains: the extracellular 
antigen-specific domain, a transmembrane element and the intracellular 
signalling domain (Figure 1.9). The extracellular domain is responsible for the 
recognition and binding to the target antigen of interest. The binder can be of 
different types; the most commonly used is a single chain variable fragment 
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(scFv) derived from an antibody. Alternatively, target binding may be achieved 
using a ligand specific for a receptor or an antigen-binding fragment (Fab). 
When compared to engineered TCR, CARs have the advantage that they 
recognize not only peptides but any type of macromolecules. Nevertheless, 
an important drawback of CARs, which is not characteristic of TCRs, is that 
they can only bind to cell surface antigens. The antigen-binding moiety is 
followed by the spacer which is connected with the transmembrane domain. 
The spacer should be flexible and of optimal length in order to allow the binder 
to reach the target of interest214. The CAR intracellular domain contains the 
signalling motifs necessary for the activation of the receptor and is connected 
with the extracellular domain via a transmembrane element. The simplest 
CAR signalling domain consists of the CD3ζ chain, adapted from the CD3 
signalling complex (normally associated with the TCR). The CD3ζ chain 
contains three immune-receptor tyrosine-based activation motifs (ITAMs) 
which are phosphorylated upon the attachment of the binder to the antigen of 
interest. The phosphorylation events are followed by the activation of more 
downstream signalling pathways which are responsible for the production of 




Figure 1.9: Adoptive CAR T-cell immunotherapy. Patient-derived T-lymphocytes are isolated 
by leukapheresis or blood sampling and are genetically engineered (for example with a 
retroviral or lentiviral vector) to express the desired cell surface chimeric antigen receptor 
(CAR). Subsequently the T-cells are expanded ex-vivo and then re-injected into the patient. 
Chimeric antigen receptors consist of three different parts: the extracellular domain, the 
transmembrane element and the endodomain. The extracellular region consists of the binding 
domain (which can be an scFv derived from a monoclonal antibody, a peptide or a receptor 
ligand) and a spacer of optimal length and flexibility (e.g. CD8, CD28). A transmembrane 
domain follows (e.g. CD28, CD4) and serves to connect the extracellular regions with the 
endodomain. The endodomain contains the CAR signalling domain. The simplest CAR 
endodomain generally contains the CD3ζ chain; nevertheless, most CARs that are being 
tested in clinical trials additionally include one or two co-stimulatory modules (e.g. CD28, 4-
1BB, OX40). 
The first in vitro experiments with CAR engineered T-cells, 
incorporating the CD3ζ signalling domain (1st generation CARs), showed that 
the CAR T-cells were able to mediate cytotoxic responses against antigen-
expressing cancer cells; nevertheless these responses were not highly 
potent215. Further studies were focused on the improvement of the signalling 
domain in order to enhance the immune responses. This was achieved by the 
addition of either one (2nd generation CAR) or two co-stimulatory motifs (3rd 
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generation CAR) in the intracellular domain, such as CD28, OX40, 4-1BB etc 
(Figure 1.10)216,217. 
 
Figure 1.10: Schematic representation of first, second and third generation CARs. First 
generation CARs have incorporated the CD3ζ signalling chain (or another module that signals 
similarly), which provides signal 1 and thus results in T-cell activation upon antigen ligation to 
the CAR’s binding domain. Second generation CARs utilise CD3ζ to provide signal 1 but they 
also have incorporated a co-stimulatory molecule upstream of CD3ζ, which provides signal 
2. Delivery of both signal 1 and signal 2 is required for optimal T-cell activation. The signalling 
domain of third generation CARs contains the CD3ζ chain and two co-stimulatory modules. 
First – 1st; second – 2nd, third – 3rd.   
1.3.4.2 CARs: from the bench to the clinic 
 As previously mentioned, CAR T-cells have shown remarkable 
responses in haematological malignancies in which CD19 proved to be a very 
attractive target. This success has been based upon the use of second 
generation CARs in which either CD28 or 4-1BB have been incorporated 
upstream of CD3z. In a historic moment, the first CAR T-cell therapy was 
recently approved by the FDA for the treatment of children and young adults 






1st generation 2nd generation 3rd generation
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Several reports illustrate the clinical efficacy of CD19-targeted CAR T-
cell immunotherapy of B-cell malignancy. In a trial conducted by Porter and 
colleagues in the University of Pennsylvania, 14 adults with refractory, 
relapsed chronic lymphocytic leukaemia (CLL) were treated with anti-CD19 
CAR T-cells (CTL019 – comprising a 4-1BB based second generation 
CAR)208. Three patients achieved a complete response (CR), 5 patients had 
a partial response (PR) while 6 had no response. The overall response rate 
was 53%208. The same group has also treated 10 CLL patients in a Phase II 
dose optimisation trial, again using the CTL019 CAR approach. The results of 
this study indicated that 2 of the patients had CR and 2 of them PR with an 
overall response rate 40%209. 
In another trial, Kochenderfer et al. used anti-CD19 CAR T-cells for the 
treatment of 15 patients with either diffuse large B-cell lymphoma (DLBCL, 
n=9), indolent lymphoma (n=2) or CLL (n=4)210. Complete remissions were 
observed in eight patients. Four patients were partial responders, one had 
stable lymphoma and, in two cases, the results were not evaluable. 
Noticeably, four of the complete responders were DLBCL patients. 
Unfortunately, acute toxicities were observed, including neurological toxicities, 
while one patient died 16 days after injection for unknown reasons. Despite 
these toxicities, this was first study that showed complete responses in DLBCL 
patients and importantly the most durable CR was still ongoing at 23 months 
after treatment210. 
Remarkable results have also been seen in a trial where 25 patients 
aged 5-22 years old and five older patients with refractory or relapsed acute 
lymphoblastic leukaemia (ALL) were treated with CTL019 CAR T-cells211. 
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Remarkably, CR were seen in 90% of patients (27/30 patients) while 
sustained remissions were observed in 15 out of 22 evaluable individuals (7 
months average follow-up)211. Additionally, it has been reported that 63 ALL 
patients were treated with CTL019, with 83.2% overall response rate218. 
These impressing results led to the approval of the first CAR T-cell therapy 
(tisagenlecleucel, marketed by Novartis as Kymriah) in the USA and its 
release to the market. The product is administered in a single dose and is 
designated for patients with refractory and/or refractory ALL. According to the 
manufacture’s dosing instructions, patients with body weight equal or less 
than 50kg will receive a single dose of 0.2-0.5x106 CAR-positive viable T-cells 
per kg while patients with body weight higher that 50kg will receive 0.1-2.5 
x106 CAR-positive viable T-cells219. Tocilizumab, a monoclonal antibody 
directed against the receptor of interleukin-6 (IL6-R), was also approved 
together with Kymriah for the management of cytokine release 
syndrome218,220. 
1.3.4.3 The challenges of CAR T-cell immunotherapy 
In contrast with these striking findings, CAR T-cell immunotherapy has 
progressed much more slowly in regard to the treatment of solid tumours. 
Nonetheless, various CAR T-cells have been engineered and tested against 
solid tumour cells in pre-clinical studies, while some of these experimental 
therapies are already in early phase clinical trials. Some examples include the 
administration of anti-mesothelin CAR T-cells in mesothelioma patients, anti-
GD2 CAR T-cells for the treatment of patients with neuroblastoma221,222 and 
ErbB-targeted CAR T-cells in patients with head and neck cancer223. 
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Nonetheless, a variety of reasons account for the slower progress of CAR T-
cell immunotherapy in patients with solid malignancies. Some of these 
challenges are considered in the section that follows. 
1.3.4.3.1 Tumour microenvironment 
One major obstacle that CAR T-cells have to overcome is the 
immunosuppressive microenvironment, which typifies solid tumours. 
Malignant cells require the support of the tumour microenvironment in order 
to proliferate, invade and metastasise. Different cell subsets are reported to 
contribute to tumourigenesis and modulate immune suppression. This include 
tumour-associated macrophages (TAM), cancer-associated fibroblasts 
(CAF), myeloid-derived suppressor cells (MDSC), tumour-associated 
neutrophils (TAN) and Tregs193,224–227. For example, M2 polarised 
macrophages secrete immunosuppressive cytokines, such as IL-10 and TGF-
β which supress T-cell function228,229. Additionally, they produce cytokines, 
such as CCL20 and CCL22, that recruit Tregs230,231. Another mechanism by 
which TAMs suppress T-cell function is by the depletion of L-arginine, which 
results in downregulation of the CD3ζ chain in T-lymphocytes232.  
Different strategies have been designed which are focused on 
remodelling or re-educating the tumour microenvironment. Illustrating this, IL-
12 secreting CARs have been engineered and are being investigated by 
multiple researchers. For example, Pegram et al. have constructed a CD19-
specific CAR which constitutively secretes this cytokine and enabled the CAR 
T-cells to eradicate tumour in mice, even in the absence of chemotherapy 
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preconditioning233. Moreover, Yeku O. et al. reported that IL-12 “armoured 
CAR T-cells” can alter the tumour microenvironment and deplete tumour-
associated macrophages234. Another strategy for overcoming the tumour 
immunosuppressive microenvironment is through combinatorial treatment of 
CAR T-cells with checkpoint inhibitors. Blocking of the inhibitory receptor PD-
1 and its interaction with its ligand PD-L1 has emerged as a promising 
immunotherapeutic approach. John et al. were the first to show that 
combination of a HER-2 specific CAR treatment together a PD-1 blocking 
antibody significantly enhanced anti-tumour response in HER-2 transgenic 
mice235. In agreement with this study, a case report was recently published in 
which a patient with refractory DLBCL was treated with pembrolizumab, a PD-
1 inhibitor, administered following treatment with CD19 CAR T-cells236. The 
authors have suggested that, although the patient did not initially respond to 
CAR T-cell treatment, enhanced proliferation of CD19 CAR T-cells was 
observed post treatment with pembrolizumab. This suggests a possible 
enhancement of CAR T-cell response due to PD-1 inhibition236. In another 
novel approach, CRISPR/Cas9 technology was used in order to knock out 
PD-1 in T-cells engineered with CAR molecules237. In the same study, the 
TCR gene was also disrupted simultaneously with PD-1 in order to produce 
“universal” allogeneic CAR T-cells237. 
1.3.4.3.2 Potency, persistence and proliferation 
Second and third generation CARs have demonstrated significantly 
improved potency when compared to first generation CARs. The most 
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extensively used CARs have incorporated the CD3ζ signalling domain and 
endodomain sequences derived from either the CD28 or 4-1BB co-stimulatory 
molecule. These two distinct signalling domains have been reported to 
enhance efficacy and persistence of CAR T-cells. Notably however, CARs 
incorporating CD28 present a potent response characterized by shorter CAR 
T-cell persistence while CAR T-cells with 4-1BB show enhanced persistence 
in patients238. Kawalekar et al. have reported that the two distinct co-
stimulatory molecules can affect significantly the differentiation status and 
metabolic profile of the T-cell populations239. CD28 CAR T-cells promoted the 
growth of effector memory T-cells with enhanced glycolysis. In contrast, 4-
1BB CAR T-cells present central memory phenotype and increased fatty acid 
oxidation239.  
Another way of improving CAR T-cell potency, proliferation and 
persistence is by ameliorating the effects of T-cell exhaustion due to tonic 
signalling. In a novel approach, Eyquem et al. have engineered CAR T-cells 
in which the CAR is not randomly integrated into the T-cell genome240. In 
contrast, the gene encoding for this receptor was specifically integrated into 
the T-cell receptor α constant (TRAC) locus using CRISPR/Cas9 technology, 
rendering its expression subject to tight regulation by endogenous 
transcription factors. This new CAR design resulted in superior CAR T-cell 
activity when compared to a CD19-28z conventional CAR, with enhanced 
anti-tumour activity and reduced T-cell exhaustion240. In another study, Long 
et al. replaced the CD28 co-stimulatory molecule of constitutive activated 
(tonic signalling) CAR T-cells with 4-1BB.  The incorporation of 4-1BB reduced 
T-cell exhaustion241. 
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In another approach, IL-17 receptor was constitutively co-expressed 
with CAR T-cells242. The aim of this study was to provide signal 3 in CAR T-
cells in order to improve their efficacy and persistence upon targeting solid 
tumours. The researchers suggest that co-expression of IL-17R can result in 
CAR T-cell stimulation without the need of exogenous addition of cytokines242. 
1.3.4.3.3 Trafficking 
Trafficking of CAR T-cells to the site of tumours is a major challenge 
for targeting solid malignancies. Different reasons might be responsible for 
poor T-cell trafficking. These include the inability of T-cells to penetrate the 
tumour due to fibrotic phenotype and downregulation of chemo-attractive 
cytokines238. To overcome this, various groups have co-expressed a 
chemokine receptor in CAR T-cells that binds a cognate chemokine secreted 
by the tumour cells243–245.  For example, K. Moon and colleagues have co-
expressed a mesothelin-targeting CAR together with the CCR2 chemokine 
receptor244. The latter is specific for the C-C motif chemokine ligand 2 (CCL2). 
The co-expression of CCR2 resulted in increased T-cell infiltration within the 
tumour and improved therapeutic efficacy in mice with established 
mesothelioma tumours244. 
1.3.4.3.4 On-target off-tumour toxicities 
One of the major obstacles to effective CAR T-cell immunotherapy is 
the lack of tumour specificity of the targeted antigen. It is highly desirable in 
this regard to target an antigen that allows discrimination between malignant 
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and normal cells. Expression of the cognate antigen in healthy tissues poses 
risk for significant toxicities due to “off-tumour” engagement of normal cells.  
A number of factors have contributed to the success of CD19-targeted 
CAR T-cell immunotherapy for the treatment of B-cell malignancies. The 
CD19 glycoprotein is a hallmark of B-cells, and is also found on virtually all B-
cell derived malignancies246,247. Its expression is minimal in cell types other 
than those of the B-lineage, a factor that makes it an ideal target for 
immunotherapy. It is now known that patients treated with anti-CD19 CAR T-
cells commonly develop B-cell aplasia, since normal B-cells are also 
eliminated together with the malignant cells248–250. However, B-cell aplasia is 
considered a manageable on target off tumour toxicity as patients can be 
treated with intravenous or subcutaneous immunoglobulin replacement 
therapy (IVIg/ SCIg)208,251.  
Targeting solid tumours with CAR-engineered T-cells has proven 
challenging for various reasons. Severe cases of off-tumour toxicities have 
forced researchers to be extremely cautious in their choice of targeted antigen 
and in the design of clinical trials. 
The efficacy of autologous T-cells modified to express an anti-CAIX 
CAR has been investigated in two different Phase I clinical trials for the 
treatment of patients with metastatic renal cell carcinoma252,253. Severe liver 
toxicity was observed in both clinical studies. Liver biopsies revealed 
expression of the CAIX antigen on bile duct epithelium, which resulted in CAR 
T-cell infiltration to these tissues252,253. 
A variety of solid malignancies - including breast, ovarian and colon 
cancer – exhibit overexpression of the receptor tyrosine-kinase protein ErbB2 
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(HER-2), which makes the latter an attractive immunotherapeutic target254. 
HER-2 is also found on normal epithelial cells such as in the gastrointestinal 
and respiratory tracts255. A HER-2-specific third generation CAR was 
developed which contained an scFv domain based on trastuzumab, a widely 
used anti-HER-2 monoclonal antibody217. The efficacy and safety of this CAR 
was investigated in a Phase I/II clinical trial of patients with metastatic cancer 
(NCT00924287). This study was terminated after treatment of the first patient 
who received 1x1010 anti-HER-2 CAR T-cells, administered intravenously 
over approximately 30 minutes. Unfortunately, she died within days of 
receiving CAR T-cell immunotherapy due to respiratory and multi-organ 
failure256. The authors speculated that the death of the patient resulted from 
the recognition of HER-2-positive lung cells (either parenchymal or 
endothelial) by the anti-HER-2 targeted CAR T-cells. This recognition caused 
the release of pro-inflammatory cytokines, leading to severe pulmonary 
toxicity and oedema256. Others have subsequently investigated the efficacy 
and safety of HER-2-directed CAR T-cells in clinical trials and have not 
reported any significant toxicities (NCT00902044)257. Differences in the scFv 
domain or endodomain of the CARs, injected CAR T-cell dose and pre-
conditioning of the patients might be responsible for the different results 
obtained in these trials217,256–258.  
Carcinoembryonic antigen (CEA) is a large glycoprotein that is 
overexpressed in colorectal carcinoma and in other epithelial cancers. It is 
also expressed in normal epithelial cells throughout the gastrointestinal tract, 
such as in the intestinal epithelium259. In a distinct but related 
immunotherapeutic approach, T-cells have been engineered to express an 
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anti-CEA TCR260. The efficacy and safety of the engineered T-cells was tested 
in three patients with metastatic colorectal cancer261. Notably, all three 
patients developed severe inflammatory colitis, due to destruction of normal 
colon epithelial cells by the CEA-targeted T-cells. This was considered to be 
a dose-limiting toxicity which resulted in the termination of the clinical trial 
(NCT00923806). 
A potential target for the treatment of multiple myeloma with CAR-
engineered T-cells is the B-cell maturation antigen (BCMA). Similarly to CD19, 
the expression profile of BCMA is also lineage restricted in the sense that it is 
only found in plasma cells, both malignant and non-malignant262. Results 
published from an ongoing Phase I clinical trial showed that, as expected, 
multiple myeloma patients treated with anti-BCMA CAR T-cells also 
developed loss of normal plasma cells (NCT02215967)263. The authors 
suggested that, in some cases, this toxicity could also be manageable with 
immunoglobulin replacement therapy263.  
CD33 and CD123 are two targets that are over-expressed in myeloid 
malignancies. Consequently, CAR T-cells directed against these targets have 
been developed and are currently under investigation in clinical trials 
(NCT01864902, NCT02623582)264–266. Nevertheless, both antigens raise 
safety concerns as they are also expressed in normal haematopoietic cells 
and other healthy tissues. No evidence of on-target off-tumour toxicity due to 
treatment with autologous anti-CD33 or anti-CD123 CAR T-cells has been 
reported as yet in these studies267. The efficacy of allogeneic CD123-specific 
CAR T-cell immunotherapy is also being investigated in two other clinical trials 
for the treatment of patients with either AML or blastic plasmacytoid dendritic 
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cell neoplasm (BPDCN)268. These two trials were placed on hold by the FDA 
in September 2017 after the death of one BPDCN patient and the presentation 
of severe adverse events in a second AML patient post CAR T-cell treatment. 
These severe adverse events were reported to be related with CRS268. 
New strategies have been developed in order to improve tumour-
specific antigen discrimination. Wilkie et al. were the first to co-express two 
CARs with different antigen specificity in primary human T-cells269. In this 
approach, one CAR incorporated a CD3ζ endodomain and the second 
receptor contained a co-stimulatory module. By this means, a complete T-cell 
activating signal is only delivered when both antigens are recognised269–271.  
In a similar way, a novel CAR T-cell circuit was designed where the 
presence of both antigens was required for CAR signalling. In this approach, 
a synthetic Notch (synNotch) receptor specific for antigen A is co-expressed 
with a CAR specific for antigen B272. Transcriptional activation of the CAR 
gene is allowed only upon recognition of antigen A by the Notch receptor. 
Thus, the tumour cells are eliminated only in the presence of both antigen A 
and B272. These synNotch receptors can be used for other purposes as they 
can be modified to activate the transcription of any desirable element upon 
antigen recognition273,274. For example, they can allow secretion of different 
cytokines, alter T-cell differentiation or deliver therapeutic agents such as 
monoclonal antibodies273,274. 
An additional way of regulating off-tumour toxicities is by co-expressing 
an inhibitory CAR receptor (iCAR), together with a signalling CAR, in order to 
restrain CAR T-cell activity upon antigen engagement. In this approach, the 
inhibitory CAR is specific for an antigen expressed in healthy tissues while the 
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signalling CAR has specificity for an antigen expressed on malignant cells. 
Thus, the signalling CAR is allowed to signal and eliminate the tumour cells 
only in the absence of the normal tissue-associated antigen. To achieve this, 
Fedorov et al. have designed two distinct iCARs which have incorporated 
either the PD-1 or CTLA-4 inhibitory domain275. 
1.3.4.3.5 Other safety concerns and control mechanisms 
In addition to “on-target off-tumour toxicities”, patients treated with CAR 
T-cell immunotherapy can present other severe adverse events such as 
cytokine release syndrome (CRS) and neurotoxicity. Cytokine release 
syndrome is characterized by elevated production of inflammatory cytokines, 
such as IL-6, IL-2, IL-10 and IFN-γ, due to uncontrolled in vivo CAR T-cell 
activation. Cytokine release syndrome can range in severity from mild to life 
threating and includes a range of features including fever, and major organ 
failure (e.g. cardiac dysfunction and respiratory failure). 
Treatment of CRS is focussed on ameliorating these features without 
affecting the efficacy of CAR T-cells. Therapies directed against IL-2 and IFN-
γ would probably affect the efficacy of CAR T-cell therapy. For this reason, 
Fitzgerald et al. selected tocilizumab for treatment of ALL paediatric patients 
with CRS post CD19 CAR T-cell infusion276. As previously mentioned, 
tocilizumab inhibits IL-6R, which blocks the interaction of IL-6 with its receptor. 
According to the authors of the study, blocking IL-6 interaction with IL-6R does 
not seem to influence the anti-tumour efficacy of CAR T-cells while it 
significantly improved clinical features of CRS276. 
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Neurotoxicity has also been described in patients treated with CAR T-
cells277,278. Patients with neurotoxicity present symptoms such as confusion, 
aphasia and seizures. In some cases, this toxicity can be lethal as five patients 
treated with CD19-specific CAR T-cells have died due to cerebral oedema279. 
The cause of this toxicity is not yet clearly understood. Nevertheless, there 
have been some suggestions that the neurotoxicity observed in patients 
treated with CAR T-cells might be caused due to intracerebral CRS or due to 
direct off-tumour toxicity277,278. 
In order to increase safety of CAR T-cell immunotherapy, different 
control mechanisms have been designed which allow regulation of CAR T-cell 
activity. These include suicide and elimination systems and drug-inducible 
CARs. Di Stasi et al. and Zhou et al. validated the efficacy of an inducible 
caspase 9 (iCasp9) suicide switch in patients who developed toxicity (eg graft 
versus host disease) following haploidentical stem-cell transplantation280,281. 
In this system, the pro-apoptotic protein caspase 9 undergoes dimerisation 
and is thus activated only upon administration of a small-molecule drug. In 
another approach, a drug-inducible CAR was designed282. The structure of 
this ON-switch CAR receptor is split into two separate polypeptides: the first 
consists of the scFv, the co-stimulatory molecules and one drug-inducible 
dimerisation domain, while the other polypeptide consists of the CD3ζ 
signalling domain of the CAR molecule and the second dimerisation motif. 
Upon addition of the drug, the two domains form heterodimers which allow the 
CAR to signal. The activity of the CAR can be tuned depending on the 
concentration of the administered drug282.  
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In summary, the ability to reprogram T-cells to target tumour cells has 
revolutionised the way cancer patients are treated. The success of treating 
haematological malignancies with CAR T-cells is evident. Nevertheless, 
through clinical experience, some of the challenges of CAR T-cell 
immunotherapy have been revealed, especially for targeting solid tumours.   
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1.4 Overview of this PhD Project 
1.4.1 Rationale 
Breast cancer has the highest rate of cancer incidence in females 
worldwide. Despite many advances in treatment strategies and improvement 
in survival rates, breast cancer is still ranked as the 2nd most common cause 
of cancer death in women.  
The field of immunotherapy has shown remarkable progress in the last 
decades and was characterized by the journal Science in 2013 as the 
“Breakthrough of the year”. A very promising immunotherapeutic strategy 
entails adoptive T-cell therapy where T-cells are isolated from cancer patients, 
expanded ex-vivo and re-infused back to the patients. Based on this, the 
concept of CAR T-cell therapy was developed where T-cells are engineered 
to target antigen expressed on the cell surface of tumour cells. Engineered 
CAR T-cells have shown exceptional results in clinical trials for the treatment 
of patients with refractory leukaemia. One important drawback of this 
approach is the “on-target off-tumour toxicity” observed in many patients 
owing to engagement of target in normal tissues. Such toxic events have 
already caused the death of some patients, mandating the development of 
safer CAR T-cells approaches. 
MUC1 is a large glycoprotein that is expressed in 90% of breast cancer 
patients, even in the individuals with triple negative breast cancer, a subtype 
with poorer outcome. MUC1 is considered as a very promising target for three 
reasons. First, MUC1 is transcriptionally upregulated in several tumour types, 
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including breast cancer. Second, MUC1 has the valuable characteristic of 
being aberrantly glycosylated in tumour cells in comparison with normal cells. 
This aberrant glycosylation exposes epitopes that are not seen in the normal 
tissues and is responsible for the immunogenic properties of the tumour-
associated MUC1 (TA-MUC1). This has been exploited by the generation of 
antibodies, such as HMFG2 and TAB004, which are able to detect TA-MUC1. 
Third, MUC1 is normally expressed in a polarised manner on the luminal (e.g. 
inaccessible) surface of epithelial cells, but this polarity is lost in cancer cells, 
making the target accessible to immunotherapies such as CAR-engineered T-
cells. A pilot project conducted by the National Cancer Institute (NCI) has 
ranked MUC1 as the second most attractive antigenic target for the 
development of immunotherapeutic approaches283. 
Based on the above, MUC1 seems to be a propitious target antigen for 
the development of CAR T-cell therapies, with less risk for the development 
of on-target off-tumour toxicity. Despite its unique characteristics, no 
significant advances have been made towards this direction. A reason for this 
might be the fact that MUC1 has a very large extracellular domain (200-
500nm), which makes its targeting very challenging.  
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1.4.2 Aim of the PhD project 
The aim of this PhD project was to develop a safe and effective MUC1-
based CAR T-cell approach. In this approach, the anti-tumour capacity of a 
newly-developed MUC1 CAR named TAB28z has been evaluated in both the 
in vitro and in vivo setting. As previously mentioned, this CAR (named 
TAB28z) contains an scFv domain derived from TAB004 antibody (Figure 
1.11). TAB004 has been generated by Curry et al. and has been shown to 
recognize TA-MUC1 on pancreatic cancer tumour cells284. TAB28z CAR is a 
second generation CAR which signals via CD3ζ and CD28. Throughout this 
project, TAB28z was compared with two other 2nd generation MUC1 CARs, 
namely H28z and HDF28z which have been previously developed in the lab 
by Wilkie et al.. Thus, I sought to investigate whether this newly developed 
MUC1 CAR demonstrates superior activity when compared to these two 
previously generated MUC1 CARs.  
H28z and HDF28z CAR T-cells similarly signal via CD3ζ and CD28 
(Figure 1.11). Both contain a scFv derived from another MUC1 antibody with 
specificity for TA-MUC1, named as HMFG2. The HDF28z CAR has 
incorporated a longer hinge (IgD), which provides enhanced flexibility and 
reach to the binding domain of the CAR. Throughout the project, I used three 
non-signalling (truncated) CARs as controls, which match each of the three 
signalling CARs (Figure 1.11). The six CAR constructs will be further 




Figure 1.11: MUC1-specific CARs. Three signalling and three non-signalling CARs have been 
used throughout this project. All six CAR constructs have specificity for MUC1. TAB28z, H28z 
and HDF28z are second-generation CARs which signal via CD3ζ and CD28. TAB28z has a 
scFv derived from the TAB004 MUC1-specific antibody while H28z and HDF28z contain a 
scFv derived from the HMFG2 antibody. HDF28z has incorporated an IgG and IgD hinge, 
which provides length and flexibility to the binding domain of the CAR. Three non-signalling 
CARs, named as TABTr, HTr and HDFTr are additionally used throughtout this project as 
negative controls. Each of these match the relevant signalling CAR. 
Of note, both HMFG2 and TAB004 antibodies bind to the VNTR region 
of MUC195,284. Specifically, TAB004 has been reported to recognise the 
peptide epitope in position aa 950-958 while HMFG2 binds to a peptide 
sequence which is repeated in the MUC1 VNTR (UniProtKB #P15941) (Table 
1.3) 95,284.  
Table 1.3: Epitope binding sequence of TAB004 and HMFG2 anti-MUC1 antibodies. 
Antibody Epitope binding sequence Position- Amino acids (aa) 
TAB004 STAPPVHNV 950-958 
HFMG2 PDTRPAPGSTAPPAHGVTSAPDTR Repeated sequence 
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The TAB004 antibody has been generated by immunising Balb/c mice 
with MUC1-positive pancreatic tumours, previously generated i MUC1 
transgenic mice. TAB004 has been reported to detect MUC1 in tumours 
isolated from stage 2-4 pancreatic cancer284. Additionally, TAB004 could bind 
to MUC1 in cancer stem cells (CSCs) isolated from pancreatic cancer 
patients284. Furthermore, the specificity of TAB004 was investigated in a 
breast cancer mouse model, where it showed detection of early and 
metastatic breast cancer285. Currently, TAB004 antibody is being 
commercially developed by OncoTAb Inc., a start-up company established by 
Professor Pinku Mukherjee286. The company has generated their first 
commercially-available product, named as AgkuraTM Personal score. 
AgkuraTM is a non-invasive blood test which is being offered for breast cancer 
detection, in supplementation to mammogram, for women with dense breast 
tissue. Its technology is based on detecting circulating MUC1 with the use of 
TAB004 antibody286. 
The HMFG2 antibody was produced by immunising Balb/c mice with 
delipidated human milk fat globule (HMFG) followed by milk epithelial cells287. 
HMFG protein is found to be expressed in the lactating mammary gland and 
in primary and metastatic breast cancer tumours. Burchell et al. have shown 
that HMFG2 detects MUC1 in serum of breast cancer patients288. It has also 
been shown to detect malignant epithelial cells in pleural and peritoneal 
effusions from patients with other epithelial-based malignancies, such as 
ovarian, prostate, pancreatic, lung and colon cancer289,290. Additionally, 
HMFG2-radiolabelled antibody (123I) has been used in patients to localise 
ovarian, breast, and gastrointestinal tumours291,292. This antibody also detects 
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MUC1 expressed in some luminal epithelial cells such as in normal resting 
breast, albeit weakly292. 
As previously explained, on-target off-tumour toxicities pose a 
significant risk in CAR T-cells immunotherapy. For this reason, I explored the 
possibility of TA-MUC1 being recognised by CAR T-cells in an off-tumour 
setting. 
1.4.3 Objectives of the PhD project 
As described, the aim of this PhD project was to investigate the potential 
of TAB28z CAR for the treatment of MUC1-positive breast carcinoma. For this 
purpose, multiple objectives were set. These are: 
1. In vitro characterization of TAB28z CAR T-cells: 
i) Generation of negative-control CAR constructs 
ii) Generation of stable packaging cell lines 
iii) Assessment of binding preference of MUC1-specific CAR T-
cells to tumour-associated glycoforms 
iv) Validation of CAR expression in human primary T-cells 
v) Assessment of in vitro cytotoxic activity against a panel of breast 
cancer cell lines and 
vi) Target-dependent production of pro-inflammatory cytokines by 
CAR T-cells 
2. MUC1 expression on activated T-cells and its effect on MUC1-specific 
CAR T-cell populations 
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3. Establishment of breast cancer xenograft model in NSG mice 
4. Investigation of in vivo activity of TAB28z CAR T-cells and comparison 
with HMFG2-based CARs. 
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Chapter 2: Materials and Methods 
  
 88 
2.1 Molecular Biology Techniques 
2.1.1 SFG retroviral vector 
Plasmid DNA encoding for the SFG retroviral vector was a gift of Dr 
Michel Sadelain (Memorial Sloan Kettering Cancer Center, New York, NY, 
USA) and contains the long terminal repeats (LTRs) of the Moloney murine 
leukaemia virus	MoMLV), responsible for driving the transcription of the 
inserted gene. The vector also contains the psi (ψ) packaging signal 
downstream of the 5’LTR. Psi packaging element is necessary for the 
encapsulation of the inserted genome into viral particles293,294. 
2.1.2 Engineering of CAR constructs 
Six MUC1-specific CARs were used in this project, namely TAB28z, 
H28z, HDF28z and their matched negative-control CARs TABTr, HTr and 
HDFTr. The latter contain a truncated and signalling defective endodomain in 
which only the membrane proximal three amino acids of the CD28 
endodomain are present. All constructs were expressed using the SFG 
retroviral expression vector293. 
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Figure 2.1: MUC1-specific CAR constructs. In total, six CAR constructs have been used 
throughout this project; three signalling intact CARs, TAB28z, H28z and HDF28z and three 
truncated CARs with a defective signalling domain. All six were cloned into SFG retroviral 
vector containing the 5’ and 3’ long terminal repeat (LTR) sequences and the psi (ψ) 
packaging signal. Additionally, they include the human CD8α leader sequence. TAB28z and 
TABTr constructs contain the heavy and light chains of the TAB004 antibody while H28z, HTr, 
HDF28z and HDFTr contain contain the heavy and light chains of the HMFG2 antibody. The 
three signalling intact CARs include CD28 (hinge/transmemberane/ endodomain – signal 2) 
and CD3ζ (endodomain - signal 1). HDF28z and HDFTr have an IgD hinge and IgG1 hinge 
plus Fc spacer while TAB28z contains a myc epitope tag which provides an alternative 
detection method. The three truncated CARs lack CD3ζ while only the membrane proximal 
three amino acids of the CD28 endodomain are present. 
2.1.2.1 Construction of TAB28z, H28z, HDF28z and HDFTr 
The TAB28z, H28z, HDF28z and HDFTr CARs were previously 
generated by colleagues and contain an scFv domain specific for MUC1295. 
The scFv domain of TAB28z is derived from the TAB004 MUC1-specific 
antibody while the scFv domain of H28z, HDF28z and HDFTr is derived from 
the HMFG2 MUC1-specific antibody284,287. TAB28z, H28z and HDF28z 
contain the CD3ζ signalling domain and the CD28 co-stimulatory 
endodomain. As mentioned previously, HDFTr contains a defective signalling 
domain. 
Ψ
CD8α ΤAB004 VH linker ΤAB004 VL Myc tag CD28 CD3ζ5’ LTR 3’ LTR
Ψ CD8α HMFG2 VH linker HMFG2 VL CD28 CD3ζ5’ LTR 3’ LTR
Ψ
CD8α HMFG2 VH linker HMFG2 VL CD28 CD3ζ5’ LTR 3’ LTRIgD IgG Fc
Ψ
CD8α ΤAB004 VH linker ΤAB004 VL CD285’ LTR 3’ LTR
Ψ CD8α HMFG2 VH linker HMFG2 VL CD285’ LTR 3’ LTR
Ψ










The TAB28z CAR has not been previously tested and its activity has 
been evaluated in this project. The H28z and HDF28z CARs were used for 
comparative purposes while HDFTr was used as a negative control.  
2.1.2.2 Construction of TABTr and HTr 
2.1.2.2.1 Cloning Strategy 
Plasmids encoding for the TABTr and HTr negative-control CARs were 
generated by sub-cloning, following restriction digestion of SFG containing 
plasmids. Two previously existing truncated CARs archived in the lab were 
used for this purpose, namely SFG V9-truncated (V9Tr) and SFG CT4-
truncated (CT4Tr) (Dr Daniela Achkova)296. Initially, the scFv domains of 
TAB28z and H28z plasmids were isolated by Nco1-Not1 digestion. Similarly, 
the desired vector backbone sequences (SFG, spacer, transmembrane and 
truncated signalling domain) were isolated from V9-truncated and CT4-
truncated, through Nco1-Not1 digestion. The TABTr construct was generated 
by ligating the TAB28z-derived scFv with the V9-truncated vector backbone 
while HTr was generated through ligation of the H28z-derived scFv with the 
CT4-derived vector backbone sequence. 
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2.1.2.2.2 Gel extraction of DNA fragments following restriction 
digestion of plasmids 
Nco1 and Not1 restriction endonucleases (NEB, USA) were used to 
cleave the plasmids mentioned above and extract the DNA fragments of 
interest.  
Table 2.1: Example of restriction digestion reaction prior to DNA extraction by agarose gel 
electrophoresis. Reagents and quantities used in the digestion reaction prior to gel extraction 
of the desired DNA fragments (insert and vector) are listed. 
Reagent Plasmid 1 (insert extraction) 
Plasmid 2 
(vector extraction) 
Nuclease-free water Up to 100 μl final volume 
Up to 100 μl final 
volume 
NEB Buffer (10x) 10 μl 10 μl 
NEB enzyme 2 5 μl (50 units) 5 μl 
NEB enzyme 1 5 μl (50 units) 5 μl 
DNA 5 μg 5 μg 
Table 2.2: Expected size of DNA fragments after restriction digestion with Nco1/ Not1. The 
fragments of interest are indicated in red. 
 
1:  V9Tr  
      1. 6582 bp (vector) 
      2. 141 bp 
2:  TAB28z 
       1. 7033 bp 
       2. 804 bp (insert) 
3:  CT4Tr 
       1. 6570 bp (vector) 
       2. 1710 bp 
       3. 528 bp 
4:  H28z  
       1. 7020 bp 
       2. 789 bp (insert) 
 92 
The digested DNA products were subjected to electrophoretic 
separation on a 1% agarose gel containing ethidium bromide (see Section 
2.1.2.2.3 for description of agarose gel electrophoresis). Bands of the desired 
size were extracted with the use of UV light (Table 2.2). The extracted bands 
were purified with a DNA purification kit (Promega, USA) and the DNA 
fragments were ready for ligation. 
2.1.2.2.3 Agarose gel electrophoresis 
In order to prepare the 1% agarose gel, 0.3 grams of UltraPure agarose 
(ThermoFisher Scientific, USA) were added to 30ml of 1x TBE solution 
contained in a microwavable flask. The solution was microwaved for 2 minutes 
until the agarose was completely dissolved. The mixture was allowed to cool 
down and, when the temperature reached 50˚C, ethidium bromide was added 
to a final concentration of 0.5μg/ml. The solution was then poured slowly into 
a gel tray containing well combs. The gel was allowed to sit at room 
temperature for 30 minutes and was then placed into the gel tank filled with 
1x TBE, followed by the removal of the combs. The digested reactions 
together with the 1kb DNA ladder (NEB, USA) were prepared accordingly by 
adding 1x gel loading dye (NEB, USA) and were loaded carefully into the 
wells. The gel was run at 80V for approximately an hour. The gel was 
visualised using a UV light device and the DNA fragments were isolated using 
a sterile razor blade and were placed at 4˚C until further processing.  
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2.1.2.2.4 Ligation reactions 
Restriction digestion led to the generation of DNA fragments with 
compatible sticky ends (Table 2.2) thus allowing their ligation. Fragment 1 
obtained from SFG V9Tr was ligated with fragment 2 derived from TAB28z in 
order to generate TABTr. To generate SFG HTr, fragment 1 from CT4Tr was 
ligated with fragment 2 from H28z. The ligation was achieved by mixing the 
insert and vector of interest with QuickLigase (NEB, USA) for 5 minutes at 
room temperature (2.1.2.2.4). The ligated products were then validated by 
transforming Escherichia (E.) coli competent cells and by screening the DNA 
isolated from bacterial clones (See sections 2.1.3 - 2.1.6). 
Table 2.3: Ligation reactions. Reagents and quantities used in ligation reactions are listed. 
Reagent Quantity 
Nuclease-free water Up to 20 μl 
NEB Quick Ligase buffer 10 μl 
Vector 50ng 
Insert 37.5 ng 
NEB Quick Ligase 1 μl 
 
2.1.3 Plasmid transformation of Escherichia coli 
The aforementioned DNA constructs were scaled-up by transforming 
DH5-alpha chemicaly competent E. coli (Life Technologies, USA). Plasmid 
DNA (1μl) was mixed with 50μl DH5-alpha cells and placed on ice for 30 
minutes. The mixture was incubated in 42°C for 90 seconds (heat shock) and 
then placed back on ice for 5 minutes. Super optimal broth with catabolite 
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repression (SOC) medium (250µl) (Invitrogen, USA) was then added and the 
mixture was placed in a bacterial shaker for 1 hour (37°C, 220rpm). Finally, 
the bacteria-SOC medium mixture was spread onto pre-warmed Lysogeny 
broth (LB) agar plates containing ampicillin and incubated overnight at 37°C 
to allow the antibiotic-resistant bacterial clones to grow (see 2.1.4 for 
preparation of agar plates). All the plasmids have an ampicillin resistance 
gene. Consequently, only bacterial clones that contained the plasmid were 
expected to survive and grow on the ampicillin-containing agar plates. 
On the day following plasmid transformation, several bacterial clones 
were picked from the agar plate. A yellow tip was used to pick individual 
colonies which were dropped in a Falcon tube containing 5ml LB medium with 
ampicillin (1ml of 50mg/ml ampicillin was added to 500ml of LB broth). Falcon 
tubes were then placed in the bacterial shaker (37°C, 220rpm) and left 
overnight. 
2.1.4 Preparation of LB agar plates for bacterial 
growth 
Initially, a bottle containing 500ml of LB agar was placed in the 
microwave and heated for 20 minutes at 40% power. The melted LB agar was 
allowed to cool down for 15 minutes at room temperature and ampicillin was 
then added (1ml of 50mg/ml ampicillin was added to 500ml of LB agar). After 
thorough mixing, the ampicillin-containing LB agar was poured into Petri 
dishes (10ml solution per Petri dish). The LB agar was allowed to set and the 
agar plates were stored afterwards at 4ºC. 
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2.1.5 Mini-plasmid preparation 
On the following day, DNA was extracted from each of the bacterial 
clones that were picked. A low-yield “miniprep” plasmid extraction procedure 
was performed to determine if the bacterial clones contained the expected 
plasmid DNA. A QIAprep Miniprep Kit (Qiagen, Germany) was used to extract 
the DNA, according to the manufacturer’s protocol. The DNA was eluted in 
50μl of nuclease-free water (Ambion, USA).  
2.1.6 Validation of plasmid DNA with restriction 
enzyme digestion 
Plasmid DNA digestion with the appropriate restriction endonucleases 
was performed in order to validate the purified plasmid. The miniprep DNA 
was incubated together with the reagents listed in Table 2.4 for one hour at 
37°C. The digested products were separated on a 1% agarose gel containing 
ethidium bromide by electrophoresis (see Section 2.1.2.2.3). 
Table 2.4: Screening digest of Miniprep DNA with restriction endonucleases. Enzymes and 
buffer were purchased from New England BioLabs (NEB, USA). 
Reagent Quantity (μl) 
Nuclease-free-water Up to 30 
NEB buffer (10x) 3 
NEB enzyme 1 0.5 (5 units) 
NEB enzyme 2 0.5 (5 units) 
Miniprep DNA 0.5-1μg 
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2.2 Cell culture 
All cells were cultured in a humidified incubator at 37°C containing 5% 
CO2 in air. All tumour cell lines and retroviral packaging cell lines were 
propagated in D10 medium while primary human T-cells were cultured in R5 
medium. 
D10 medium 
• DMEM media (Lonza, Switzerland) 
• 20mM L-Glutamine (Sigma-Aldrich, USA) 
• 10% foetal bovine serum (FBS) (Sigma-Aldrich, USA) 
R5 medium 
• DMEM media (Lonza, Switzerland) 
• 20mM L-Glutamine (Sigma-Aldrich, USA) 
• 5% human AB serum (Sigma-Aldrich, USA) 
• 50,000U penicillin/50mg streptomycin (Sigma-Aldrich, USA) 
2.2.1 Culture of immortalised cell lines 
2.2.1.1 Breast cancer cell lines 
A panel of breast cancer cell lines was characterised for expression of 
MUC1 prior to investigating the target-dependent cytotoxic activity of the 
MUC1 CAR T-cells. These cell lines consisted of T-47D, MCF7, BT-20, MDA-
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MB-468, ZR-75-1 and MDA-MB-231. The characteristics of these cell lines 
are listed in Table 2.5297,298.  
Table 2.5: Characteristics of the breast cancer cell lines used throughout this project. ER – 
oestrogen receptor; PR – progresterone receptor; HER-2 – ErbB2 receptor. 
Cell line Morphology Origin of cells ER/ PR/ HER-2 
T-47D Ductal carcinoma Metastatic site; pleural effusion ER+, PR+, HER-2 - 
MCF-7 Luminal Metastatic site; pleural effusion ER+, PR-, HER-2 - 
BT-20 Basal Mammary gland ER-, PR-, HER-2 - 
MDA-MB-468 Basal Metastatic site; pleural effusion ER-, PR-, HER-2 - 
ZR-75-1 Luminal Metastatic site; ascites ER+, PR-, HER-2 - 
MDA-MB-231 Basal Metastatic site; pleural effusion ER+, PR+, HER-2 - 
 
The cell lines listed above were propagated in D10 medium. 
2.2.1.2 Retroviral packaging cell lines 
A critical step in the generation o CAR T-cells is the genetic 
modification of T-lymphocytes to stably express the CAR construct of interest. 
This was achieved by delivering a retroviral vector that carries the CAR 
transgene into pre-activated T-cells. The retroviral vector is delivered to the 
cells by appropriately pseudotyped viral particles produced by retroviral 
packaging cell lines.  
Retroviruses are considered a useful tool in the field of gene therapy 
as they have the ability to integrate their genome into the DNA of a host cell. 
Retroviral virions include two copies of singe-stranded RNA consisting of at 
least four genes, gag, pol, pro and env299,300. Each of these genes encode for 
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viral proteins with different function. Gag encodes for the structural proteins 
necessary for the viral core. Pol encodes for integrase, RNA H and reverse 
transcriptase. Env directs expression of the proteins related to the viral 
envelope and lastly, pro encodes for protease which is responsible for the 
processing of gag and pol proteins300. The structural features of a retroviral 
particle are shown schematically in Figure 2.2.  
 
 Figure 2.2: Schematic representation of the structure of a retroviral particle. Two-single 
stranded RNA (ssRNA) molecules are included inside the capsid (CA) together with the viral 
proteins, namely protease (PR), integrase (IN) and reverse transcriptase (RT). Capsid is 
surrounded by the matrix (MA) while the lipid bilayer forms the outer layer. Surface envelope 
protein (SU) and transmembrane envelope protein (TM) form the envelope of the viral particle. 
The retroviral life cycle is summarised in Figure 2.3. Infection of the 
host cell by retroviruses is initiated when the glycoproteins of the viral 
envelope attach to their receptors expressed on the surface of the host cell. 
Upon recognition, the viral envelope is fused with the cell membrane and the 
viral RNA is released to the cytoplasm301. A viral protein, named reverse 
transcriptase, converts the viral RNA into double-stranded DNA which is then 
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transferred inside the host cell nucleus. Viral DNA is unable to entry the cell 
nucleus; nevertheless, it can enter the nucleus during mitosis after the 
dissolution of the nuclear membrane302. The next step is the integration of the 
double-stranded DNA (dsDNA) to the host cell genome in order to form the 
provirus. This process occurs in an almost random manner throughout the 
host cell genome. The integrated provirus is then transcribed to yield mRNA 
that encodes for viral proteins, a process mediated by RNA polymerase II. The 
mRNA is exported from the nucleus and is translated by the host-cell 
translation machinery. These translated proteins are further processed by a 
viral protease and are encapsulated into viral particles. The newly formed viral 
particles exit the infected cell through a process known as budding303. 
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Figure 2.3: Life cycle of retrovirus. Infection of the host cell by the retrovirus begins when the 
viral envelope proteins bind to their receptors expressed on the cell membrane of the host 
cell (1). The viral and cell membranes are fused and the capsid including the ssRNA is 
released into the cytoplasm (2). ssRNA is reverse transcribed to cDNA (3) and is transported 
to the nucleus upon mitosis (4). Viral cDNA is integrated to the host cell DNA, thus forming 
the provirus (5). Provirus is transcriped to mRNA by the host cell’s transcription machinery 
(6). The latter is translated, leading to the production of viral proteins (7). The latter are further 
processed by viral protease and subsequently are encapsulated together with new viral RNA 
in order to form new viral particles. The newly formed viral particles exit the host cell through 
budding (8) and they undergo maturation in order to initiate the infection of a host cell (9). 
As mentioned above, retroviruses are often used in CAR T-cell 
immunotherapy to achieve stable expression of the gene of interest. 
Nevertheless, the ability of retrovirus to replicate is undesirable. For this 
reason, replication-defective retroviral vectors are used in which the four viral 
genes, gag, pol, pro, env are replaced by the gene of interest. Since these 
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viral proteins are necessary for the infection of the host cell, dedicated 
packaging cells that provide the missing proteins in trans are used to produce 
the retroviral vector for delivery to and integration within T-cells.  
Four different retroviral packaging cell lines have been used throughout 
this PhD, namely H29, PG-13, HEK 293T VECs and HEK 293T cells. 
2.2.1.2.1 H29 cells 
The H29 packaging cell line is derived from human 293 cells which 
have been engineered to express the Moloney murine leukaemia virus 
(MoMLV) gag and pol proteins and the vesicular stomatitis virus (VSV)-G 
envelope protein304. VSV-G pseudotyped virus is produced in an inducible 
manner, under the control of tetracycline. Thus, the production of the 
pseudotyped viral particles is allowed only when the cells are not propagated 
in tetracycline. The regulation of the VSV-G expression from tetracycline is 
essential as the VSV-G protein is toxic to the 293T cells, owing to 
syncytialization304. H29 cells were obtained as a gift from Dr Michel Sadelain 
(Memorial Sloan Kettering Cancer Center, New York, NY, USA) and were 
cultured in D10 medium. The medium also contained 2μg/ml tetracycline 
(Calbiochem, USA) to suppress the expression of VSV-G protein, 0.3mg/ml 
G418 to maintain the expression of gag-pol and 2μg/ml puromycin to maintain 
the tetracycline-regulated expression of VSV-G. 
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2.2.1.2.2 PG-13 cells 
PG-13 are retrovirus-packaging cells derived from TK-NIH/3T3 cells305. 
PG-13 cells contain the MoMLV gag-pol proteins and the envelope protein of 
gibbon ape leukaemia virus (GALV). Derived GALV pseudotyped retroviral 
particles can infect host cells of varying species origin, including human cells. 
Importantly however, it cannot be used to transduce murine cells. The virus 
that is produced is of high titre, generally >106 colony forming units 
(CFU)/ml305. PG-13 cells were obtained from the European Collection of 
Authenticated Cell Cultures (ECACC) and were cultured in D10 medium. 
2.2.1.2.3 HEK 293T cells 
HEK 293T (293T) cells are a subtype of the human embryonic kidney 
(HEK) cells, which have been transfected to express a mutant form of the 
SV40 T-antigen306. HEK 293T cells were propagated in D10 medium. 
2.2.1.2.4 HEK 293T VEC cells 
HEK 293T VEC packaging cells, pseudotyped with either RD114 or 
GALV envelope are derived from HEK 293T cells and were obtained as a gift 
from Dr Manuel Caruso (CHU de Québec Research Centre, Canada). The 
latter have been transfected to express the gag and pol proteins of the MoMLV 
virus together with the RD114 or the GALV envelope. These packaging cells 
are reported to produce viral titres of above 1x107 CFU/ml307. HEK 293T VEC 
cells were propagated in D10 medium. 
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2.2.2 Generation of stable retroviral packaging cell 
lines expressing CAR constructs  
2.2.2.1 Generation of TAB28z-expressing packaging cells 
An overview of the method used in this project to generate stable 
retroviral packaging cells for SFG TAB28z is indicated in Figure 2.4. Initially, 
H29 cells were transfected with the plasmid vector of interest. The vector was 
then packaged into transiently produced viral particles that had the VSV-G 
envelope. The latter allows the viral particles to be delivered in the PG-13 
packaging cell line for stable production of GALV pseudotyped retroviral 
vector that carries the transgene. 
The transfection of H29 cells with TAB28z-encoding SFG plasmid DNA 
was achieved using the poly-ethylenimine (PEI) transfection reagent (Sigma-
Aldrich, USA). The H29 cells were plated in tetracycline containing-medium in 
order to reach 90% confluence in a 6 well plate by the day of transfection. On 
the day of transfection, the tetracycline containing medium was replaced with 
2ml of tetracycline-free D10 and cells were returned to the incubator for 2 
hours. Subsequently, 1.5μl of 1mM PEI and 50μg of the vector of interest were 
mixed with 1.5ml of serum-free DMEM medium and incubated for 20 minutes. 
The H29 cells were washed three times with serum-free medium and the 
mixture was added to the cells. The cells were incubated in the incubator for 
2 to 2.5 hours and the mixture was removed by replacing it with 3ml of D10. 
To generate a stable retroviral packaging cell line, supernatant from the 
transfected H29 cells was harvested and transferred every day to a different 
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well of under-confluent PG-13 cells (approximately 30% confluent)308. The 
viral supernatant was filtered through a 0.45μm pore-size filter (Corning, USA) 
prior to its addition to the PG-13 cells. 
As mentioned before, the virus produced by HEK 293T VEC packaging 
cells is of higher titre in comparison with that produced by the PG-13 cells. For 
that reason, HEK 293T VECs carrying the RD114 envelope were also 
engineered to express the CAR transgene, aiming to achieve high T-cell 
transduction efficiency. To achieve this, PG-13 cells that produce SFG 
TAB28z were trypsinized in order to reach 90% confluency by the next day. 
The viral supernatant was then harvested from these cells and was added to 
under-confluent HEK 293T VECs. The viral supernatant was filtered through 
a 0.45μm pore-size filter (Corning, USA) prior to its addition to the 293T VECs. 
The same process was repeated until over 80% of the 293T VECs expressed 
the CAR transgene, as determined by flow cytometry (see section 0). 
 
Figure 2.4: Schematic representation of the experimental process undertaken to generate 
TAB28z-expressing packaging cells. H29 cells were transfected to express TAB28z CAR 
plasmid with the use of poly-ethylenimine (PEI) agent. H29-produced viral supernatant (VSV-
G envelope) was then used to transduce PG-13 cells. Subsequently, supernatant harvested 
from PG-13 packaging cells (GALV envelope) was transferred to HEK 293T VECs expressing 







PG-13 HEK 293T VECs-RD114
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2.2.2.2 Generation of H28z, HDF28z and HDFTr-expressing packaging 
cells 
 PG-13 packaging cells expressing individually the H28z, HDF28z and 
HDFTr CAR transgenes were made previously by colleagues. HEK 293T 
VECs expressing the RD114 envelope were furthered transduced to express 
the CARs following the method described in Section 2.2.2.1 (Figure 2.5). 
 
Figure 2.5: Schematic representation of the experimental process undertaken to generate 
H28z, HDF28z and HDFTr-expressing packaging cells. Supernatant harvested from PG-13 
packaging cells (GALV envelope) expressing the CAR construct of interest was transferred 
to HEK 293T VECs expressing the RD114 envelope. 
2.2.2.3 Generation of TABTr and HTr-expressing packaging cells 
HEK 293T VECs expressing the GALV envelope were transduced to 
express the TABTr and HTr CAR through the method of simultaneous triple 
transfection of gag-pol, env and CAR-encoding plasmids (Figure 2.6). HEK 
293T cells (1.5x106 cells) were plated in one 100mm plate per CAR construct, 
and were placed in the cell culture incubator. The cells were re-suspended in 
10ml D10 medium. The HEK 293T cells were ready for transfection when they 
had confluency at 50-60%. For each plate, a mixture (A) of 470μl plain DMEM 
(Lonza, Switzerland) and 30μl of GeneJuice (Novagen, Germany) was 
Viral supernatant 
(GALV pseudotyped) 
PG-13 HEK 293T VECs-RD114
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prepared and incubated for 5 min in the hood. Subsequently, a mixture (B) of 
12.5μg DNA containing all three plasmids (Table 2.6) was added to mixture A 
and was incubated for 15 min in the hood. The mixture A+B was then added 
drop-wise into the plate. The plates were incubated in a cell incubator and at 
48 hours post transfection the viral retroviral supernatant (10ml) was collected 
from each plate. 
Table 2.6: Triple Transfection. Three different plasmids were used in total of 12.5μg per plate: 
1.RD114 (envelope), 2.Gag-Pol, 3.CAR construct. 
Plasmid Quantity per plate (μg) 
RD114 3.125 
gag-pol 4.6875 
CAR construct 4.6875 
 Total = 12.5 
 
Subsequently, 3ml of the collected supernatant was filtered (0.45μm-
pore filter) and transferred to under-confluent HEK 293T VCs expressing the 
GALV envelope. D10 medium (10ml) was added to the 100mm cell plate 
which was incubated for additional 24 hours. The supernatant was harvested, 










Figure 2.6: Schematic representation of the experimental process undertaken to generate 
TABTr and HTr-expressing packaging cells. HEK 293T cells were “triple transfected” to 
express the constructs of interest. Viral supernatant was harvested at 48 hours and 72 hours 
post-transfection and transferred to HEK 293T VECs expressing the GalV envelope. 
2.2.3 Binding of MUC1-specific CARs to MUC1-IgG 
fusion proteins 
The binding of TAB004 and HMFG2 scFv to different MUC1 glycoforms 
was investigated. Specifically, 2 x 105 TAB28z and H28z-expressing HEK 
293T VEC cells were incubated with 200μg/ml MUC1 ectodomain-mouse IgG 
fusion proteins (decorated with T, ST, Tn or STn) on ice for 30 minutes295. 
Secondary goat anti-mouse IgG AlexaFluor 647-conjugated antibody was 
then added which allowed the detection of binding to each of the fusion 
proteins by flow cytometry. TAB28z and H28z HEK 293T VEC cells were 
stained with mouse IgG1 AlexaFluor 647-conjugated antibody as isotype 
controls. To correct for the difference in CAR expression on VEC cells, the 
mean fluorescence intensity (MFI) of binding was normalized to the MFI of 
CAR expression (MFI of bound glycoform/MFI of CAR-positive cells). The 
method of detection of CAR expression is described in Section 0). 
The IgG fusion proteins decorated with T, ST, Tn or STn were provided 
as a gift by Dr Richard Beatson (King’s College London, UK) and were 
produced as described by Bäckström by using wild-type or ldlD-mutant309 
Chinese hamster ovary (CHO) cells310–312. 
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2.2.4 Isolation of Peripheral Blood Mononuclear cells 
and activation of T-cells 
Primary human peripheral blood mononuclear cells (PBMC) were 
isolated from healthy donors using Ficoll-Paque (GE Healthcare, UK)-based 
density gradient centrifugation. This protocol was approved by the Research 
Ethics Committee of Guy’s Hospital (09/H0804 192; use of Donor Blood 
samples for pre-clinical development). Initially the blood was transferred into 
a Falcon tube that contained 5ml of citrate-dextrose anticoagulant (Sigma-
Aldrich, USA). Ficoll-paque (15ml) was transferred into a 50ml Falcon tube 
and 25ml of anticoagulated blood was very slowly layered onto the ficoll, 
avoiding mixing between the two layers. The Falcon tube containing the 
layered blood was then centrifuged at 1150g for 25 minutes (acceleration and 
brake settings=0). The PBMC layer (buffy coat) was transferred into a new 
50ml Falcon tube using a Pasteur pipette, diluted to a final volume of 50ml 
PBS and then centrifuged at 550g for 10 minutes. The supernatant was 
aspirated and the cells were re-suspended in 50ml of PBS and the 
centrifugation step was repeated. The cells were re-suspended in 10ml of R5 
medium and counted. Following this step, the T-cells were activated with 
CD3/CD28 beads (Life Technologies, UK). After counting the cells, the 
required amount of beads was removed (3:1 or 1:1 PBMC:beads) and placed 
in a 15ml Falcon tube. The beads were washed three times with wash buffer 
consisting of 1 part R5 medium mixed with 9 parts PBS. After each wash, the 
beads were recovered by placing the Falcon tube on a magnet (Dynal magnet, 
ThermoFisher Scientific, UK). The waste was aspirated using a vacuum 
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pump. After the final wash, the beads were re-suspended in R5 medium in the 
required volume in order to achieve a PBMC density of 3x106 cells/ml.  
2.2.5 Retroviral transduction of T-cells 
Twenty-four hours after activation of the T-cells, IL-2 (Novartis, 
Switzerland) was added (100units/ml). On the same day, the HEK 293T VEC 
retroviral packaging cells were passaged by trypsinisation in order to reach 
90% confluency by the next day. On the following day, 3ml of retrovirus 
containing supernatant was collected from the packaging cells and transferred 
to a non-tissue culture treated 6 well plate that had been pre-coated with 
RetroNectin (RN, Takara, Japan). For the preparation of the RN- coated 
plates, 200μg of RN was re-suspended in 12ml PBS. Two ml of the resulting 
solution was transferred using a Pasteur pipette to each well of a non-tissue 
culture plate (Sigma-Aldrich, U.S) and allowed to coat the well for at least 2 
hours at room temperature or overnight at 4°C. Activated T-cells (contained 
within 1x106 activated PBMC) were added next, together with IL-2 
(100units/ml). Usually, 2 x 106 T-cells were transduced for each CAR T-cell 
construct. Expression of the CAR of interest by transduced T-cells was 
determined on day 5 and day 10 post activation by flow cytometry (described 
in section 0).  
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2.2.6 Culture of activated and CAR transduced T-cells 
Following activation and/ or retroviral transduction, T-cells were 
cultured in R5 medium with additional supplementation of IL-2 (100u/ml). 
Fresh R5 medium and IL-2 were added to cell cultures every second day.  
2.2.7 Viable T-cell count using trypan blue exclusion 
test 
Assessment of T-cell count was performed at day 10 post transduction 
with the use of trypan blue exclusion test313. T-cells were stained with trypan 
blue (GE Healthcare, USA) and the viable cell number was determined 
manually with a haemocytometer. The total cell number was calculated by 
multiplying the cell number/ml and the total volume (ml) of T-cells. 
2.2.8 Measurement of cytotoxic activity of MUC1-
specific CAR T-cells by MTT assay 
The in vitro cytotoxic activity of MUC1-specific CAR T-cells was 
investigated by performing co-cultivation assays. In order to perform these 
experiments, CAR T-cells were expanded for 10 days post transduction and 
were then added to confluent breast cancer cell monolayers as per the 
scheme indicated in Table 2.7. The cytotoxic potential of the anti-MUC1 CAR 
T-cells was investigated against three breast cancer cell lines expressing 
different levels of MUC1. These consisted of T-47D (MUC+++), MDA-MB-468 
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(MUC1++) and ZR-75-1 (MUC1+) cell lines. All three signalling-intact MUC1 
CARs (e.g. TAB28z, H28z and HDF28z) were included in these experiments, 
together with the matched truncated CARs (TABTr, HTr and HDFTr). Non-
transduced cells were also added to the tumour monolayers in order to identify 
any non-specific T-cell activity. Each reaction was performed in triplicate in 
individual experiments. 
Table 2.7: Co-cultivatation conditions used to examine cytotoxic activity of CAR T-cells 









48-well 0.125 x 106 0.5 x 106 1ml 
24-well 0.25 x 106 1 x 106 2ml 
 
The cytotoxicity of CAR T-cells against individual breast cancer cell 
lines was measured using the MTT reduction assay. This asay allows for the 
measurement of cell viability based on cell metabolic activity and is based on 
the reduction of MTT314. MTT, or 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, is a tetrazolium salt and its reduction depends 
on the concentration of intracellular NADH and NADPH. Viable cells convert 
the yellow-coloured MTT dye into purple-coloured formazan crystals. Dead 
cells lose the ability to reduce MTT as they lack metabolic activity. 
Quantification of the formed formazan product is achieved by reading the 
absorbance, after its solubilisation315. 
Tumour cell destruction was measured at three different time points, 
namely 24 hours, 48 hours and 72 hours after the addition of CAR T-cells to 
the tumour monolayers. Triplicates of tumour cells alone (without the addition 
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of T-cells) served as control reactions. The results were analysed by 
normalizing the absorbance of each well to the mean of the absorbance of 
tumour cells alone.  
At each of the time-points, the supernatant from the co-culture plates 
was aspirated and the wells were gently washed with PBS in order to remove 
residual T-cells from the tumour monolayers. Subsequently, 250μl (48-well 
plate) or 500μl (24-well plate) of 1/10 MTT dye (diluted in D10 medium) were 
added to each well and the plate was incubated in the cell incubator for 2 
hours. The MTT dye (Sigma-Aldrich, USA) was aspirated and 300μl (48-well 
plate) or 500µl (24-well plate) of DMSO (VWR International, USA) was added 
to each well in order to re-suspend the formed formazan crystals. The 
absorbance was measured at a wavelength of 570nm with a FLUOstar 
Omega plate reader. Tumour cell viability was determined using the following 
formula: 
%	#$%%	&'()'%'*+ = -(&$.(/$	01	23	#2 − #5%*5.$	.$(#*'267(&$.(/$	01	23	*5825.	#$%%7	(%26$ 9 ∗ 100 
2.2.9 Measurement of IFN-γ and IL-2 release by 
activated CAR T-cells 
The production of IFN-γ and IL-2 by T-cells is an indication of whether 
they have undergone activation following contact with tumour cells. At 48 
hours after establishment of the co-cultivation (described in Section 2.2.8), 
supernatant was harvested from each well in order to investigate the 
production of IFN-γ and IL-2 by sandwich enzyme-linked immunosorbent 
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assay (ELISA). The assays were performed by using the Human IFN-g Ready-
Set-Go kit (eBioscience, UK) and the Human IL-2 Ready-Set-Go kit 
(eBioscience, UK), according to the manufacturer’s instructions. In summary, 
a 96-well plate was coated with the capture antibody and afterwards blocking 
buffer was added in order to prevent any non-specific binding. The samples 
were added to the plate, together with a series of dilutions of the IFN-γ or IL-
2 standard, and any antigen present was bound by the capture antibody. An 
antigen-specific biotin-coated detection antibody was then added to the plate. 
Afterwards, avidin-conjugated horseradish peroxidase (HRP) was added to 
each well, which recognised the detection antibody. Finally, TMB (3,3’,5,5’-
Tetramethylbenzidine) substrate was added which was converted by HRP to 
a soluble blue product. The reaction was stopped by the addition of sulphuric 
acid and the absorbance was measured at 450nm with the FLUOstar Omega 
plate reader (BMG Labtech, UK). All optical density (OD) values were 
corrected by subtraction of background values generated using the medium 
alone control. A six-point standard curve was plotted using the serial two-fold 
diluted standard samples (top concentration 500pg/mL) and a line of best fit 
was generated by log transformation of the data, plotting concentration 
against OD. Cytokine concentrations contained within unknown samples were 
interpolated from the linear portion of the standard curve and were corrected 
for dilution as appropriate. 
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2.2.10 Flow-cytometry analysis 
Flow cytometry analysis was performed as detailed below using the 
Becton Dickinson (BD) LSR Fortessa cytometer with DIVA software. The 
results were analysed using FlowJo software (version 10).  
2.2.10.1 Investigation of expression of cell-surface molecules 
2.2.10.1.1 Protocol 
In order to investigate cell-surface expression of different molecules, a 
universal protocol was used. The amounts of antibodies/peptides that were 
used for staining reactions are specified in the sections below. 
1. Cells (0.5-1 x 106) cells were added into FACS tubes (12x75mm round-
bottom). 
2. The cells were washed with 2ml PBS and were centrifuged at 400g for 
5 minutes. 
3. The cell pellet was re-suspended in 100μl PBS and the primary 
antibody or directly-conjugated antibody was added to each sample. In 
some cases, an isotype control was added instead of the primary 
antibody, which served as the negative-control in order to define the 
gate for the positively-stained populations. 
N.B: when Fc block was used, this was added 10 minutes prior to the 
addition of the primary antibody. 
4. The samples were incubated for 30 minutes on ice. 
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5. Step 2 was repeated.  
6. The cell pellet was either: 
a. Re-suspended in 100 μl and then the secondary antibody 
was added (in the case of non-conjugated primary 
antibodies). 
b. Re-suspended in 300 μl and the samples were analysed by 
flow cytometry (in the case of conjugated primary 
antibodies). 
7. In the case of a., the cells were incubated for 30 minutes on ice in dark 
conditions. 
8. The samples were washed with 2ml PBS and centrifuged for 5 minutes 
at 400g.  
9. The cell pellet was re-suspended in 300μl and the samples were 
analysed using the flow cytometer. 
2.2.10.1.2 Primary antibodies 
The primary antibodies used in the flow-cytometry experiments are 
listed in the table below. The table also includes additional details, such as 
the reactivity, host species, isotype and the immunogen which was used for 
the production of the antibody.  
Other details, such as which the secondary antibodies and isotype 
controls are used in each experiment, the amount of each antibody used and 
the catalogue number, are mentioned in the following sections.
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Table 2.8: Primary antibodies used in the flow-cytometry assays. 
Name Specificity Species reactivity Immunogen Recognised epitope Clonality Clone number 
Host 
species Isotype Conjugation References 
MUC1 24mer peptide 
(APPAHGVTSAPDTRP
APGSTAPP) 
 Human - - - - - - biotin 295 
HMFG1 MUC1 Human 
Intact mucin from 
human milk fat 
globule (HMFG) 
PDTR region of MUC1; 
strong reactivity with 
normal epithelial cells 
Monoclonal - Mouse BALB/c IgG1, κ’ - 316–319 
HMFG2 MUC1 Human 




PDTR region of MUC1; 
strong reactivity with 
tumour-associated 
MUC1; some reactivity 
with resting and strong 
reactivity with lactating 
breast 
Monoclonal - Mouse BALB/c IgG1, κ’ - 316–319 
SM3 MUC1 Human Stripped HMFG 
PDTR region of MUC1; 
strong reactivity with 
tumour-associated 
MUC1; little to no 
reaction with benign or 
non-malignant cells 
Monoclonal - Mouse BALB/c IgG1, κ’ - 320 
5E5 MUC1 Human 
Fully glycosylated 
MUC1 Tn peptide 
(60-mer) 
MUC1 Tn; GSTA region 
of MUC1 
(HGVTSAPDTRPAPGS
TAPPA). Minimal to no 
reactivity with benign or 
normal epithelial cells 
Monoclonal - Mouse BALB/c IgG1, κ’ - 321 







CD3 ε-chain (both 
extracellular and 
intracellular) 
Monoclonal UCHT1 Mouse BALB/c IgG1, κ’ FITC 322 
CD8 CD8 Human Human peripheral blood lymphocytes CD8 α-chain Monoclonal SK1 Mouse BALB/c IgG1, κ’ PE-Cy7 
323 
CD45RO CD45RO Human 
IL-2-dependent 
human T-cell line 
(CA1) 
CD45 (180kDa isoform) Monoclonal UCHL1 Mouse BALB/c IgG2α, κ’ PE 
324 
CCR7 CCR7 Human CCR7-transfected human cell line CCR7 Monoclonal 150503 Mouse IgG2α APC - 
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PD-1 Monoclonal MIH4 Mouse IgG1, κ’ PE - 
TIM-3 (CD366) TIM-3 Human Recombinant human TIM-3 TIM-3 Monoclonal F38-2E2 Mouse IgG1, κ’ APC - 
CTLA-4 (CD152) CTLA-4 Human 
Human CTLA-4 
extracellular 
domain fused with 
Fc portion of 
human IgG1 
Extracellular domain of 
CTLA-4 Monoclonal L3D10 Mouse BALB/c IgG1, κ’ PE 
325 
 118 
2.2.10.1.3 Expression of MUC1-specific CARs 
Cell surface expression of MUC1-specific test and control CARs in 
transduced human T-cells was determined at day 5 and day 10 post 
transduction. Cells were stained with a MUC1-derived 24mer peptide that 
contains the HMFG2 and TAB004 epitope and with the following sequence: 
biotinyl (TAPPAHGVTSAPDTRPAPGSTAPP). Bound MUC1 peptide was 
detected by the addition of streptavidin-PE (Life Technologies, UK) (Table 
2.9)295. The CAR-positive population was defined by staining non-transduced 
T-cells in exactly the same way as the transduced T-cell populations.  
The expression of MUC1-specific CARs in retroviral packaging cells 
was determined in a similar way. Parental (non-transduced) cells were used 
as negative control. 
Table 2.9: Detection of cell surface expression of MUC1-specific CARs. This table lists the 
antibodies/peptides used for the detection of CAR expresion, the quantity used per sample 






number  Company 
Biotinylated MUC1 24mer 
peptide 7.5μg/ml - NeoMPS, US 
Streptavidin-PE 5μg/ml S866 Life Technologies, USA 
2.2.10.1.4 MUC1 expression on breast cancer cell lines  
Surface expression of MUC1 on breast cancer cell lines was 
determined by stainingthe cells with a biotinylated HMFG2 antibody followed 
by streptavidin-PE. Mouse IgG1-biotinylated (κ’) antibody was used as an 
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isotype control (Table 2.10). Incubations were carried out in the dark and on 
ice for approximately 20 minutes. Samples were washed twice in PBS after 
each incubation step. 
Table 2.10: Detection of expression of MUC1 on breast cancer cell lines. This table lists the 
antibodies used for the MUC1 detection, the amount of each of antibody added per sample 








antibody 2μg/ml - - 
Mouse IgG1-biotinylated (κ’) 
isotype control 20μl* 555747 
BD Pharmingen, 
USA 
Streptavidin-PE 5μg/ml S866 Life Technologies, USA 
2.2.10.1.5 MUC1 expression on T-cells 
Surface expression of MUC1 on T-cells was determined at different 
time points post-activation using HMFG2 biotinylated antibody followed by 
streptavidin-PE. Additionally, three other biotinylated MUC1-specific 
antibodies were used for comparison purposes, namely HMFG1, SM3 and 
5E5, followed by streptavidin-PE. It should be noted that human Fc block was 
added to the samples prior the addition of the primary antibodies (Table 2.11). 
The MUC1-specific antibodies were kindly provided as a gift by Professor Joy 
Burchell (King’s College London, UK). Cells stained with mouse IgG1-
biotinylated isotype control followed by streptavidin-PE were used as negative 
control. 
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Table 2.11: Expression of MUC1 on T-cells. This table lists the antibodies used, the amount 
added per sample and the catalogue number. *As per manufacturer’s protocol. 
Antibody Amount per sample 
Catalogue 
number Company 
FcR block (TruStain FcX) 5μl* 422302 BioLegend, UK 
HMFG2-biotinylated 
antibody 2μg/ml - - 
HMFG1-biotinylated 
antibody 2μg/ml - - 
SM3-biotinylated antibody 2μg/ml - - 
5E5-biotinylated antibody 2μg/ml - - 
Mouse IgG1-biotinylated (κ’) 
isotype control 20μl* 555747 
BD Pharmingen, 
USA 
Streptavidin-PE 5μg/ml S866 Life Technologies, USA 
2.2.10.1.6 MUC1 expression on CD4+ and CD8+ T-cells 
Surface expression of MUC1 on CD4+ and CD8+ T-cell populations was 
investigated at day 5 post T-cell activation. In order to define the CD4 and 
CD8 T-cell populations, mouse anti-human CD3-FITC and CD8-PECy7 
directly-conjugated antibodies were used (Table 2.12). To generate negative 
control samples, cells were stained with biotinylated mouse IgG1(κ’) (isotype 
control) instead of HMFG2. 
Anti-mouse IgG compensation beads (CompBeads, BD) were stained 
accordingly in order to set up the compensation. 
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Table 2.12: Surface expression of MUC1 on CD4 and CD8 T-cells. This table lists the 
antibodies used for the detection of MUC1 on CD4 and CD8 T-cells, the amount of each 
antibody added per sample and the catalogue number. *As per manufacturer’s protocol. 
Antibody Amount per sample 
Catalogue 
number Company 
FcR block (TruStain FcX) 5μl* 422302 BioLegend, UK 
HMFG2-biotinylated 
antibody 2μg/ml - - 
Mouse IgG1-biotinylated 
(κ’) isotype control 20μl* 555747 
BD Pharmingen, 
USA 
Streptavidin-PE 5μg/ml S866 Life Technologies, USA 
CD3-FITC 20μl* 555332 BD Pharmingen, USA 
CD8-PECy7 5μl* 344712 BioLegend, UK 
2.2.10.1.7 T-cell differentiation  
Stage of differentiation of CD4+ and CD8+ CAR T-cells was determined 
at day 10 post T-cell transduction by staining the cells with anti-human CD3-
FITC, CD8-PECy7, CD45RO-PE and CCR7-APC antibodies (Table 2.13). 
Fluorescence minus one (FMO) controls were used to define positive 
and negative populations. Stained anti-mouse IgG compensation beads were 
also used to achieve correct compensation settings. 
Table 2.13: Determining stage of differentation of CD4 and CD8 T-cells. This table lists the 
antibodies used, the amount added per sample and the catalogue number. *As per 
manufacturer’s protocol. 
Antibody Amount per sample 
Catalogue 
number Company 
CD3-FITC 20μl* 555332 BD Pharmingen, USA 
CD8-PECy7 5μl* 344712 BioLegend, UK 
CD45RO-PE 20μl* 555493 BD Pharmingen, USA 
CCR7-APC 10μl* FAB197A BD Pharmingen, USA 
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2.2.10.1.8 Expression of exhaustion markers 
The expression of three exhaustion markers, PD-1, TIM-3 and CTLA-
4 was investigated on CD4 and CD8 T-cells with the use of anti-human CD3-
FITC, CD8-PECy7, PD-1-PE, TIM-3-APC and CTLA-4 PE antibodies. 
Table 2.14: Expression of PD-1, TIM-3 and CTLA-4. This table lists the antibodies used, the 
amount added per sample and the catalogue number. *As per manufacturer’s protocol. 
Antibody Amount per sample 
Catalogue 
number Company 
CD3-FITC 20μl* 555332 BD Pharmingen, USA 
CD8-PECy7 5μl* 344712 BioLegend, UK 
PD-1-PE 20μl* 557946 BD Pharmingen, USA 
CTLA-4-PE 20μl* L3D10 BioLegend, UK 
TIM-3 APC 5μl* 345012 BioLegend, UK 
 
As previously stated in section 2.2.10.1.7, FMO controls were used in 
order to deine the positive and negative-stained populations and 
compensation was set up using appropriately stained anti-mouse 
compensation beads. 
2.2.10.1.9 Detection of viable human T-cells in mouse spleens and 
peritoneal fluid of mice treated with CAR T-cells 
The percentage of human viable T-cells in peritoneal fluid and in spleen 
harvested by mice was investigated by staining the samples with mouse anti-
human CD3-FITC conjugated antibody. The cells were incubated with mouse 
Fc block prior to staining. In order to define live cells, 7AA-D viability dye 
solution was added to the samples prior to the acquirement of data and 
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incubated in the dark for 5min. The samples were not washed after the 
addition of 7AA-D dye. 
Cells incubated previously with DMSO and stained with 7AA-D were 
used as positive to control in order to define the gate of live/dead cells in the 
dot plots. Additionally, γδ T-cells stained with IgG1-FITC and 7AAD were used 
as negative control in order to define the gate for the CD3-positive population. 
γδ T-cells stained with both CD3-FITC and 7AA-D were used as positive 
control. Compensation was set up accordingly by using single stained 
samples. 
Table 2.15: Detection of human viable T-cells in peritoneal fluid and in spleens post treatment 
of mice with CAR T-cells. This table lists the antibodies used, the amount added per sample 
and the catalogue number. *As per manufacturer’s protocol. 
Antibody Amount per sample 
Catalogue 
number Company 
CD3-FITC 20μl* 555332 BD Pharmingen, USA 
Mouse IgG1-FITC 
(κ’) isotype control 20μl* 555909 
BD Pharmingen, 
USA 
7AA-D 5μl* 420404 BioLegend, UK 
 
2.2.10.2 Maintenance and calibration of flow cytometer 
The BD LSR Fortessa cytometer was cleaned thoroughly before and 
after each use with FACS Rinse maintenance solution (BD, USA), FACS 
Clean decontamination solution (BD, USA) and with distilled water in order to 
maintain the flow-cytometer’s fluidic system.  
A quality control procedure was applied daily to ensure that the flow 
cytometer’s performance is optimal. For this purpose, BD FACSDiva™ 
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2.3 Breast cancer in vivo model 
The animal studies were conducted under the Project Licence of 
Professor Joy Burchell (PPL No. 77/7794) and under my Personal Licence 
(PIL No. IA5692FB4). All experimental procedures were performed in 
accordance with the UK Home Office guidelines. 
2.3.1 NOD scid gamma (NSG) mice 
Female NOD.Cg-Prkdcscid IL-2rgtm1WjlISzJ mice, commonly known as 
NOD scid gamma (NSG), were used in all the in vivo experimental studies 
mentioned in this project327. These mice, originally developed at the Jackson 
Laboratory by Dr Leonard Shultz, carry two mutations which result in severe 
immunodeficiency. The first mutation is in the DNA repair complex named as 
Prkdc, which causes severe combined immunodeficiency (SCID) 
accompanied by lack of B and T-cell populations, owing to the failure of V(D)J 
recombination. The second mutation is in the IL-2 receptor common gamma 
chain, which results in deficient cytokine signalling and consequently in 
reduced NK cell numbers and impaired NK cell cytotoxic activity327,328. Owing 
to the NOD genetic background, macrophages and dendritic cells are also 
defective in these mice. 
 126 
2.3.2 Generation of luciferase-positive breast cancer 
cells 
Breast cancer tumour cells were injected either subcutaneously in 
close proximity to the mammary fat pad or in the peritoneal cavity (i.p) of NSG 
mice and the tumour growth was measured regularly with bioluminescence 
imaging (BLI) or with calliper measurements. 
2.3.2.1 Retroviral transduction of breast cancer cell lines with 
ffluc_tdTomato 
In order to allow for bioluminescence detection, T-47D and MDA-MB-
468 cells were retrovirally transduced to express firefly luciferase (ffluc). 
Tandem dimer (td)Tomato fluorescent protein was co-expressed with firefly 
luciferase in order to be able to determine the transduction efficiency (Figure 
2.7)329. PG-13 retroviral packaging cells expressing the SFG ffluc_tdTomato 
retroviral vector were used for this purpose. The ffluc-tdTomato-positive PG13 
packaging cells were previously made by colleagues.  
 
Figure 2.7: Schematic represantation of the SFG firefly luciferase_tdTomato retroviral vector. 
Firefly luciferase (ffluc) and tdTomato fluorescent protein were stoichiometrically co-
expressed in an SFG retroviral vector, which contained the 5’ and 3’ long terminal repeats 
(LTR) and the psi (ψ) packaging signal. The Thosea Asigna-derived ribosomal skip 2A peptide 
(T2A) was inserted between the ffluc and tdTomato in order to achieve equimolar expression 
of the two proteins330. 
Ψ firefly luciferase 
(ffluc) tdTomato
5’ LTR 3’ LTRT2A
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Fresh supernatant harvested from confluent PG-13 cells was filtered through 
a 0.45μm pore-size filter and was added to under-confluent tumour cells. This 
process was repeated daily until the tumour cells were highly positive for the 
ffluc_tdTomato construct (see section 2.2.2.1 for details of the protocol).  
2.3.2.2 Validation of expression of ffluc and tdTomato in breast cancer 
cell lines 
The transduction efficiency of the SFG ffluc_tdTomato construct was 
determined by flow-cytometry by detecting the tdTomato fluorescent protein 
(max. excitation 554nm). 
In addition, the expression of ffluc was validated by performing an in 
vitro luciferase reporter assay. In this assay, 1x105 cells were diluted 10-fold 
and 150μg/ml D-luciferin (Regis Technologies, USA) was added to each well. 
Emitted luminescence was measured with the FLUOstar Omega plate reader 
(BMG Labtech, UK). 
2.3.3 Establishing breast cancer xenograft mouse 
model 
As mentioned above, ffluc_tdTomato expressing tumour cells were 
injected either in the peritoneal cavity (i.p) of female NSG mice or 
subcutaneously in close proximity to mammary fat pad. The number of tumour 
cells injected in each experiment are specified in the sections below. 
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2.3.3.1 Subcutaneous administration of tumour cells 
2.3.3.1.1 Preparation of the tumour-cells prior to subcutaneous 
injection 
To establish tumour models, female NSG mice received a pre-specified 
tumour cell dose, as indicated in Table 2.16. The tumour cells were 
trypsinized, counted and the required number of tumour cells was acquired. 
The cells were re-suspended in 400μl cold PBS + matrigel (PBS: matrigel 1:1) 
per mouse. The mixture was kept on ice until it was injected into the mice. 
Table 2.16: Tumour cell injection in the mammary fat pad of female NSG mice. The different 
cell doses of T-47D and MDA-MB-468 injected are listed in this table. Three mice per group 
were allocated in each cell dose group. 
Cell line Group A Group B Group C 
T-47D 0.5x106 2x106 5x106 
MDA-MB-468 0.1x106 0.5x106 2x106 
2.3.3.1.2 Injection of tumour cells subcutaneously 
The mouse was shaved and ethanol was spread across the right side 
of the abdomen in order to visualise the fatty tissue of the mammary gland. 
The mouse was immobilized by the scruff method and the cells (400μl PBS-
matrigel) were injected subcutaneously in close proximity to the mammary fat 
pad. A 27G sterile needle (BD Microlance, USA) placed on a 0.5ml syringe 
(Terumo, Japan) was used for the injection. The cells were injected 
subcutaneously, proximal to the mammary fat pad. 
Tumour growth was measured using a calliper tool and the tumour 
volume was calculated using the ellipsoid volume formula331 as follows: 
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2.3.3.2 Intra-peritoneal injection of tumour cells 
2.3.3.2.1 Preparation of the tumour-cells prior to i.p injection  
As indicated previously, female NSG mice received a pre-specified 
tumour cell dose. The tumour cells were trypsinized, counted and the required 
number of tumour cells was acquired (Table 2.16). The cells were re-
suspended in 200μl cold PBS (per mouse) and were kept on ice until their 
injection into the mice. 
Table 2.17: Tumour cell injection in the peritoneal cavity of female NSG mice. The different 
cell doses of T-47D and MDA-MB-468 injected are listed in this table. Three mice per group 
were allocated in each cell dose group. 
Cell line Group A Group B Group C Group D 
T-47D 0.5x106 2x106 5x106 10x106 
MDA-MB-468 0.5x106 2x106 0.5x106 - 
2.3.3.2.2 Intraperitoneal injection of tumour cells  
A sterile 27G needle was placed on a 1ml syringe (BD, USA) and 200μl 
of cells in PBS was drawn up, removing any air bubbles.  The mouse was 
restrained by the scruff method and was held in a way that its head was tilted 
back. The needle was inserted either to the left or right lower quadrant of the 
animal’s abdomen and the cells were injected. 
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2.3.4 Intraperitoneal injection of T-cells 
In the two therapeutic experiments described in this thesis, mice with 
established tumours were treated either with MUC1-specific CAR T-cells or 
with non-transduced T-cells or PBS. The treatment was injected i.p, in a 
process similar to that described in Section 2.3.3.2. The cell dose injected is 
described for the individual experiments. Five to six mice were allocated to 
each treatment group.  
2.3.5 Bio-luminescence (BLI) imaging 
To quantify tumour growth using bio-luminescence imaging, mice were 
injected i.p with D-luciferin (150mg/kg; Regis Technologies, USA) and were 
imaged under 2% isoflurane anaesthesia, 12 minutes post injection. The 
image was acquired with the use of the IVIS Lumina platform (PerkinElmer, 
USA). Data were analysed using Living Image software (PerkinElmer, USA). 
The mice were imaged by using a 25cm field of view (FOV), with medium 
binning factor (=2) and auto-exposure.  
2.3.6 Persistence of CAR T-cells in in vivo mouse 
model 
2.3.6.1 Peritoneal lavage 
In order to harvest the T-cells from the peritoneal cavity post 
euthanasia of the mice, the technique of peritoneal lavage was used. For this 
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purpose, 5ml of cold PBS was injected in the peritoneal cavity of each mouse. 
A 27G sterile needle (BD Microlance, USA) placed on a 5ml syringe (Terumo, 
Japan) was used for the injection. Post PBS injection, the peritoneum was 
gently massaged. The mouse was sprayed with ethanol and a small incision 
was made in the inner skin of the peritoneum. The fluid was collected in a 
50ml cold Falcon tube using a Pasteur pipette and was placed on ice. 
 In order to prepare the samples for flow-cytometry analysis, 10ml of 
cold PBS was added in each sample and was centrifuged for 5min at 400g. 
The supernatant was aspirated and the pellet was re-suspended in 10ml cold 
PBS. This was followed by a centrifuge step (5 min, 400g). The supernatant 
was aspirated and the pellet was re-suspended in 500μl and placed on FACS 
tubes. These were kept on ice until the initiation of the staining protocol 
(2.2.10.1.9). 
2.3.6.2 Harvesting of spleens 
Upon euthanasia of the mouse, sterile scissors and forceps were used 
in order to make an incision across the peritoneum. The spleen was harvested 
and placed in a 5ml tube containing 3ml of cold PBS. The sample was placed 
on ice until further processing. 
Prior to flow-cytometry analysis, the spleens were mechanically 
dissociated and single-cell suspensions were prepared. The cell suspension 
was transferred to a 15ml Falcon tube and 10ml of cold PBS was added. The 
cells were pelleted by centrifugation at 500g for 5min. The supernatant was 
aspirated and the pellet was re-suspended in 5ml of 1x red blood cell (RBC) 
lysis buffer (eBiosciences, USA). The cell suspension was incubated with the 
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lysis buffer for 5min. Post incubation, the cells were centrifuged at 500g for 
5min and the supernatant was aspirated. The pellet was re-suspended in 5ml 
of PBS and centrifuged at 400g for 5 min. The supernatant was aspirated, the 
cells were re-suspended in 500μl and transferred to a FACS tube. The 
samples were kept on ice until initiation of the staining protocol (2.2.10.1.9). 
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Chapter 3: In vitro characterization 




3.1.1 MUC1-adoptive T-cell therapy 
In adoptive T-cell therapy, patient-derived PBMCs are isolated and 
different cell populations, such as T-cells or dendritic cells, are expanded. 
These can be further manipulated in distinct ways. One strategy includes the 
activation of CTLs or DCs by presenting to them tumour-associated peptides, 
such as those derived from MUC1332. The activated cell populations are 
expanded ex vivo and are then adoptively transferred back to the patient. 
These activated cells can either specifically eliminate tumour cells, in the case 
of CTLs, or enhance anti-tumour immune responses, in the case of antigen-
loaded DCs333.  
Several clinical trials have been performed in which the effectiveness of 
CTLs or pulsed dendritic cells has been explored. In some cases, the 
combination of both approaches was shown to has some  benefit in the 
patients’ outcome334. In one combinatorial study, Kondo et al. treated 20 
patients with unresectable or recurrent pancreatic cancer with both MUC1-
pulsed dendritic cells and activated CTLs. Based on the results, one patient 
with metastatic disease showed complete response and four patients 
presented stable disease334.  
In another approach, patient-derived T-cells are isolated and engineered 
to express MUC1-specific CARs on their surface. Few research groups have 
engineered MUC1-specific CAR T-cells and have investigated their anti-
tumour activity using pre-clinical in vitro and in vivo models. Wilkie et al. 
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developed various versions of a MUC1-specific CAR, as published in a study 
in 2008295. In this paper, a 3rd generation MUC1-specific CAR named HOX 
showed the most promising efficacy. This CAR consists of a binding domain 
based on the HMFG2 antibody and it signals via CD3ζ, CD28 and OX-40. 
Additionally, this CAR has incorporated a longer hinge (IgD), which provides 
enhanced flexibility to the binding domain of the CAR. Mice bearing MUC1-
positive tumours showed delayed tumour growth after treatment with HOX-
engineered CAR T-cells295,335.  In a novel subsequent approach, Wilkie et al. 
co-expressed an anti-ErbB2 CAR (signals via CD3ζ alone) together with a 
MUC1-specific chimeric co-stimulatory receptor (containing CD28 alone). 
Their results showed that both antigens were required in order to achieve 
maximal tumour cell cytotoxicity and T-cell activation269. More recently, Posey 
et al. showed control of tumour growth in leukaemia and pancreatic cell 
xenograft models using a 2nd generation MUC1-specific CAR336,337. The latter 
contained an scFv based on 5E5 MUC1-Tn specific antibody (refer to section 
1.2.3.2)336,337. 
Clinical testing of MUC1 specific CAR T-cells has been limited to date. 
The efficacy of two different SM3-based MUC1-specific CAR T-cells has been 
investigated in a Phase I clinical trial, although data from only a single patient 
has been reported as yet338. One set of CAR T-cells contained an SM3-based 
CAR co-expressed with IL-12. The second set contained a CAR with a 
modified SM3 scFv to achieve increased binding of the CAR to MUC1. The 
latter lacked co-expression of IL-12. In this trial, these two types of MUC1-
specific CAR T-cells were injected using the intratumoral route in two different 
lesions in a patient with metastatic seminal vesicle malignancy.  Based on a 
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published case report, the lesion treated with the modified-SM3 CAR T-cells 
showed significant tumour necrosis while no difference was observed in the 
lesion treated with the SM3-IL12 CAR338.  
Four other clinical trials are currently recruiting patients in order to test 
MUC1-specific CARs in patients with different types of malignancy. Distinct 
strategies are being evaluated. In two Phase I/II clinical trials (NCT02617134 
and NCT02587689), the effectiveness and safety of MUC1-redirected CAR T-
cells is being investigated in patients with solid malignancies339,340. In the 
NCT02839954 trial, the efficacy and safety of NK cells transduced with a 
MUC1 CAR is being evaluated341. Lastly, in a Phase I/II clinical trial 
(NCT03179007) patients with an advanced solid tumour burden are being 
treated with MUC1 CAR T-cells that are engineered to  secrete PD-1 and 
CTLA-4 checkpoint inhibitors342. 
3.1.2 Aim 
The aim of the work presented in this chapter was to undertake in vitro 
characterization of a newly developed MUC1-specific CAR, named TAB28z. 
Throughout this project, this CAR has been compared with two previously 
developed CARs, named H28z and HDF28z. The in vitro characterization of 
these CAR molecules included the investigation of (i) their binding properties 
to different TA-MUC1 glycans, (ii) their cytotoxic activity against a panel of 
breast cancer lines and (iii) measurement of their ability to produce pro-




3.2.1 Expression of MUC1 in human breast cancer 
cell lines 
The first step undertaken was to investigate the expression of tumour-
associated (TA) MUC1 in a panel of human breast cancer cell lines using flow-
cytometry (see Table 2.5 for the characteristics of the breast cancer cell lines 
tested). Cells were stained with the HMFG2 antibody, which detects several 
tumour-associated MUC1 glycoforms, including those decorated with T, Tn, 
sialyl T and sialyl Tn. This analysis demonstrated a broad range of cell surface 
MUC1 expression in these cells lines. High MUC1 expression was detected 
on T-47D and BT-20 cells. By contrast, MDA-MB-468 and MCF7 showed 
intermediate levels of expression while ZR-75 had low levels of MUC1 (Figure 
3.1). No MUC1 expression was detected on the surface of MDA-MB-231. 
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Figure 3.1: Expression of MUC1 in a panel of human breast cancer cell lines. Cell surface 
expression of the MUC1 mucin was determined in T-47D, BT-20, MDA-MB-468, MCF7, ZR-
75 and MDA-MB-231 cell lines by flow cytometry. Herein histogram overlays are represented. 
The detection of MUC1 was achieved using HMFG2 biotinylated antibody followed by 
streptavidin PE (red histogram), while biotinylated IgG1, stained in the same way, was used 
as isotype control (blue histogram). Similar results were obtained in three independent 
replicate experiments. 
3.2.2 Investigation of the activity of MUC1-specific 
CAR T-cells in vitro 
As it has been stated in the Hypothesis of the Research Project, I set 
out to compare the anti-tumour activity of TAB28z CAR T-cells with that of T-
cells engineered to express two other MUC1-specific CARs named H28z and 
HDF28z, which have been previously developed by colleagues in our 
research group. All three CARs are of second generation design since they 
contain a fused CD28 and CD3ζ endodomain216. Three additional non-
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signalling anti-MUC1 CARs were included in the experiments mentioned 
below, as negative controls. In these control CARs, the endodomain contains 
only the membrane three proximal amino acids from CD28, thereby 
abrogating all signalling capacity. These control CARs, named TABTr, HTr 
and HDFTr respectively, contain an identical ecto- and transmembrane 
domain to that present in the corresponding signalling CARs (TAB28z, H28z 
and HDF28z respectively). The TABTr and HTr retroviral constructs were 
newly engineered for the purpose of this study, while HDFTr had previously 
been generated by a colleague295. 
3.2.2.1 Construction of TABTr and HTr retroviral plasmids 
TABTr and HTr DNA plasmids were generated by molecular cloning as 
previously described (see section 2.1.2.2). Upon completion, the DNA 
plasmids were validated by diagnostic restriction digestion. Both TABTr and 
HTr DNA plasmids gave the expected pattern of fragments, confirming that 
the cloning was successful (Figure 3.2). 
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Figure 3.2: Screening digestion of TABTr and HTr plasmids. The TABTr and HTr retroviral 
plasmids were generated by molecular cloning. Plasmid DNA was extracted from five 
bacterial clones for each of the constructs and was digested with NcoI and XhoI 
endonucleases. The resultant DNA fragments were separated by electrophoresis on a 1% 
agarose gel. Digestion of plasmid DNA from all candidate TABTr bacterial clones (#1-5) 
resulted in the expected fragments, specifically a fragment of 6346kb (vector backbone) and 
a second smaller fragment of 1040kb (insert). Similarly, digestion of #1-5 candidate ΗΤr 
plasmids revealed the expected two bands, the sizes of which were 6347kb (vector backbone) 
and 1012kb (insert).  
3.2.2.2 Generation of stable retroviral packaging cell lines expressing 
the CAR transgenes 
The next step undertaken before testing the functionality of these 
MUC1-specific CARs in primary T-cells was to generate stable retroviral 
packaging cell lines that could be used to deliver the CAR transgene to human 
T-cells. First, PG-13 retroviral packaging cells were transduced in order to 
produce retrovirus-containing supernatant encoding for the TAB28z CAR 
transgene. This was achieved by following a two-step procedure, described in 
Materials and Methods section (section 2.2.2.1). H28z, HDF28z and HDFTr 
PG-13 cells had been made by previous lab members. In each case, viral 















293T VEC packaging cells. Based on the literature, HEK 293T VEC are 
expected to produce high viral titres thus resulting in higher T-cell transduction 
efficiency (Appendix)305,307. TABTr and HTr HEK 293T VEC packaging cells 
were generated directly using the triple transfection method (section 2.2.2.3). 
All six MUC1-specific CARs/ truncated controls were highly expressed in the 
packaging cells, with expression levels ranging between 78% to 93.5% 
(Figure 3.3).  
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Figure 3.3: Expression of MUC1-specific CARs and matched truncated controls in HEK 293T 
VEC packaging cells. HEK 293T VEC packaging cells were transduced to express the MUC1-
specific CARs, either using viral supernatant from PG-13 cells (TAB28z, H28z, HDF28z, 
HDFTr) or by triple transfection (TABTr, HTr). Retroviral particles produced by the HEK 293T 
VEC cells were pseudotyped with the RD114 envelope (TAB28z, H28z, HDF28z, HDFTr) or 
by the gibbon ape leukaemia virus envelope (GALV - TABTr, HTr). Representative histogram 
plots show the cell surface expression of CARs following flow cytometry analysis. Detection 
of the CARs was achieved using a human MUC1-derived 24mer biotinylated peptide 
(encompassing 1.2 MUC1 tandem repeats and containing the epitope recognised by all 
CARs), followed by streptavidin PE (red histograms). Non-transduced HEK 293T VEC cells 
were stained in the same way and were used as negative control (blue histograms). Data are 
representative of three independent replicate experiments, all of which yielded similar results. 
3.2.2.3 Specificity of MUC1-specific CARs to tumour-associated MUC1-
glycoforms 
Tumour-associated MUC1 is characterized by aberrant glycosylation 










1.2). These core-1 or unglycosylated glycans are predominantly expressed on 
cancer cells and include the glycans T, Tn and their sialylated forms, ST and 
STn343. As previously stated, the TAB28z CAR contains an scFv binding 
domain derived from the TAB004 MUC1-specific antibody while the H28z and 
HDF28z CARs have an scFv derived from the HMFG2 antibody (also 
preferentially binds to tumour-associated glycoforms of MUC1)284,295. A 
binding assay was performed using HEK 293T VEC retroviral packaging cell 
lines for H28z and TAB28z to identify and characterize the binding preference 
of these CARs to MUC1 carrying the four tumour-associated glycans, T, ST, 
Tn and STn. Expression of these CARs by the retroviral packaging cells is 
shown in Figure 3.3. To undertake this study, recombinant human MUC1 
ectodomain (containing 32 tandem repeats)-mouse IgG1 fusion proteins 
decorated with each of these glycans were used310,312. Binding was detected 
by the addition of PE-conjugated goat anti-mouse IgG. Owing to limited 
availability of these reagents, only a single experiment could be undertaken. 
While only limited conclusions can be drawn as a result, these data show that 
both TAB28z and H28z bound to all four tumour-associated MUC1 glycoforms 
(Figure 3.4). Differences in relative binding to MUC1-Tn and MUC1-ST and 




Figure 3.4: Binding of MUC-specific CARs to tumour-associated MUC1 glycoforms. A) The 
histograms demonstrate the binding of each CAR to the four different glycoforms. TAB28z 
and H28z-expressing HEK 293T VEC retroviral packaging cells were incubated for 30min 
with T, ST, Tn and STn-decorated MUC1 ectodomain-mouse IgG fusion proteins. The binding 
of the CARs to each of the fusion proteins was determined by flow-cytometry, after the 
incubation of cells with goat anti-mouse AlexaFluor 647-conjugated antibody (red 
histograms). TAB28z and H28z HEK 293T VEC cells were stained with mouse IgG1 
AlexaFluor 647-conjugated antibody as isotype controls (blue histograms). The percentage 
of the binding, as well as the median fluorescence intensity (MFI), are mentioned within each 
histogram. B) The CAR expression was investigated by staining the cells with the 24mer-
MUC1 peptide, followed by streptavidin PE (red histograms). Parental (untransduced) HEK 
293T VEC cells were stained in the same way and were used as a negative control (blue 
histograms). The data shown here are derived from one experiment. 
3.2.2.4 Detection of CAR expression by retrovirus-transduced Τ-cells 
After validating the recognition of tumour-associated glycoforms by the 
MUC1-specific CARs, it was necessary to investigate whether these CARs 
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could be successfully expressed in human T-cells. Peripheral blood 
mononuclear cells (PBMCs) were isolated from healthy donors and activated 
T-cells were retrovirally transduced to individually express the three signalling-
competent MUC1-specific CARs, TAB28z, H28z and HDF28z. The 
expression of the matched control-CARs, TABTr, HTr and HDFTr was also 
investigated. The surface expression of the CARs was validated using flow 
cytometry. As shown in representative histograms, all six different CARs were 
expressed at high levels on the surface of the transduced T-cells, allowing 
meaningful comparison of their cytotoxic activity against MUC1-positive 
breast cancer cell lines (Figure 3.5). Transduction efficiency ranged between 
43% and 75%.  Surface expression of TAB28z, H28z and HDF28z on day 11 
post T-cell transduction was 68±11% (mean ± SD, n=8), 61±14% (n=8), 
58±11% (n=8) respectively. Surface expression of TABTr, HTr and HFTr was 
35±8% (mean ± SD, n=5), 37±12% (n=5) and 37±9%(n=9) respectively.  
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Figure 3.5: Expression of MUC1-specific CARs by retrovirus-transduced T-cells. Activated T-
cells were engineered by retroviral transduction to express the indicated MUC1-specific CARs 
or truncated controls. Representative histogram plots showing cell surface CAR expression 
in retrovirus transduced healthy donor T-cells, as detected by flow cytometry. Eleven days 
after transduction, T-cells were stained with the biotinylated MUC1-24mer peptide, followed 
by streptavidin-PE. The CAR expression levels are represented by red histograms. Non-
transduced T-cells were stained in the same way as previously described and were used as 
negative control (blue histograms). The percentage (%) of positive cells is indicated. Cytotoxic 
activity of MUC1-retargeted CAR T-cells against a panel of breast cancer cell lines 
The anti-tumour activity of the signalling-competent CARs was 
investigated by performing co-cultivation experiments in which CAR T-cells 
were co-cultured with human breast cancer cell lines expressing various 
levels of MUC1. The breast cancer cells that have been used are T-47D 
(MUC1+++), MDA-MB-468 (MUC1++) and ZR-75 (MUC1+). Cytotoxicity was 
measured after 24h, 48h and 72h of co-culture. The three matched truncated 









together with non-transduced T-cells. Based on the results shown herein, all 
of the signalling-competent CARs exhibited significant cytotoxic activity 
against T-47D cells (Figure 3.6A). By 72h, the number of viable tumour cells 
was less than 20%. Similarly, these CAR T-cells achieved significant killing of 
MDA-MB-468 tumour cells, which was apparent even from the 24h time point 
(Figure 3.6B). By contrast, minimal cytotoxic activity was observed against the 
lowest MUC1-expressing cells, ZR-75 (Figure 3.6C). Neither the truncated 
CARs or the non-transduced cells caused any background cytotoxic activity. 
The three signalling-competent CAR T-cells, TAB28z, H28z and HDF28z, 
performed similarly and there was no statistical difference between their 
cytotoxic activity in these assays. 
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Figure 3.6: Cytotoxic activity of MUC1-specific CAR T-cells against a panel of breast cancer 
cell lines. T-cells were engineered to express the indicated test or control CARs and 5 x 105 
T-cells were added to confluent tumour cell monolayers (A - T-47D; B- MDA-MB-468 and C - 
ZR-75), propagated in a 24-well plate. Non-transduced T-cells were additionally used to 
investigate any non-specific cytotoxic activity. Co-cultures were maintained for 24, 48h and 
72h and tumour cell-viability was measured at each time-point using an MTT assay. In these 
graphs, the percentage of tumour cell viability has been expressed relative to a matched well 
containing tumour cells-only (% cell viability = (ODco-culture reaction / ODtumor-cells only) x 100). Data 
show mean + SD of n=5 independent replicate experiments. Statistical analysis was 
performed by One-way ANOVA, followed by Tukey post hoc test. Asterisks above each bar 
represent the statistical significance when compared to non-transduced T-cells. The asterisks 
above each bar graph represent the significance of cytotoxic activity when compare to non-
transduced T-cells. P value 0.01 to 0.05; ** à P value 0.001 to 0.01; *** à P value 0.0001 to 

































































































































































































































































































































































































































































3.2.2.5 Quantification of Interferon (IFN)-γ production by MUC1 re-
targeted CAR T-cells 
The activation of MUC1-retargeted CAR T-cells upon recognition of 
target antigen was further investigated by quantification of IFN-γ release. 
Signalling competent MUC1-specific CAR T-cells produced significant 
amounts of IFN-γ upon recognition of MUC1 on the breast cancer cell lines 
(Figure 3.7A). Higher amounts were produced upon co-culture of the 
signalling competent CAR T-cells with T-47D. TAB28z-engineered T-cells 
released significantly more IFN-γ than H28z- or HDF28z-expressing T-cells 
when co-cultured with MDA-MB-468 cells.  
In these experiments, T-cells that were cultured in the absence of 
tumour cells were used as a further negative control. Notably, background 
cytokine release was observed by the signalling competent CAR T-cells 
(Figure 3.7B), whereas non-transduced T-cells and truncated control CAR T-
cells (e.g. expressing TABTr, HTr or HDFTr) did not demonstrate this pattern.  
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Figure 3.7: Quantification of IFN-γ production by MUC1-specific CAR T-cells. Supernatants 
were collected after 48h from the co-cultivation experiments described in Fig. 3.2.6 and were 
analysed for IFN-γ by sandwich ELISA. A) IFN-γ release was investigated upon co-cultivation 
of CAR T-cells together with the indicated breast cancer cell lines. B) IFN-γ production by T-
cells alone. These negative-control reactions were kept in the same conditions as the T-cells 
which were co-cultured with the tumour cells. Data shown are mean + SD of n=5-9 
independent replicates. Statistical analysis was performed with One-way ANOVA, followed 
by Tukey post hoc test. The asterisks above each bar graph represent the significance of 
cytotoxic activity when compare to non-transduced T-cells. P value 0.01 to 0.05; ** à P value 
0.001 to 0.01; *** à P value 0.0001 to 0.001; **** à P value < 0.0001, ns à not significant. 
3.2.2.6 Quantification of IL-2 release by MUC1-specific CAR T-cells 
The ability of the MUC1 re-targeted CAR T-cells to produce cytokines 
in response to antigen-dependent stimulation was further investigated by 
quantifying the production of IL-2. All three signalling-intact MUC1-specific 
CAR T-cell populations produced significant levels of IL-2 when co-cultivated 
with MUC1+++ T-47D tumour cells. Notably, TAB28z-expressing, but neither 
H28z or HDF28z-expressing T-cells produced detectable levels of IL-2 when 
co-cultivated with MDA-MB-468 cells or ZR-75 cells. As expected, truncated 
















































































































































































































Additionally, T-cells that were cultured in the absence of tumour cells did not 
release IL-2. 
 
Figure 3.8: Quantification of IL-2 production by MUC1-specific CAR T-cells. A) Supernatants 
were collected 24h post co-culture of CAR T-cells with T-47D, MDA-MB-468 and ZR-75 
tumour cells (as described in Figure 3.2.6) and were analysed for IL-2 content by sandwich-
ELISA. B) IL-2 ELISA was also performed on supernatants collected from T-cells that were 
cultured under similar conditions, except that they were maintained in the absence of tumour 
cells. These served as an additional negative control. Data shown are mean + SD of n=3 
independent replicates. Statistical analysis was performed with One-way ANOVA, followed 
by Tukey post hoc test. N.d – non detectable. It should be noted that supernatants were 
thawed in advance of analysis, which may have compromised stability of cytokine detected 
in this assay. P value 0.01 to 0.05; ** à P value 0.001 to 0.01; *** à P value 0.0001 to 0.001; 
























































































































































































In this chapter, I have undertaken an initial assessment of the activity of 
a newly developed MUC1-specific CAR, named TAB28z. This CAR has been 
engineered in collaboration with Professor Pinku Mukherjee (University of 
North Carolina at Charlotte, NC, USA), who provided the scFv sequence from 
the TAB004 antibody. Here, I aimed to characterize the in vitro anti-tumour 
activity of this newly developed CAR using breast cancer cell lines that 
express a range of levels of MUC1. Comparison was made with two other 
MUC1-specific CARs that had previously been developed in our lab using the 
HMGF2 scFv sequence, named H28z and HDF28. In addition, a panel of 
endodomain-truncated control CARs were also included in this analysis.  
The first step of this PhD project was to investigate the expression of TA-
MUC1 in a panel of breast cancer cell lines. TA-MUC1 was detected on the 
surface of various tumour cell lines by flow cytometry analysis using the 
HMFG2 anti-MUC1 antibody. HMFG2 antibody was used for the detection of 
MUC1 for two main reasons: 1) it is known to react strongly with malignant 
cells and less well with normal epithelial cells288,320, 2) H28z and HDF28z 
CARs contain a binding domain (scFv) derived from the HMFG2 antibody295. 
The surface expression of TA-MUC1 was investigated in a panel of six 
different breast cancer cell lines with different morphological and genotypical 
characteristics (Table 2.2). MUC1 was detected on five out of six tumour cell 
lines, a result that supports the frequent expression of TA-MUC1 in diverse 
molecular subtypes of breast cancer124. Other groups have investigated the 
expression of TA-MUC1 in various human breast carcinoma cell lines, 
 153 
consistent with my results344. The sole inconsistency is related to the MUC1 
expression on ZR-75. Specifically, Walsh et al. have reported high detection 
levels of MUC1 on the surface of these cells, while my results indicate low 
surface expression344. This inconsistency could be explained by the usage of 
a different anti-MUC1 antibody (BC2), the difference in the passage number 
of the cells, general differences in the handling of the cells, or other unknown 
technical reasons.  
Before I proceeded to the in vitro characterization of the MUC1-specific 
CAR T-cells, I designed and cloned two negative control CARs, named TABTr 
and HTr. These matched the signalling-intact CARs, TAB28z and H28z. The 
matched negative-control CAR for HDF28z, named HDFTr, had already been 
developed in the lab previously. The generation of the full panel of signalling 
and defective-signalling CARs was necessary in order to ensure that the 
activity of the signalling CARs is dependent on antigen recognition and 
resultant signalling by the CAR endodomain. The cloning of TABTr and HTr 
was successful, as evident from the validation restriction digest of the DNA 
minipreps (Figure 3.2). 
Gamma retroviral vectors, such as SFG, are commonly used for the 
genetic modification of T-cells (reviewed by S. Bear et al.)345. Stable 
packaging cell lines release virion particles which contain the CAR-expressing 
retroviral vectors and are widely used for T-cell transductions. This 
methodology provides a robust, safe and inexpensive way of CAR expression 
in human T-cells346. For the above reasons, HEK 293T VEC packaging cells, 
pseudotyped with either the RD114 or GALV envelope, have been used 
throughout this PhD project in order to achieve stable CAR expression by T-
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cells. The expression levels of the CARs in these cells were high for all the 
CAR constructs (>70%, Figure 3.5). 
It is known that HMFG2 and TAB004 MUC1 antibodies both bind to the 
VNTR region of MUC1284,288. The binding capacity of HMFG2-based CARs to 
different MUC1 glycoforms has already been reported by Wilkie et. al295. 
Nevertheless, no information has been available related to the binding 
preference of TAB004 to different TA-MUC1 glycoforms (patent #US-2011-
0123442)284,285,347. For this reason, it was essential to characterize and 
compare the binding pattern of TAB004-based and the HMFG2-based CARs. 
A binding assay was performed in which the binding preference of TAB28z 
and H28z CARs to different under-glycosylated glycoforms was evaluated. 
Four different glycoforms were used, T, sialyl-T, Tn and sialyl-Tn. The binding 
profile of the H28z CAR agrees with the results published by Wilkie et al., 
where they show that H28z CAR binds less well to the sialyl-T glycoform (49% 
ST binding, 85% T, 85% STn, 87% Tn)295. Overall, both TAB28z and H28z 
CARs showed similar binding preferences, although definitive conclusions 
cannot be drawn owing to lack of availability of glycosylated MUC1-Fc fusion 
proteins, which precluded repeat experimentation. One noted difference in the 
experiment that was performed is the ability of H28z to bind better to the Tn 
glycoform. This could potentially provide an advantage for the HMFG2-based 
CARs since the MUC1 Tn glycan is known to be overexpressed in the majority 
of breast cancers312,337,348.  
Next, it was essential to demonstrate that the TAB28z CAR can be 
successfully expressed in primary human T-cells. This was validated using 
flow cytometry (surface expression). High CAR surface expression is 
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desirable in CAR T-cell immunotherapy in order to achieve optimal CAR 
activity. 
To investigate the in vitro anti-tumour activity, MUC1-specific CAR T-
cells were co-cultivated with three different cell lines expressing various levels 
of MUC1. TAB28z CAR T-cells exhibited significant cytotoxic activity against 
T-47D and MDA-MB-468 tumour cells. Nevertheless, this activity did not prove 
superior when compared to H28z and HDF28z CAR T-cells. A notable 
observation was the fact that all three MUC1-specific CAR T-cells eliminated 
the MDA-MB-468 cells (MUC1++) more effectively in comparison with the T-
47D cells (MUC1+++). This difference was most apparent at the 24h time-
point post initiation of the co-culture. One possible explanation for this 
observation is that the MDA-MB-468 are more susceptible to T-cell-mediated 
cytotoxicity, in comparison with T-47D cells. Another surprising observation 
was that the number of viable MDA-MB-468 cells was progressively increased 
upon their co-culture with the TAB28z CAR T-cells. It could be hypothesized 
that TAB28z CAR T-cells could not control tumour growth due to high cell 
growth rate. This pattern was not observed in the co-cultures with H28z and 
HDF28z CAR T-cells. Potentially, this could reflect differences in affinity, 
recycling kinetics and/or tumour-associated glycoform preference of the 
CARs, a point that warrants further study using glycosylated MUC1-Fc fusion 
proteins.  
As expected, non-transduced T-cells and signalling-defective anti-
MUC1 CARs showed no background cytotoxic activity against the MUC1-
positive breast cancer cell lines. Importantly, all three signalling-intact MUC1-
specific CAR T-cells showed limited cytotoxic activity against ZR-75 cells, 
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which expressed low levels of MUC1. In the clinical setting, the latter has a 
double-edged significance. Minimal killing of low-antigen expressing cells 
could be advantageous as normal cells can potentially express low levels of 
TA-MUC1. In contrast, it could be considered a disadvantage as it might lead 
to tumour-escape where low-expressing MUC1 tumour cells will not be 
eliminated. The latter is emerging as a significant problem in CAR T-cell 
immunotherapy of CD19-expressing malignancy349. 
MTT assay gave a clear indication for the magnitude of CAR T-cell-
mediated cytotoxicity against each of the cell lines. Nevertheless, this assay 
is not ideal for the comparison of the observed cytotoxicity between the 
different cell lines in different time-points as each of these cell lines has 
different growth rate. For this reason, no solid statements can be made in 
regards with the differences observed between T-47D and MDA-MB-468. 
Chromium (Cr51)-release assay is considered the gold standard for the 
measurement of cell-mediated cytotoxicity.  In this assay, cell death is 
measured by quantifying the release of radioactivity from chromium-labelled 
cells350. The protocol requires a 4-hour incubation of the effector cells with the 
target cells, whilst MTT requires at least 24-hours of co-culture351. The latter 
gives an advantage to 51Cr-release assay over MTT for the comparison of cell-
mediated cytotoxicity observed between the different cell lines. Nevertheless, 
51Cr-release assay requires specific facilities for the handling and disposal of 
radioactive elements, which makes the use of this technique impractical. It 
was not possible to perform the 51Cr-release assay during this PhD project as 
the lab facilities do not comply with these requirements. Additionally, high 
spontaneous release of 51CR by some target cells can be observed. Other 
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assays have been developed as alternatives for the measurement of cell 
viability in vitro. Similar to MTT, the principle of some of these assays is 
dependent to the enzymatic activity of the target cells. Some examples are 
the lactate dehydrogenase (LDH) assay and the luciferase reporter assay352. 
LDH is released in the cell supernatant upon cell lysis. Cell death is quantified 
upon a colorimetric enzymatic reaction, which results to the conversion of 
tetrazolium salt (INT) into formazan crystals353,354. The luciferase reporter 
assay requires the transduction of the target cells with a luciferase reporter 
gene355. The produced bioluminescence is measured upon the addition of 
luciferin. Only live cells are able to produce luminescence due to the 
requirement of ATP. Both LDH and luciferase assay are easy and 
straightforward to perform. Additionally, cell cytotoxicity can be measured in 
multiple time points by using the co-cultured reactions that were initially set 
up. Direct comparison of 51Cr-release and luciferase reporter assay has 
shown that luciferase assay is superior due to increased kinetics and reduced 
signal-to-noise ratio356. Nevertheless, similarly with MTT, both LDH and 
luciferase assay require longer incubation period of the effector cells with the 
target cells, thus making them inappropriate for the comparison of cell-
cytotoxicity observed against various cell lines. Flow-cytometric assays are 
also being used for quantifying cell-mediated cytotoxicity. In these 
experiments, cells are labelled with a fluorescent dye, such as CFSE357. 
Additional staining of the cells allows for the differentiation between effector 
and target cells. The advantage of flow-cytometry-based experiments is that 
multiple fluorescent markers can be used. 
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 The incorporation of the elongated hinge in the HDF28z CAR did not 
seem to improve its anti-tumour activity in vitro. Wilkie et al. have reported that 
the incorporation of a longer spacer resulted in increased secretion of IFN-γ 
and improved proliferation, nevertheless no such benefit was observed in my 
results (See Chapter 4 for total T-cell count)295. Qin et al. have also suggested 
that incorporation of a hinge resulted in better expansion of anti-mesothelin 
CAR T-cells. In parallel, and in agreement with my results, the hinge-
incorporated CAR did not present improved anti-tumour activity when tested 
in vitro. Nevertheless, it showed improved anti-tumour activity when this was 
further investigated in tumour-bearing mice (See Chapter 5 for the 
investigation of the in vivo efficacy of MUC1-specific CAR T-cells)358. 
In support of the results showing the cytotoxic activity of MUC1 
retargeted CAR T-cells, all three signalling-intact CARs produced significant 
levels of IFN-γ upon antigen recognition. Interestingly, lower levels of IFN-γ 
were produced by the MUC1-specific signalling intact CAR T-cells when 
cultured with the MDA-MB-468 cells, despite their significant cytotoxic activity. 
Differences in expression of inhibitory molecules by the three breast cancer 
cell lines under study might potentially have influenced the ability of T-cells to 
produce IFN-γ. As reported by Mittendorf et al., the T-cell inhibitory molecule 
PD-L1 is detected on high levels in the surface of MDA-MB-468 cells while T-
47D cells showed lower PD-L1 surface expression82. Further experiments 
need to be conducted in order to explore this hypothesis and to investigate 
the levels of PD-L1 and other inhibitory molecules in these breast cancer cell 
lines.  
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Another interesting observation was that TAB28z CAR T-cells achieved 
significantly higher production of IFN-γ compared to H28z and HDF28z CAR 
T-cells, when co-cultured with the MDA-MB-468 cells. The expression pattern 
of TA-MUC1 glycoforms in MDA-MB-468s could potentially explain this result. 
Preliminary data presented here showed that the TAB28z CAR may bind the 
MUC1-ST glycan more efficiently, in comparison with the HMFG2-based CAR 
(Figure 3.4). The expression pattern of different glycans in MDA-MB-468 cells 
is not known and would be interesting to explore it in future experiments.  
The most unexpected result obtained in this analysis was the 
demonstration of significant IFN-γ secretion by all three signalling-intact 
MUC1 CAR T-cell populations in the absence of MUC1-positive tumour cells. 
Importantly, this pattern was not observed with non-transduced T-cells or 
signalling-defective CAR T-cells. Additional experimental reactions are 
required to be included in this assay in order draw any conclusions. These 
would be: a) co-culture of MUC1-specific CAR T-cells with a MUC1-negative 
cell line in order to validate the pattern of IFN-γ production in the absence of 
MUC1 from tumour cells, and b) co-culture of MUC1-positive cell lines with a 
non-specific (irrelevant) CAR. The latter would indicate whether this 
background CAR T-cell activation is a phenomenon associated solely with the 
MUC1-specific CARs under investigation. 
Others have reported activation of CAR T-cells independently of antigen 
engagement, for a variety of reasons. First, it has been widely reported that 
inclusion of the IgG1 Fc spacer in the extracellular domain of the CAR 
molecule can cause T-cell activation due its crosslinking by other Fc receptors 
that present in accompanying innate immune cells359,360. Although the 
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HDF28z CAR contains an IgG1 Fc spacer, this is not present in either the 
TAB28z or H28z. Consequently, this cannot be the explanation for the 
background IFN-γ production. Second, a number of studies have reported that 
the scFv domain of a CAR could mediate tonic signalling since certain 
elements within the scFvs could promote aggregation (and thus crosslinking) 
of the CAR receptors241,361. A third possible explanation for this tonic signalling 
is the expression of cognate antigen on activated T-cells241. This hypothesis 
has been further investigated in Chapter 4. 
In addition to IFN-γ secretion, the production of IL-2 by the MUC1-
specific CAR T-cells was also investigated. IL-2 was detected only in the 
supernatant derived from the TAB28z co-cultured T-cells. Nonetheless, 
issues with sample storage may mean that these levels represent an 
underestimate of IL-2 release by these cells. 
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3.4 Conclusions  
In this chapter, I initially investigated the surface expression of MUC1 in 
various breast cancer cell lines. MUC1 was, as expected, detected in the 
majority of breast cancer cell lines. The next step undertaken was to create 
negative-control (signalling-defective) CARs, named as TABTr and HTr, 
which match the signalling CARs TAB28z and H28z respectively. The in vitro 
characterization of TAB28z included the validation of recognising distinct TA-
MUC1-glycoforms. I then validated that TAB28z CAR can be successfully 
expressed on the surface of human primary PBMCs, activated with 
CD3/CD28 paramagnetic beads. TAB28z proved effective in eliminating 
MUC1-positive tumour cells. This activity was accompanied by significant 
production of IFN-γ upon antigen-stimulation. Nevertheless, the activity of 
TAB28z did not seem superior when compared to that of H28z and HDF28z 
CAR T-cells. An unexpected observation was the background production of 
IFN-γ by all three signalling CAR T-cells, in the absence of co-culture with 
tumour cells. This led to the hypothesis that these CAR T-cells might tonically 
signal. One suggested hypothesis for this observation is the detection of 
MUC1 on activated T-cells by the anti-MUC1 CARs during their in vitro 
expansion. This possibility has been explored in Chapter 4.  
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Chapter 4: MUC1 expression on 
activated T-cells and its effect on 





The fundamental role of the immune system is the protection of 
individuals from invading pathogens. To accomplish this, both the innate and 
adaptive arms of the immune system are required. Innate immunity is the first 
defence line against foreign antigens and it refers to non-specific defence 
mechanisms, such as macrophages and neutrophils, that take place in the 
site of infection362. On the other hand, adaptive immunity elicits antigen-
specific responses. T-lymphocytes are the main defence mechanism of 
adaptive immunity. A broad variety of T-cell receptors are expressed on the 
T-cell surface. These receptors encompass specificity against the vast 
majority of pathogens in order to be able to provide protection upon antigen 
encounter. The T-cell receptor repertoire is generated in thymus via somatic 
recombination of TCR genes362. At this stage, elimination of self-reactive T-
cells and establishment of self-tolerance is crucial in order to prevent 
autoimmunity (negative selection). Various mechanisms are in place in order 
to ensure that self-tolerance is established. These mechanisms are part either 
of central tolerance, which occur in primary lymphoid organs, or of peripheral 
tolerance, which take place in the lymphocytes once they have migrated 
outside thymus362. Both types of self-tolerance will be analysed further in the 
next section, with focus on the peripheral tolerance. 
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4.1.1 T-cell central and peripheral tolerance 
As previously described, central tolerance occurs in the thymus. 
Medullary thymic epithelial cells (mTECs) play an important role in the process 
of negative selection. mTECs have the property to process and present 
various peripheral antigens which are not normally found in they thymus, a 
process that is controlled by the autoimmune regulator gene (AIRE)363. Auto-
reactive T-cells with high affinity to self-peptide-MHC complexes get deleted, 
as they pose great risk autoimmunity. Alternatively, T-cells with high affinity to 
a self-antigen can undergo functional diversion to form T-regulatory cells, 
known as natural Tregs (nTregs)364. On the other hand, low-affinity self-
peptide-MHC complexes get spared365. Natural Tregs are CD4-positive and 
are characterised by upregulation of FoxP3 and expression of CD25 and 
CTLA-4362. nTregs cells can escape to the peripery and contribute further to 
the establishment of tolerance by producing anti-inflammatory cytokines and 
by modulating the activation status of APCs. Despite the mechanisms of 
central tolerance in place, there is still the possibility that not all autoreactive 
T-cells will be eliminated due to the fact that not all self-antigens are 
expressed in the thymus366. Thus, tolerance mechanisms that operate in the 
periphery are additionally required. The mechanisms of peripheral tolerance 
include ignorance, suppression by Tregs (iTregs), deletion and anergy. 
Naïve self-reactive T-cells with low affinity to self-antigen might never 
be activated as the threshold for T-cell activation in the periphery is higher 
than that for T-cell deletion in the thymus366,367. This phenomenon is named 
as peripheral ignorance. Ignorance is also achieved when activation of self-
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reactive T-cells is physically prevented by the restriction of self-antigen into 
immune privileged sites368. 
Various environmental factors present in the periphery can influence 
naïve CD4 T-cells to differentiate into Tregs362. This subset of Tregs is known 
as induced Trges (iTregs) and it contributes further to the establishment of 
tolerence, together with the nTregs. The mechanisms by which Tregs promote 
immune tolerance include the production of anti-inflammatory cytokines and 
the influence of the maturation stage of the dendritic cells. iTregs, similar to 
nTregs, are characterised by expression of CD25 and CTLA-4362. Immature 
dendritic cells (also known as tolerogenic DCs), play also an important role in 
the establishment of peripheral tolerance. Immature DC are characterized by 
reduced expression of MHC molecules and of costimulatory ligands, such as 
CD80 and CD86.  The latter results in impaired T-cell activation and 
proliferation. Lack of co-stimulation leads to tolerance either by inducing 
anergy or deletion of self-reactive T-cells369–372. The mechanism by which T-
cells decide to undergo either anergy or deletion is still under investigation. 
Deletion of autoreactive T-cells is mediated by apoptosis upon activation of 
Fas-mediated and Bim-2-mediated apoptotic pathways362.  
As previously mentioned, lack of T-cell co-stimulation results in 
functional unresponsiveness (anergy). Anergic self-reactive T-cells do not 
undergo apoptosis. They remain viable, but at the same time they lose their 
responsiveness to antigen exposure. This functional unresponsiveness is 
accompanied by downregulation of self-reactive TCR and IL-2 expression. 
Importantly, removal of the recognised self-antigen restores the functionality 
of self-reactive T-cells. Inhibitory receptors, such as PD-1 and CTLA-4, 
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additionally contribute to the establishment of peripheral tolerance and the 
induction of T-cell anergy by inhibiting T-cell response with the attenuation of 
the PI3k and Akt signalling pathways. PD-L1 can also mediate the conversion 
of naïve CD4 T-cells to iTregs373.  
 Some of the mechanisms of tolerance mentioned above can also be 
exploited by tumour cells in order to escape inhibition and killing by immune 
cells. Adoptive T-cell immunotherapy aims to break this tolerance established 
by tumour cells by introducing to them tumour-specific T-cell receptors, such 
as CARs and TCRs, with high affinity. Despite the enormous therapeutic 
potential that these strategies have, engineered T-cells can also present 
immune dysfunction. 
Various distinct types of T-cell dysfunction have been described, one of 
them being anergy which has been mentioned in the previous section. Other 
types of T-cell dysfunction include exhaustion and senescence. Senescence 
is a permanent and irreversible phenomenon characterised by telomere 
shortening and cell cycle arrest upon extensive cell proliferation (Hayflick 
limit). Exhaustion occurs upon chronic exposure of a T-cell to an antigen, 
accompanied by continuous T-cell activation. T-cell exhaustion is observed in 
conditions such as chronic infection, chronic inflammation and cancer. 
Exhausted T-cells are characterised by dysfunction, decreased production or 
pro-inflammatory cytokines (such as IL-2, IFN-γ and TNF-α) and upregulation 
of inhibitory receptors (such as PD-1, Tim33 and Lag-3). Importantly, 
exhausted T-cells are unable to restore their function upon removal of the 
stimulus. Different studies have reported that adoptively transferred T-cells 
can also become exhausted, even in the absence of interaction with tumour 
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cells. This have been attributed to tonic CAR T-cell signalling and to the 
inhibitory effector of the tumour microenvironment241,374. 
4.1.2 Aim 
In Chapter 3, I have presented results showing unexpected secretion of 
IFN-γ by all three signalling-intact MUC1 CAR T-cell populations, when 
cultured in the absence of MUC1-positive tumour cells. Background T-cell 
activation could potentially cause CAR T-cell dysfunction. Additionally, as 
discussed previously, expression of the targeted antigen by non-malignant 
cells raises significant concerns about the safety of an experimental CAR T-
cell immunotherapeutic approach. For this reason, I sought to investigate if 
background CAR T-cell activation resulted from the expression of so called 
“tumour-associated” (TA) glycoforms of MUC1 by activated T-cells, leading to 
a form of on target off tumour toxicity. This hypothesis was explored by (i) 
further characterisation of the in vitro behaviour of the MUC1-specific CAR T-





4.2.1 Expression of TA-MUC1 on peripheral blood 
mononuclear cells following T-cell activation 
Previous investigators have demonstrated that MUC1 is expressed by 
activated T-cells375–378. However, Correa et al. reported that TA-glycoforms of 
MUC1 recognised by the HMFG2 antibody have been reported to be absent 
on T-cells378. Given the background production of IFN-γ by the experimental 
CAR T-cells under study, I wished to confirm that the HMFG2 antibody does 
not bind to MUC1 on these cells.  
To test this, a time-course assay was performed in which non-
transduced primary human T-cells were activated using paramagnetic beads 
coated with CD3 and CD28 antibodies. Serial expression of MUC1 was 
monitored by flow cytometry using the HMFG2 MUC1-specific antibody. 
Expression of CD69 was also investigated in these experiments as a marker 
of T-cell activation379. As expected, Figure 4.1 demonstrates that cell surface 
expression of CD69 became evident as early as three hours post T-cell 
activation, with peak expression at day 3, followed by a progressive decline 
thereafter. Minimal levels of MUC1 were detected on PBMCs prior to T-cell 
activation (indicated as ‘0’ in the graph) and at the early time-points post 
activation (30min, 3h and 1 day). However, cell surface MUC1 expression 
progressively increased subsequently, with peak levels of HMFG2 binding 
found on days 5 to 7 post activation. Thereafter, cell surface MUC1 expression 
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progressively declined. Minimal co-expression of MUC1 and CD69 was 
























































Figure 4.1: Expression of TA-MUC1 on cells prior to and post T-cell activation. PBMCs were 
isolated from healthy volunteers and T-cells were activated with anti-CD3/anti-CD28 beads. 
T-cells were expanded as per usual (IL-2 and R5 medium supplementation every other day).  
Surface expression of MUC1 was investigated in different time-points, prior and post T-cell 
activation. Detection of TA-MUC1 was achieved by flow cytometry using the HMFG2 anti-
MUC1 antibody followed by streptavidin-PE. In parallel, expression of CD69 (blue-triangle 
line) and co-expression of MUC1 and CD69 were investigated. Surface detection of MUC1, 
CD69 and MUC1+CD69+ is presented herein as percentage (%). Two different negative 
controls were used during the flow cytometry analysis for each of the time-points. These 
included cells stained with: 1) mouse IgG1-biotinylated isotype control followed by 
streptavidin-PE and CD69-APC, and 2) HMFG2-biotinylated followed by streptavidin-PE and 
mouse IgG1κ’-ΑPC. A) Represenative results of n=3 are shown herein as dot plots. Each dot 
plot corresponds to a specific time-point as indicated. B) Data shown herein are mean + SEM 
of n=3 independent replicates from different donors; MUC1+ - red-square line; CD69+ - blue-
triangle line; MUC1+ CD69+ – black-dot line.  
4.2.2 Expression of TA-MUC1 on CD4 and CD8 T-cells 
The data presented in section 4.2.1 indicate that TA-MUC1 can be 
detected on PBMC cultures following T-cell activation. To determine if this 
involved CD4+ or CD8+ T-cell subsets, I next investigated the expression of 
MUC1 on these two T-cell populations. This analysis was performed on day 5 
post T-cell activation as it has been shown previously that, at this time-point, 
cell surface MUC1 is detected at maximum levels. Furthermore, a broader 
panel of donors was tested in order to assess the donor dependence of these 
findings. Figure 4.2 shows that MUC1 was expressed at significantly higher 
levels on the surface of activated CD4+ T-cells in comparison with the CD8+ 
cell subset (Figure 4.2). Mean expression of MUC1 on CD4 T-cells was 30% 
while on CD8 T-cells was 18.5%.  
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Figure 4.2: Expression of TA-MUC1 on CD4 and CD8 T-cells. Surface expression of TA-
MUC1 on CD4 and CD8 T-cells was investigated using flow cytometry analysis at day 5 post 
T-cell activation. Detection of MUC1 was achieved by using the HMFG2 biotinylated antibody, 
followed by PE-conjugated streptavidin. T-cells stained with biotinylated mouse IgG1 isotype 
control, followed by streptavidin PE, were used as negative control. As previously mentioned, 
PBMCs were isolated from healthy volunteers and T-cells were activated with anti-CD3/anti-
CD28 coated paramagnetic beads. T-cells were expanded as per usual (IL-2 and R5 
supplementation every other day). Surface expression of MUC1 is presented herein as 
percentage. Data shown are mean + SD of n=7 independent replicates from different donors. 
Statistical analysis was performed with a paired Student’s t-test. 
4.2.3 In vitro expansion of MUC1 re-targeted CAR T-
cells 
Given the fact that HMFG2 binding was found on activated CD4+ and 
CD8+ T-cells, I next characterised the possible effects of recognition of cell 
surface MUC1 on the in vitro expansion of the CAR-engineered T-cells under 
study. As previously described, CAR T-cells were expanded for 10 days post 
retroviral transduction. All three signalling anti-MUC1 CARs were used in 





















   





truncated CAR T-cells and non-transduced T-cells, both of which served as 
negative controls. It needs to be clarified that the non-transduced T-cells were 
treated and expanded in exact same conditions as the transduced T-cell 
populations. The only difference is that during the process of transduction, 
DMEM media was used for mock transduction, instead of viral supernatant. 
Assessment of cell count was performed by trypan exclusion (see section 
2.2.7). Notably, unexpected differences were observed in the cell number of 
the distinct CAR T-cell populations. All three signalling-intact MUC1-specific 
CAR T-cell cultures presented significantly lower total cell numbers when 
compared to non-transduced T-cells or to their matched signalling-defective 
CAR T-cell populations. 
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Figure 4.3: Total T-cell count following in vitro expansion of MUC1 re-targeted CAR T-cells. 
PBMCs were activated with anti-CD3/anti-CD28 beads and were transduced at 48h in order 
to express each of the CAR constructs. CAR T-cells were expanded for 10 days post 
transduction and were then counted using the trypan blue exclusion test. Data shown are 
mean + SD of n=5 independent replicates. Statistical analysis was performed with One-way 
ANOVA, followed by Tukey post hoc test. The asterisks above each data set indicate the 
statistical significance of this data group in comparison with non-transduced activated T-cells 
(where no line is present) or between groups (where a line is present). * à P value 0.01 to 
0.05; ** à P value 0.001 to 0.01; *** à P value 0.0001 to 0.001; **** à P value < 0.0001. 
4.2.4 CAR T-cell enrichment  
If MUC1 expressed on activated T-cells could engage MUC1 CARs, 
this might be expected to stimulate the CAR T-cells during their expansion, 
leading to their enrichment over time. To test this, CAR T-cell transduction 
efficiency was evaluated by flow cytometry on day 5 post transduction (see 
2.2.11.1.2) and was re-evaluated on day 11. All three T-cell populations 
containing signalling-intact MUC1-specific CARs demonstrated a significant 
increase in the percentage of CAR-positive cells present on day 11, in 








































































TAB28z, H28z and HDF28z respectively demonstrated an average 24%, 20% 
and 31% increase in CAR expression over this period. By contrast, none of 
the signalling-defective anti-MUC1 CAR T-cell cultures presented a similar 
pattern of enrichment (Figure 4.4D-F). 
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Figure 4.4: CAR T-cell enrichment during in vitro culture. Cell surface expression of the 
indicated CAR by human T-cells was investigated on day 5 and day 11 post T-cell 
transduction. The detection of CAR molecules on T-cells was evaluated using flow cytometry 
after addition of the MUC1 24mer peptide, followed by strepavidin-PE, as previously 
described in section 2.2.11.1.2. A-C) Signalling intact MUC1-specific CAR T-cells 
demonstrated a significant increase in the percentage of CAR-positive cells between day 5 
and day 11 post T-cell transduction. Data are represented with box plots, showing minimum 
and maximum values, and are derived from n=9 independent replicates in the case of A-C,F 
and n=5 in the case of TABTr and HTr CAR T-cell populations. Statistical analysis was 
performed for each graph with a paired Student’s t-test. * à P value 0.01 to 0.05; ** à P 












































































































































































































4.2.5 Detection of MUC1 with different MUC1-specific 
antibodies 
To establish the generality of these findings, three other anti-MUC1 
antibodies were next used to detect MUC1 expressed on activated T-cells. As 
before, T-cells used herein were non-transduced and were activated with anti-
CD3/anti-CD28 beads. The antibodies included in these experiments are 
HMFG1, SM3 and 5E5287,320,380. HMFG2 was additionally used for comparison 
purposes. Staining of activated T-cells was performed as described in section 
2.2.10.1.5. In summary, different MUC1 levels were detected by each of these 
antibodies. Staining of T-cells with HMFG2 and HMFG1 antibodies showed 
broadly similar MUC1 surface expression, with mean expression levels of 
16% and 13% respectively (Figure 4.5). By contrast, staining with the SM3 
antibody demonstrated the highest levels of MUC1 (60%) while 5E5 showed 
minimal binding to the T-cells (2%).  
 As 5E5 showed no reactivity with MUC1 expressed on T-cells, I sought 
to investigate whether the 5E5 epitope might be suitable for a CAR T-cell-
based immunotherapeutic approach for breast cancer. For this reason, 
detection of MUC1 by the 5E5 antibody was further investigated. In this 
experiment, five different breast cancer cell lines were stained with the 5E5 
antibody and its reactivity was investigated with flow cytometry. The panel of 
breast cancer cell lines consisted of T-47, MDA-MB-468, ZR-75, SKBR3 and 
MCF7. Jurkat cells were additionally included as a positive control. MUC1 was 
detected on these cell lines at various levels, ranging from 0.5% to 50% 
(Figure 4.5B). As shown in the dot plots below, minimal MUC1 expression was 
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detected in the MDA-MB-468, ZR-75 and SKBR3 cell lines. Around 8% of T-
47D cells were stained positively for MUC1 with the 5E5 antibody while MCF7 




Figure 4.5: Detection of MUC1 with different MUC1-specific antibodies. A) The HMFG2, 
HMFG1, SM3 and 5E5 antibodies were used to detect MUC1 on the surface of activated 
human T-cells by flow cytometry (day 12 post T-cell activation). In each case, cells were 
stained with a biotinylated primary antibody followed by streptavidin-PE. Cells stained with 
biotinylated mouse IgG1 followed by streptavidin-PE were used as negative-control. Data 
shown are mean + SEM of n=7 independent replicates. B) The 5E5 antibody was used for 
the detection of MUC1 in a panel of five breast cancer cell lines, using flow cytometry analysis. 
The cells were stained with the biotinylated 5E5 antibody, followed by streptavidin PE. Jurkat 
cells stained in the same way were used as a positive control (known to express high levels 
of Tn – add a reference). Cells stained with biotinylated mouse IgG1 isotype control followed 
by streptavidin PE, were used as negative control. The results from this analysis are 































   











4.2.6 MUC1 expression on MUC1-specific CAR T-cell 
populations 
The data presented above indicate that TA-MUC1 was detected on the 
surface of human, non-transduced activated T-cells. Given these findings, I 
next investigated serial expression of MUC1 post T-cell activation by the CAR 
T-cells under study. This was achieved by staining all six CAR T-cells 
populations (signalling-intact and non-signalling control CARs) with the 
HMFG2 anti-MUC1 antibody. Non-transduced T-cells were also included in 
these experiments. It should be noted that T-cells were transduced to express 
the different CAR molecules on day 2 post activation. 
In general, MUC1 was detected at the highest levels either on day 5 or 
day 7 post T-cell activation, while levels had declined by day 14 (Figure 4.6).  
Surprisingly, different levels of MUC1 were observed on each T-cell 
population, with this difference being most apparent at day 7. At this time-
point, MUC1 expression was observed to be higher in the H28z+ and HTr+ 
CAR T-cells, with mean expression levels of 49% and 31% respectively 
(Figure 4.6). Non-transduced T-cells presented a mean of 24% MUC1 
expression while HDF28z+ and HDFTr+ CAR T-cells showed 10% and 15% 
average expression respectively. Notably, MUC1 was detected at lower levels 
in the TAB28z+ and TABTr+ CAR T-cell populations with 6% and 3% average 
expression respectively (Figure 4.6). While differences were not statistically 
significant, these data confirm that TA-MUC1 could also be detected on these 
CAR T-cell populations. 
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Figure 4.6: MUC1 expression on the indicated MUC1-specific CAR T-cell populations. Cell 
surface expression of MUC1 on the six different CAR T-cell populations was investigated 
using flow cytometry on day 5, day 7 and day 14 post T-cell activation. T-cells were stained 
with biotinylated HMFG2 antibody, followed by streptavidin PE. T-cells stained with 
biotinylated mouse IgG1 isotype control, followed by streptavidin PE, were used as negative 
control. As previously mentioned, PBMCs were isolated from healthy volunteers and T-cells 
were activated with CD3/CD28 beads. T-cells were expanded as per usual (IL-2 and R5 
supplementation every other day) and they were retrovirally transduced to express the CAR 
molecules at day 2 post activation. Data shown are mean + SEM of n=3 independent 
replicates. Statistical analysis was performed with One-way ANOVA, followed by Tukey post 
hoc test. No statistically signifficant differences were observed. 
4.2.7 CD4+ and CD8+ composition of MUC1-retargeted 
CAR T-cells 
The percentage of CD4-positive and CD8-positive T-cells within each 
CAR T-cell population was defined by flow cytometry analysis. This analysis 
demonstrated that the CAR T-cell populations under study consisted of 
broadly similar proportions of CD4+ and CD8+ T-cells (Figure 4.7). None of the 
minor differences observed between populations reached statistical 
significance. In these experiments, non-transduced T-cells were also included 












             














as an additional control. The latter contained a similar proportion of CD4+ and 
CD8+ cells to the CAR T-cell populations mentioned above (Figure 4.7). 
 
Figure 4.7: Proportion of CD4+ and CD8+ T-cells present in MUC1-specific CAR T-cell 
populations. The percentage of CD4+ and CD8+ T-cells in each CAR T-cell population was 
defined using flow cytometry, performed on day 11 post T-cell transduction. For this purpose, 
cells were stained with CD3-FITC and CD8-PECy7 conjugated antibodies. Non-transduced 
T-cells were also included in these assays. The positive and negative populations were 
defined by using fluorescence minus one (FMO) controls. Data shown are mean + SEM of 
n=2-3 independent replicates. Statistical analysis was performed with One-way ANOVA, 
followed by Tukey post hoc test. No statistically significant differences were observed 
between groups.  
4.2.8 Investigation of activation status of MUC1-
specific CAR T-cells 
If MUC1 re-targeted CAR T-cells could engage TA-MUC1 expressed 
on cells within the culture, this would be expected to activate the cells, perhaps 
leading to cell loss via fratricide or activation-induced death, enrichment of 
transduced cells and release of IFN-g. To test if the MUC1 re-targeted CAR 































between the signalling-intact and signalling-defective CAR T-cell populations 
under study. Surface CD69 expression was measured by flow cytometry 
analysis which was performed at two distinct time-points, namely at day 5 and 
at day 11 post T-cell transduction. A similar tendency was observed at both 
time-points, although it was more apparent on day 11 post transduction 
(Figure 4.8). A trend was noted whereby all three MUC1-signalling CAR T-cell 
populations presented higher detectable levels of CD69 in comparison with 
the negative-control T-cell populations, although differences were not 
statistically significant. Additionally, all T-cell populations presented increased 




Figure 4.8: Expression of CD69 by the indicated CAR T-cell populations. Surface expression 
of CD69, a T-cell activation marker, was investigated in all six MUC1-specific CAR T-cell 
populations. Non-transduced T-cells were also included in these experiments for comparison 
purposes. Expression of CD69 was determined using flow cytometry analysis, performed on 
day 5 and day 11 post T-cell transduction. Data shown are mean + SEM of n=7 independent 
replicates for Day 5 post transduction and of n=6 for Day 11 post transduction. Statistical 






























































































4.2.9 Expression of exhaustion markers on MUC1-
specific CAR T-cells 
Constitutive activation of MUC1 CAR T-cells by cell surface MUC1 
would be expected to promote the exhaustion of these cells, owing to tonic 
signalling. To investigate this, I measured the expression of T-cell exhaustion 
markers in the distinct MUC1 re-targeted CAR T-cell populations. Cell surface 
expression of PD-1, TIM-3 and CTLA-4 was investigated in both CD4+ and 
CD8+ subsets in all cases. Non-transduced T-cells were also included in these 
experiments as an additional control. The assay was performed at day 11 post 
T-cell transduction.  
As shown in the bar graph below, all three signalling-intact MUC1 CAR 
T-cells exhibited a trend towards higher expression of PD-1, in comparison 
with their matched-truncated control CAR T-cells (Figure 4.9A-B). This trend 
was more apparent in the CD8+ cell subset (Figure 4.9, B). Similarly, TIM-3 
presented increased surface expression in all three signalling CAR T-cell 
populations, in both CD4+ and CD8+ subsets (Figure 4.9C-D). Additionally, 
MUC1-signalling CARs presented increased expression of CTLA-4, 
nevertheless this was observed only in the CD8+ T-cell subset (Figure 4.9E-
F). As shown herein, all three-signalling MUC1-specific CARs presented 
similar expression levels of exhaustion markers to each other. It should be 
noted that despite the trend of upregulation of exhaustion markers by the three 
signalling CAR T-cells, the study was underpowered thus no strong 
statements can be made. 
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Figure 4.9: Expression of exhaustion markers on CAR T-cell populations. The surface 
expression of PD-1, TIM-3 and CTLA-4 was investigated in CD4+ and CD8+ CAR T-cell 
populations using flow cytometry analysis. The assay was performed at day 11 post T-cell 
transduction. A-B) expression of PD-1 in the six CAR T-cell populations and in non-
transduced T-cells, C-D) expression of TIM-3 in the six CAR T-cell populations and in non-
transduced T-cells, E-F) expression of CTLA-4 in the six CAR T-cell populations and in non-
transduced T-cells. Data shown are mean + SEM of n=3 independent replicates for PD-1 and 
TIM-3 expression analysis and of n=2 independent replicates for CTLA-4. No statistical 
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4.2.10 T-cell differentiation stage of MUC1-specific 
CAR T-cells 
Next, I compared the state of differentiation of the distinct CAR T-cell 
populations, making comparison with signalling defective control CAR T-cells. 
This was investigated at day 11 post T-cell transduction using flow cytometry. 
As previously described (section 2.2.10.1.7), stage of differentiation of both 
CD4+ and CD8+ cell CAR T-cells was defined with the use of CD45RO and 
CCR7 markers.  
 In regard to CD4+ T-cells, all three signalling-intact CAR T-cells 
showed a slightly increased central memory cell population (CCR7+ CD45RO-
) (Figure 4.10). Additionally, a higher percentage of cells with an effector 
memory phenotype (CCR7+ CD45RO+) was observed in the negative control 
cell populations (non-transduced cells and signalling-defective CAR T-cells) 
(Figure 4.10). 
 In regard to CD8+ T-cells, a trend towards a higher percentage of naïve 
cells was observed in the negative control T-cell populations (Figure 4.10). 
Additionally, a trend towards increased numbers of central memory T-cells 
was observed in the CD8+ signalling CAR T-cell populations (Figure 4.10). 





Figure 4.10: State of T-cell differentiation of MUC1 re-targeted CAR T-cells. Differentiation 
status of CD4+ and CD8+ T-cell subsets within the indicated the CAR T-cell populations was 
defined using flow cytometry analysis, performed at day 11 post-transduction. Non-
transduced cells were included in this analysis for comparative purposes. The four distinct 
differentiation stages, naïve, central memory, effector memory and effectors were defined 
with the use of the CD45RO and CCR7 markers and FMO controls. A) differentiation of CD4+ 
T-cells, B) differentiation of CD8+ T-cells. Data shown are mean + SEM of n=2-3 independent 
replicates. Statistical analysis was performed with One-way ANOVA, followed by Tukey post 

























































































CD4 T-cells CD8 T-cellsa) b)BA). B. 
 189 
4.3 Discussion 
Results presented in Chapter 3 indicate that all of the MUC1-specific 
signalling intact CAR T-cells under study in this thesis release IFN-g in the 
absence of co-culture with MUC1-positive tumour cells. This led to the 
hypothesis that MUC1 re-targeted CAR T-cells might recognise MUC1 
expressed on activated T-cells, resulting in their activation during in vitro 
expansion. Herein, I present results that strongly support this hypothesis.  
Based on the above, I sought to investigate if the HMFG2 antibody 
binds MUC1 on activated T-cells. HMFG2 antibody was used in these assays 
since two out of three signalling anti-MUC1 CARs contain an scFv derived 
from the HMFG2 antibody. Furthermore, this antibody has been reported to 
bind preferentially to tumour-associated glycoforms of this mucin288,295. As 
hypothesized previously, HMFG2 binding to the surface of activated T-cells 
was indeed detected, with peak levels observed at day 5 to day 7 post-
activation. MUC1 surface expression on activated T-cells have been 
previously shown in numerous studies, using different MUC1-specific 
antibodies375–378,381. Results published by Agrawal et al. have shown similar 
findings to those presented here, whereby MUC1 surface expression 
decreased over time, upon removal of mitogen. The recognition of MUC1 by 
HMFG2 on T-cells was unpredicted as a previous study by Correa et al. has 
shown lack of binding of this antibody to activated T-cells378. Experimental 
differences, such as method of T-cell activation could potentially explain these 
differences. As shown in Figure 4.1, cell surface MUC1 was absent on resting 
PBMCs. The latter supports the results of three other studies, in which MUC1 
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was not detected on resting T-cells377,378,381. A study by Chang et al. has 
shown expression of MUC1 on resting T-cells, nevertheless this was not 
validated neither by my results or by the results of the studies mentioned 
previously376. 
To track the expression of MUC1 with T-cell activation status, 
expression of CD69 was quantified. As described in section 4.2.1, MUC1 was 
detected later on following T-cell activation than was the case with CD69. This 
finding is in agreement with results published by Agrawal et al. and by Correa 
et al. as both groups have reported that MUC1 appeared in the surface of 
activated T-cells later than CD69 or CD25375,378. Agrawal et al. have also 
shown co-expression of MUC1 and T-cell activation markers (CD69 and 
CD25), with the percentage of co-expression being higher in the later stages 
post T-cell activation375. This does not agree with my results, whereby minimal 
co-expression of MUC1 and CD69 was observed. These divergent findings 
could be attributed to the use of different methods to achieve T-cell activation, 
use of the different antibodies to detect MUC1 on T-cells or other differences 
in culture conditions. Agrawal et al. used phytohemagglutinin (PHA)-activated 
T-cells and cultured the cells in the continued presence of PHA375. By contrast, 
in my experiments I activated T-cells with anti-CD3 and anti-CD28 coated 
beads and supplemented the media with IL-2 every other day. It would be 
interesting to explore further if different stimuli used to achieve T-cell activation 
could potentially affect MUC1 expression levels and the co-expression of this 
mucin with other T-cell activation markers. 
The effect of this background MUC1 recognition on T-cells on MUC1-
specific CAR T-cells was further documented. All three signalling-intact 
 191 
MUC1-specific CAR T-cell populations achieved a significantly lower total cell 
count after 10-days of expansion, in comparison with the untransduced or 
endodomain truncated control CAR T-cell populations. A possible explanation 
for this is that the CAR T-cells recognise MUC1 expressed on neighbouring 
T-cells, leading to elimination of these T-cells by fratricide. Others have 
observed reduced expansion of some CAR T-cell populations; nevertheless 
this was attributed to tonic signalling and T-cell exhaustion as no expression 
of the targeted-antigen was observed on T-cells241. Another study reported 
increased proliferation of continuously activated CAR T-cells361. Nonetheless, 
this was observed when T-cells were expanded in the absence of cytokines361. 
Consequently, it would be interesting to conduct a similar experiment in which 
expansion of MUC1-specific signalling intact and control CAR T-cells is 
compared in the absence of IL-2 support. Another explanation for the reduced 
cell count of the signalling MUC1-specific CAR T-cells could be that they 
underwent apoptosis due to activation-induced cell death (AICD). Under 
normal condition, T-cells might undergo AICD upon antigen encounter which 
leads to T-cell apoptosis via the Fas-FasL signalling pathway382. This 
phenomenon has also been documented in CAR T-cell studies. Künkele et al. 
have reported that CAR components can make the CAR T-cells more 
susceptible to FasL-mediated AICD upon prolonged antigen exposure383. A 
similar observation was made by Gargett and colleagues who reported that 
repeated antigen stimulation induced AICD to GD-2 CAR T-cells384.  
Another observation that supported the hypothesis that MUC1 CARs 
signal tonically due to target recognition on T-cells is the fact that MUC1-
signalling intact CAR T-cells underwent enrichment during their expansion. 
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Importantly, T-cells engineered to express all three signalling-defective CARs 
did not present this pattern. A similar observation has been reported by 
Frigault et al., whereby continuously activated CAR T-cells demonstrated 
enrichment during their ex vivo expansion361.  
An important question is whether the MUC1 detected on T-cells is 
decorated with core-1 (tumour-associated) or core-2 (normal) glycans. To 
explore this, I investigated MUC1 expression on T-cells using three other 
MUC1-specific antibodies (HMFG1, SM3, 5E5). Each of these antibodies has 
different reactivity with the various forms of MUC1 found in normal and tumour 
cells. SM3 specifically recognises tumour-associated glycoforms with little to 
no reaction to benign tumour cells or non-malignant cells320. HMFG1 and 
HMFG2 both react very strongly with tumour-associated MUC1316. 
Nevertheless, they have shown some reactivity with normal lactating breast, 
with HMFG1 showing stronger recognition of these tissues288,317,320.  
Notably, as shown in Figure 4.5, SM3 presented the strongest reactivity 
with T-cell-associated MUC1. This result supports the findings of Agrawal et 
al. where they have reported 54% binding of SM3 to MUC1 on activated T-
cells375. This would suggest that MUC1 detected on T-cells is mainly 
decorated with “tumour-associated” glycans. Nevertheless, this does not 
agree with Correa et al. who reported an absence of binding by the SM3 
antibody to activated or resting T-cells378. They suggested that MUC1 
expressed on activated T-cells is decorated with core-2 and not core-1 
glycans, indicated by the lack of binding of both SM3 and HMFG2 to MUC1 in 
their experiments378. The time-point at which the flow-cytometry assay is 
performed may be crucial in this regard and could potentially explain the 
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differences in results obtained in both of these studies. Correa et al. have 
shown that HMFG2 and SM3 antibodies did not recognise MUC1 on T-cells. 
Nevertheless, they do not specify in which time-point post activation the flow-
cytometry analysis was performed378. As indicated by the results shown in 
Figure 4.1, timing is important as MUC1 was undetectable by HMFG2 in the 
early time-points post activation. Another explanation could be, as mentioned 
previously, use of different protocols to culture and activate T-cells in both 
studies. Further research needs be conducted in order to understand the 
glycosylation pattern of MUC1 expressed on T-cells and to investigate if the 
method of activation has any role in influencing this process.  
Another interesting observation is that the 5E5 antibody showed 
minimal detection of MUC1 on T-cells. It is known that the 5E5 antibody 
recognises specifically the MUC1-Tn/STn glycoforms380,385. Posey et al. have 
recently generated a MUC1-specific CAR T-cell immunotherapy approach, 
where they have an engineered a CAR based on the 5E5 antibody337. In this 
approach, this MUC1-specific CAR has been used to target leukaemic and 
pancreatic tumours overexpressing MUC1-Tn337.  
As 5E5 did not show any reactivity with MUC1 expressed on T-cells, 
one could suggest that the approach developed by Posey et al. is 
advantageous. Based on this, I sought to investigate the potential of 
developing a 5E5-based CAR to target MUC1-positive breast cancer.  Thus, 
I investigated the detection of MUC1 by the 5E5 antibody in various breast 
cancer cell lines. As shown in Figure 4.5, 5E5 did not show reactivity with the 
majority of breast cancer cell lines used in this assay, with the exception of T-
47D, where minimal binding was observed and MCF7 with moderate binding 
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levels. Others have reported low surface expression of the MUC1 Tn/STn 
glycoforms in these two breast cancer cell lines385. The latter suggests that a 
5E5-based immunotherapeutic approach for the treatment of breast cancer 
might not be broadly beneficial. Additionally, it highlights the challenge in CAR 
T-cell immunotherapy in finding the right balance between targeting a widely-
expressed antigen and limiting the risk of on-target off-tumour toxicities. 
Having demonstrated that “tumour associated” glycoforms of MUC1 
are also found on activated T-cells, I explored the MUC1 expression levels on 
the different CAR T-cell populations. I hypothesized that lower MUC1 levels 
would be detected on the signalling intact CAR T-cell populations due to 
depletion of the MUC1-positive cells. Nevertheless, this was not confirmed in 
my study. An unexpected observation was that CAR T-cells engineered to 
express H28z exhibited higher levels of MUC1 in comparison with non-
transduced T-cells. This higher expression did not seem to be dependent on 
the signalling activity of the CAR as HTr also presented increased MUC1 
expression. Interestingly, the TAB004-transduced CAR T-cells demonstrated 
the lowest MUC1 surface expression. One explanation could be the different 
percentage of CD4 and CD8 subsets within each T-cell population examined 
herein. As previously indicated, CD4+ T-cells tend to present higher levels of 
MUC1 when compared to the CD8+ cell subset. Thus, a higher percentage of 
CD4+ T-cells within the high MUC1-expressing cell populations could be an 
explanation for this result. This possibility was refuted by the results shown in 
Figure 4.7, as non-significant differences were observed in the percentage of 
CD4+ and CD8+ T-cells found in these populations. Further experiments need 
to be conducted in order to understand the differences in MUC1 levels 
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between the CAR T-cell populations under study. Published results suggest 
that MUC1 expression is strongly correlated with cell proliferation rate and 
mitotic division381. Thus, a labelling experiment using a dye such as 
carboxyfluorescein succinimidyl ester (CFSE) could be performed in order to 
explore if they are any differences in the proliferation rate of the distinct CAR 
T-cell populations. 
It was also important to characterise the effect of prolonged recognition 
of MUC1 upon the anti-MUC1 re-targeted CAR T-cells. A trend towards 
increased T-cell activation was observed in all three signalling-intact CAR T-
cell population, as indicated by the increased surface expression of CD69. 
This was expected and fits with the hypothesis described above, since 
continued recognition of MUC1 by the CAR T-cells could potentially sustain 
their activation. These results are in agreement with those of Frigault et al. 
and Long et al. who both reported that constitutive CAR signalling resulted in 
increased T-cell activation241,361. 
It is known that prolonged T-cell activation can result in T-cell 
exhaustion. For this reason, expression of three exhaustion markers, PD-1, 
TIM-3 and CTLA-4 was also investigated in all CAR T-cell populations, 
hypothesizing that the signalling-CARs would present increased levels. 
Indeed, a trend towards further upregulation of exhaustion markers was 
observed in all three signalling-intact CAR T-cell populations. Long et al. have 
published similar results whereby tonic CAR signalling led to T-cell 
exhaustion241. 
Lastly, I sought to characterise the differentiation stage of signalling 
intact MUC1 specific CAR T-cells. I hypothesized that prolonged MUC1 
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recognition could potentially lead to terminal differentiation of the MUC1-
signalling CARs361. Surprisingly, a trend was observed where signalling CAR 
T-cells presented an increased central memory phenotype in comparison with 
their matched truncated controls. Nevertheless, no strong statements can be 
made due to lack of statistical significance of the data. More experimental 
repeats need to be performed in order to explore if the same trend is observed 
in a larger number of donors. 
As shown previously, MUC1 expression on activated T-cells could 
significantly hinder T-cell expansion. Additionally, signalling-intact MUC1-
specific CAR T-cells presented a trend of increased T-cell activation and up-
regulation of exhaustion markers. A potential way to overcome these issues 
would be to isolate and transduce only MUC1-negative T-cell subsets. For this 
reason, it was of crucial importance to explore if MUC1 is expressed 
selectively in either CD4 or CD8 T-cell subsets. The results presented here 
indicate that MUC1 is upregulated on both activated CD4+ and CD8+ T-cells, 
with higher expression levels on the CD4+ subset. Thus, this strategy could 
not be used in order to limit the consequences of background MUC1 
recognition. My results are in agreement with Agrawal et al., who have 
reported higher MUC1 expression on CD4-positive PHA activated T-cells in 
comparison with CD8-positive cells377. However, these findings do not agree 
with the results of Correa et al., who reported absence of reactivity with the 
HMFG2 antibody and similar levels of MUC1 expression on both CD4+ and 
CD8+ T-cells. Nevertheless, is impossible to comment further on the latter 




Different observations have led to the hypothesis that the MUC1-
signalling CARs used herein recognise MUC1 expressed on T-cells. These 
observations include the i) production of IFN-γ by signalling-intact CAR T-cells 
in the absence of exposure to MUC1-positive tumour cells, ii) reduced cell 
expansion of signalling-intact CAR T-cells and iii) enrichment of MUC1 re-
targeted CAR T-cells (but not T-cells containing matched control CARs) 
during in vitro expansion. Upon investigation, it was shown that HMFG2 bound 
to MUC1 expressed on activated T-cells. This result was unpredicted as 
previous studies have shown that the MUC1 found on T-cells carries 
predominantly “normal” extended glycan forms, which are not recognised by 
HMFG2.  
The consequences of this finding for the behaviour of CAR T-cells was 
further investigated. As discussed previously, signalling intact CAR T-cells 
presented a trend towards a more activated and exhausted phenotype. 
Despite these observations, MUC1-specific CAR T-cells demonstrated 
significant cytotoxic activity against MUC1-positive breast cancer cell lines, as 
shown in chapter 2. Thus, I sought to explore further their activity in vivo. 
These results are presented in the next chapter (Chapter 5). 
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Chapter 5: In vivo efficacy of MUC1-




5.1.1 Assessment of efficacy and safety of CAR T-
cells in pre-clinical models 
Adoptive cell therapy is rapidly moving from bench to bed-side. In light 
of this, use of pre-clinical mouse models that recapitulate human malignancies 
is mandatory prior to the transition of a therapeutic strategy into the clinic.  
One widely used mouse model for the pre-clinical assessment of 
efficacy and safety of CAR T-cell immunotherapy entails tumour xenograft 
implantation into immunodeficient mice. These models are often orthotopic, 
whereby immortalised human tumour cells are injected into the relevant 
anatomic side. An essential requirement for tolerance of cells of human origin 
(either CAR T-cells or tumour cells) is that the mice need to be 
immunodeficient. A number of commonly used immunocompromised mouse 
strains are athymic nude, NOD/SCID and SCID/Beige296,386–391. Nevertheless, 
residual mouse immune compartments in these models can potentially hinder 
the engraftment of human T-cells. In recent studies, NSG mice have 
increasingly been used for the assessment of in vivo efficacy of CAR T-
cells337,392,393. This mouse strain is advantageous due to the presentation of 
extreme immunodeficiency, thus allowing for optimal T-cell engraftment327. In 
general, xenograft mouse models have predicted accurately the efficacy of 
some CAR T-cell approaches278,394. Nevertheless, due to absence of innate 
immune system-therapy interaction, they cannot often predict different type of 
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toxicities related to CAR T-cell therapy, such as cytokine release 
syndrome211,395. 
Another type of mouse model often used by investigators involves the 
administration of murine CAR T-cells, specific for the mouse homologue of a 
human antigen, into mice with an intact immune system. In this model, murine 
T-cells are transduced with a CAR construct which has been engineered using 
murine compartments. The latter minimises the immunogenicity of the CAR 
T-cells and provides the benefit of being able to better predict toxicities related 
to either cytokine release syndrome or on-target off-tumour 
reactivity278,394,396,397. Nevertheless, there are two essential parameters 
required for the use of this model. First, the human and murine proteins must 
have very high homology. Second, a similar expression pattern should be 
observed between the mouse and human homologues398. 
5.1.2 In vivo breast cancer models for evaluation of 
CAR T-cell immunotherapy 
Various studies have evaluated the efficacy of CAR T-cells in breast 
cancer animal models. Xenograft mouse models are commonly used for this 
purpose. In these studies, different human breast cancer cell lines have been 
inoculated either subcutaneously or into the peritoneal cavity of 
immunocompromised mice. Tumour progression has been evaluated with 
either caliper measurements or bio-luminescence imaging (BLI), depending 
on the site of tumour injection. The route of administration of CAR T-cells 
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varies depending on the model, with the intravenous and intraperitoneal 
routes most commonly used.  
Subcutaneous injection of breast cancer cells in the flank of mice is 
widely used to investigate the effect of novel therapies due to its simplicity. At 
least three studies investigating the efficacy of CAR T-cells have reported the 
use of immortalised breast cancer cell lines injected subcutaneously in 
immunocompromised mice399–401. The efficacy of folate receptor-alpha (FRα)-
specific CAR T-cells was assessed in NSG mice established with MDA-MB-
231 subcutaneous tumours399. In this study, CAR T-cells were injected 
intravenously and tumour growth was monitored with both caliper and BLI, as 
the tumour cells were engineered to express firefly luciferase399. In a similar 
manner, in vivo assessment of a HER-2-specifc second generation CAR was 
performed in NOD/SCID mice inoculated subcutaneously with SKBR3 tumour 
cells400. Other cell lines used in a similar manner include MDA-MB-453 and 
HCC1954401. 
Three other studies have reported the use of xenograft models where 
immortalised human breast cancer cells have been injected in the intra-
peritoneal cavity of immunodeficient mice269,295,296.  In all instances, CAR T-
cells were administered locally in the peritoneal cavity. For example, Whilding 
et. al used a xenograft model for the assessment of efficacy of a CAR specific 
for αvβ6 integrin296. For this purpose, MDA-MB-468 cells were injected into 
the peritoneal cavity of NSG mice. 
Xenograft breast cancer models, where tumour cells are engrafted 
subcutaneously or in the peritoneal cavity, provide a non-invasive, quick and 
convenient method for the evaluation of response to treatment402. Others have 
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used immunodeficient mice to orthotopically inject breast cancer cells in the 
mammary fat pad. The latter provides the advantage of more closely 
recapitulating the human disease in mice. Nevertheless, this usually requires 
mammary fat pad clearance through surgery, a fact that makes this method 
impractical. Only one study has reported the use of this method for the 
evaluation of CAR T-cell activity, where the investigators implanted MDA-MB-
231 cells in the mammary fat pad401.  
5.1.3 Aim  
Previous results presented in Chapter 2 have indicated significant in 
vitro cytotoxic activity of TAB28z CAR T-cells against MUC1-expressing 
breast cancer cell lines. This was observed despite the continuous activation 
of CAR T-cells due to recognition of MUC1 expressed on the surface of 
activated T-cells.  
In this chapter, I present results related to the in vivo assessment of 
activity of TAB28z CAR T-cells. In parallel, its activity was compared with 
H28z and HDF28z-engineered CAR T-cells in order to investigate if this CAR 
performs in a superior manner. In detail, the data presented herein include the 
i) generation of firefly-luciferase –positive breast cancer cell lines to allow for 
bio-luminescence monitoring of tumour growth, ii) establishment of xenograft 
breast cancer mouse models, iii) in vivo evaluation of anti-tumour activity of 




5.2.1 Engineering of firefly luciferase-expressing 
breast cancer cells 
A robust way of monitoring tumour growth in mouse models entails the 
use of bio-luminescence imaging. The initial step undertaken, prior to 
designing a pilot study for the establishment of a xenograft model, was to 
generate firefly luciferase (ffluc)-expressing breast cancer cells. For this 
purpose, T-47D and MDA-MB-468 tumour cells were transduced with an SFG 
retroviral vector (Figure 5.1A, Figure 2.7) in which tandem dimer (td)Tomato 
(a red fluorescent protein), was co-expressed with ffluc. The presence of 
tdTomato allows easy assessment of transduction efficiency and flow sorting 
of cells where required. Both T-47D and MDA-MB-468 cell lines were highly 
transduced (>76%), as evaluated by detecting tdTomato with flow cytometry 
(Figure 5.1C). Furthermore, a luciferase assay was performed in order to 
validate ffluc expression by these cells. In this assay, different cell dilutions 
were used in order to define the range of detectable levels of 
bioluminescence. As depicted in Figure 5.1B, luminescence was detected in 
both cell lines upon addition of D-luciferin, with the lowest detectable levels 
produced by 104 cells. Surface expression of MUC1 was additionally validated 
in both cell lines post-transduction with ffluc_tdTomato (Figure 5.1 D).  
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Figure 5.1: Generation of firefly luciferase-expressing breast cancer cells. T-47D and MDA-
MB-468 cells were retrovirally transduced to express ffluc_tdTomato. A) Schematic illustration 
of ffluc_tdTomato retroviral construct. An SFG retroviral vector carrying the ffluc and tdTomato 
has been used for the expression of the two proteins in breast cancer cells. B) Expression of 
ffluc in breast cancer cells was validated with luciferase assay. 1x106 cells were serially 
diluted 10-fold and 150μg/ml D-luciferin was added to each well. D10 medium alone was used 
as negative control. Emitted luminescence was measured with a FLUOstar Omega plate 
reader. Data shown are mean + SD of n=3 independent replicates. C) Transduction efficiency 
of ffluc_tdTomato was evaluated using flow cytometry, by detecting the tdTomato protein (red 
histogram). Parental (non-transduced) cells were used as negative control (blue histograms). 
The histograms overlays are representative of n=5 independent replicates. D) Surface MUC1 
expression was evaluated with flow cytometry, using the biotinylated HMFG2 antibody, 
followed by streptavidin-APC (red histograms). Cells stained with biotinylated IgG1, followed 
by streptavidin-APC, were used as isotype control (blue histograms). The histograms overlays 
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5.2.2 Pilot study for establishing a breast cancer 
xenograft model. Site of injection: subcutaneous 
In order to establish a breast cancer xenograft model, a pilot study was 
performed where T-47D_ffluc and MDA-MB-468_ffluc cells were injected 
subcutaneously in the vicinity of mammary fat pad. In this study, individual 
female NSG were inoculated with different cell doses in order to evaluate 
which cell number is required for optimal tumour growth (Figure 5.2). Each 
cell-dose group included four mice. The cell doses of T-47D_ffluc investigated 
herein were 5x106, 2x106 and 0.5x106 while doses of MDA-MB-468_ffluc were 
2x106, 0.5x106 and 0.1x106 cells. Tumour growth was monitored with BLI 
imaging and expression of ffluc by tumour cells was validated once again prior 
to initiation of the study. 
Mice injected with T-47D_ffluc cells presented a progressive decrease 
in BLI signal over time (Figure 5.2C). Nevertheless, this did not correspond to 
tumour volume as tumours were observed to grow over time by caliper 
measurement (Figure 5.2A). All mice injected with T-47D_ffluc cells had to be 
euthanized at three weeks post injection due to tumour ulceration. All three 
cell doses presented a similar growth pattern without differences in the levels 
of detectable BLI signal.  
Inconsistencies were observed in the BLI signal derived from mice 
injected with MDA-MB-468_ffluc cells. Increase in bioluminescence was 
observed in mice injected with 0.1x106 cells after day 21 while decrease of 
detected signal was observed in mice injected with 2x106 cells after day 21 
(Figure 5.2D). Unstable bioluminescence pattern was observed in mice  
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Figure 5.2: Establishment of breast cancer xenograft mouse model (subcutaneous flank 
injection). Female NSG mice were injected subcutaneously with either T-47D_ffluc or MDA-
MB-468_ffluc tumour cells. T-47D cells were injected with 5x106 (blue), 2x106 (red) and 
0.5x106 cells (black). MDA-MB-468 cells were injected with  2x106 (blue), 0.5x106 (red) and 
0.1x106 cells (black). Tumour cells were injected together with matrigel. The tumour growth 
was monitored weekly by using both caliper measurements and BLI. A-B) Tumour volume as 
measured with the use calipers. C-D) Bioluminesce recorded with BLI. Data shown are mean 
± SD (n=4 mice per group). 
injected with 0.1x106 (Figure 5.2D). Additionally, these mice developed 
ulcerating tumours (data not shown). The study was terminated five weeks 
post injection due to un-related issues present in the animal facility. 
 




























































































5.2.3 Pilot study for establishing a breast cancer 
xenograft model. Site of injection: peritoneal cavity 
As the models described in sections 5.2.2 proved unsatisfactory, I next 
sought to establish a xenograft model where the breast cancer cells would be 
injected in the peritoneal cavity. Both ffluc-positive T-47D and MDA-MB-468 
cells were used in this pilot experiment. Similar to the previous study, different 
cell doses were used in each mouse group. For T-47D, cell doses investigated 
were 10x106, 5x106, 2x106 and 0.5x106 cells. In the case of MDA-MB-468, 
mice received 5x106, 2x106 and 0.5x106 cells. Tumour growth was monitored 
with BLI imaging until day 62 where the experiment terminated. Expression of 
ffluc_tdTomato in each cell line was again validated prior to the initiation of 
the study (data not shown). 
Mice inoculated with T-47D_ffluc presented no increase in BLI signal 
over-time (Figure 5.3A). This was observed with all four cell doses. Mice in 
the three groups which received the highest tumour cell doses showed a slight 
decrease in the detectable levels of luminescence until day 21, after which 
signal appeared to plateau. Upon termination of the experiment, few mice of 
each cell-dose group were dissected and no palpable tumour nodules were 
observed within the peritoneal cavity, suggesting that the tumour cells were 
dispersed (data not shown).  
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Figure 5.3: Establishment of breast cancer xenograft mouse model (site of injection peritoneal 
cavity). Groups of three female NSG mice were injected in the peritoneal cavity with the 
indicated doses of (A) T-47D_ffluc and (B) MDA-MB-468_ffluc tumour cells. Tumour growth 
was monitored approximately weekly with BLI imaging, upon injection of D-luciferin. Data 
shown are mean ± SD (n=3). 
By contrast, mice inoculated with MDA-MB-468_ffluc cells presented 
progressive tumour growth, as indicated by an increasing BLI signal (Figure 
5.3B). All three doses presented a similar tumour growth pattern. The study 
was terminated at day 49 as the mice presented distress symptoms, probably 

















































due to high tumour burden. Upon termination, mice from each cell-dose group 
were dissected and large palpable tumours were observed in the site of cell 
injection or in the peritoneal cavity. Mice from both 2x106 and 5x106 cell-dose 
groups appeared to have additional tumour nodules throughout the peritoneal 
cavity, although these were more apparent in mice that had received the 
higher tumour cell inoculum.  
5.2.4 Assessment of in vivo activity of MUC1-specific 
CAR T-cells in MDA-MB-468 xenograft model 
Assessment of the in vivo efficacy of TAB28z, H28z and HDF28z 
MUC1-specific CAR T-cells was investigated in NSG mice with established 
MDA-MB-468_ffluc peritoneal tumours. The experimental design of the study 
is depicted in Figure 5.4. Tumour growth was monitored regularly with BLI 
imaging. In parallel, weight measurements were acquired to monitor for 
toxicity. 
 
Figure 5.4: Experimental design of therapeutic study using MDA-MB-468 xenograft model.  
Thirty female NSG mice were inoculated i.p. with 2x106 MDA-MB-
468_ffluc cells. In parallel, PBMCs from a healthy donor were isolated, 




















retroviral transduction to express either TAB28z, H28z and HDF28z CAR 
molecules. Tumour engraftment was evaluated at day 26, prior to the infusion 
of CAR T-cells, and mice were then assigned into groups with similar average 
bioluminescence. Non-transduced cells were included in the experimental 
study as an indicator of non-specific anti-tumour activity. Additionally, some 
mice were treated with PBS in order to be able to evaluate tumour progression 
without any therapeutic intervention. T-cells were expanded for 12 days, 
assessed for transduction efficiency (Figure 5.5) and injected into the 
peritoneal cavity. Each group included six mice. CAR T-cells were injected at 
a dose of 8x106 CAR-positive cells (corrected for transduction efficiency). The 
injected dose of non-transduced T-cells was equal to the highest number of 
total CAR T-cells given.  
 
Figure 5.5: Transduction efficiency of CAR T-cells infused in the mice with established MDA-
MB-468_ffluc tumours. Histograms show cell expression of the TAB28z, H28z and HDF28-
CARs in tranduced T-cells. This was investigated with flow cytometry analysis, performed 
prior to CAR T-cell infusion. In order to evaluate the CAR surface expression, T-cells were 
stained with biotinylated MUC1-24mer peptide, followed by streptavidin PE (red histograms). 






Disappointingly, none of the CAR T-cell populations elicited significant 
tumour reduction ( 
A). A hint of anti-tumour activity was observed in animal 2 (A2) treated 
with TAB28z and in animals 1 (A1) and 2 (A2) treated with HDF28z ( 
B). Nevertheless, this effect was not followed further as the experiment 
had to be terminated due to mice presenting distress symptoms. Based upon 
post-mortem examination, this appeared to be related to high tumour burden 
(data not shown).  
Body weight of each individual mouse was also monitored throughout 
the study, as indicated above. Weight either progressively increased or 

























































































































































Figure 5.6: In vivo assessment of MUC1-specific CAR T-cells in MDA-MB-468 xenograft model. Female NSG mice were injected i.p. with 2x106 MDA-MB-468 
cells. Tumour growth was evaluated regularly with BLI imaging and quantified as total flux (photons/second). On day 26, indicated mice received either 8x106–
positive CAR T-cells, non-transduced T-cells or PBS, all administered i.p.  A) Mean + SD of BLI signal prior to and post treatment (n=6 mice per group). B-C) 






Figure 5.7: Weight measurements of mice used in the therapeutic study shown in Figure 5.6. 
A) Mean + SD body weight of all five mice groups (n=6 mice per group). B) Body weight of 
individual mice. Each graph represents a treament group. A1 to A6 – animal 1 to animal 6. 





















































































































observed in CAR T-cell treated mice. A few mice presented minimal weight 
decrease post-treatment, a point that could have been attributable to high 
tumour burden. 
5.2.5 Assessment of in vivo activity of MUC1-specific 
CAR T-cells in T-47D xenograft model 
Next, I sought to investigate the in vivo activity of MUC1-specific CAR 
T-cells in a less aggressive tumour model. The experimental design of the 
study is shown in Figure 5.8.  
 
Figure 5.8: Experimental design of therapeutic study using T-47D xenograft model. 
In brief, NSG mice were inoculated i.p with 0.5x106 T-47D_ffluc cells. 
PBMCs were harvested from a healthy volunteer, were activated with PHA 
and were subjected to retroviral transduction. As previously described in 
section 5.2.4, five groups of mice were treated with T-cells that had been 
engineered to express TAB28z, H28z or the HDF28z CAR, making 
comparison with control groups that received non-transduced T-cells or PBS. 
On day 18 post tumour cell injection, mice were assigned into groups with 
similar average tumour-derived bioluminescence and were treated i.p with 























animals received PBS to indicate tumour growth without the presence of any 
therapeutic intervention. In addition, non-transduced T-cells were infused at a 
number equal to the highest total T-cell dose injected in the CAR T-cell 
groups.  
Transduction efficiency of CAR T-cells was investigated on the day 
prior to T-cell infusion. Based on these data, 12x106 CAR-expressing T-cells 
were infused in each group. As shown in Figure 5.9, all three CAR T-cell 
populations presented similar CAR surface expression. 
 
Figure 5.9: Transduction efficiency of CAR T-cells infused in mice with established T-
47D_ffluc tumours. CAR surface expression was investigated using flow cytometry, 
performed on the day prior to CAR T-cell administration. T-cells were stained with biotinylated 
MUC1-24mer peptide, followed by streptavidin PE (red histograms), making comparison with 
non-transduced T-cells as negative control (blue histograms). Histograms depict transduction 
efficiency of TAB28z, H28z and HDF28 CAR T-cell populations.  
No significant tumour response was observed in the TAB28z, H28z and 
HDF28z treatment groups (A). Nevertheless, data obtained from individual 
mice suggested that tumour regression had occurred in some cases (B). 
Notably, A6 treated with TAB28z CAR T-cells, A3 with H28z and A1, A2 and 
A6 treated with HDF28z presented prolonged response to treatment until day 




once again in most of the responding mice. No similar pattern was observed 
in any of the mice treated with non-transduced cells or with PBS, indicating 
that response was probably due to the activity of CAR T-cells. Animal 6 (A6) 
treated with non-transduced T-cells presented a decrease in BLI signal at day 
40, nevertheless this could be attributed to technical fault during BLI imaging. 
Animal 1 (A1) treated with HDF28z CAR T-cells had to be culled at day 31 
due to unrelated health issues (suspected ear infection). 
Body weight of mice increased or stabilised over-time, indicating 
























































































































































Figure 5.10: Assessment of in vivo efficacy of MUC1-specific CAR T-cells in T-47D xenograft model. Female NSG mice were inoculated i.p. with 0.5x106 T-
47D_ffluc tumour cells. Tumour growth was monitored regularly with BLI imaging. On day 18 post-tumour cell injection, 12x106 CAR-positive T-cells were 
infused i.p. Additionally, mice injected with non-transduced cells and with PBS were used as controls. A) Tumour growth was evaluated regularly with BLI 
imaging, and quantified as total flux (photons/second). The graph depicts the mean ± SD of bioluminescence emission (n=6 mice per T-cell group and n=4 for 





Figure 5.11: Weight measurements of mice used in the therapeutic study shown in Figure 
5.10. A) Mean ± SD of body weight of treatment groups (n=6 mice per T-cell treatment group 
and n=4 for the PBS group). B) Body weight of individual mice. Each graph represents a 
treament group. A1 to A6 – animal 1 to animal 6. 
A)
B)


















































































































5.2.6 Persistence of MUC1 specific CAR T-cells in 
vivo 
As shown in , anti-tumour efficacy of MUC1-specific CAR T-cells was 
inadequate. For this reason, I sought to investigate if infused T-cells were still 
present in vivo, 22 days after their infusion. Upon termination of the study, 
samples of peritoneal fluid and spleen were randomly collected from two mice 
in each intervention group (TAB28z, H28z, HDF28z, non-transduced T-cells). 
Additionally, samples from one mouse injected with PBS were collected as 
negative controls. It should be mentioned that although peritoneal fluid was 
collected from two mice treated with HDF28z CAR T-cells, one sample had to 
be excluded from further analysis due to technical issues. Detection of viable 
cells was performed with flow cytometry. 
Viable human T-cells were detected in most of the peritoneal lavage 
samples collected, ranging from 0.35% to 69% (Figure 5.12B). Notably, viable 
T-cells were also observed in both samples acquired from mice treated with 
non-transduced T-cells. This suggests that persistence could be related to the 
immune compromised nature of the host and/or alloreactivity, rather than an 
anti-MUC1 CAR T-cell response. Additionally, persistence did not seem to be 
an indicator of tumour response (Table 5.1). For example, no decrease in 
tumour burden was observed in mice treated with non-transduced T-cells. 
Nevertheless, a higher percentage of viable T-cells was detected in these two 
samples in comparison with a sample acquired from a mouse treated with 
HDF28z.  
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Table 5.1: Response to treatment and detection of viable human T-cell in peritoneal fluid. In 
this table are listed i) the treatment group from which each peritoneal fluid was collected, ii) 
the percentage (%) of viable human T-cells detected and iii) response to treatment. 
Intervention Animal Response 




T-cells A1 No response 36.5 
Non-transduced 
T-cells A2 No response 25.8 
TAB28z A1 Initial response 2.09 













Minimal numbers of viable T-cells were detected in any of the processed 
spleens (Figure 5.12C). The only exception is A2 treated with TAB28z CAR 




































Figure 5.12: Persistence of MUC1 re-targeted T-cells in vivo. The presence of viable human 
T-cells was investigated in the peritoneal fluid and in spleen acquired from mice of each 
intervention group, upon termination of the study indicated in Figure 5.10. This was 
investigated by flow cytometry analysis using the 7-AAD viability dye and human anti-CD3 
FITC antibody. A) γδ T-cells were used, for convenience, as positive and negative staining 
controls. In particular, γδ Τ-cells were stained with either 7-AAD and anti-CD3 FITC (positive 
control) or with 7-AAD and IgG1-FITC (isotype) (negative control). B) Dot plots showing the 
percentage (%) of viable human T-cells detected in each peritoneal fluid sample. Two 
samples per intervention group were acquired, with the exceptions of PBS and HDF28z where 
only one sample has been analysed. C) Dot plots represent the percentage (%) of viable 
human T-cells detected in each spleen sample. Two samples per intervention group were 




In this chapter, I present results related to the evaluation of the in vivo 
efficacy of MUC1-specific CAR T-cells. Two different breast cancer xenograft 
models were used for this purpose; the MDA-MB-468 and T-47D mouse 
model in which the tumour cells have been inoculated i.p. 
Prior to the initiation of the study, I decided to establish a breast cancer 
xenograft model where assessment of tumour growth and response to 
treatment could be performed with BLI imaging. This imaging system provides 
a quantitative, objective, non-invasive and high throughput method for 
monitoring tumour growth403. Additionally, it can detect microscopic tumours 
with accuracy and high sensitivity, even before the tumours are palpable using 
caliper measurements404,405. Bioluminescence imaging requires the 
expression of a luciferase reporter gene in the cells under investigation, in 
order to achieve light emission upon interaction with its substrate. For this 
purpose, T-47D and MDA-MB-468 cells were engineered to express firefly 
luciferase. These two breast cancer cell lines were selected as MUC1 was 
detected at high levels on the cell surface.  
Breast cancer subcutaneous models are being extensively used for the 
evaluation of efficacy of various therapeutic agents. Consequently, I sought 
initially to establish a similar model. Varied doses of T-47D_ffluc and MDA-
MB-468_ffluc cells were injected subcutaneously in female NSG mice. 
However, these models proved to be inappropriate for further use for various 
reasons. Firstly, BLI signal appeared to decrease or stabilise over time (Figure 
5.2). Nevertheless, this did not correspond to actual tumour volume as these 
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xenografts increased significantly in size over time (Figure 5.2). Secondly, 
tumours in both models presented ulceration which is not desirable for animal 
welfare. Tumour ulceration is commonly observed in tumours developing 
subcutaneously and it is characterized by necrotic phenotype as a result of 
poor vascularization and lack of nutrients406,407. Others have reported 
reduction in BLI signal due to the development of necrotic and hypoxic 
tumours408–410. Similar to my observations, even though the intensity of 
bioluminescence emission decreased, tumour volume increased when 
measured by other means408–410.  This is explained by the fact that light 
emission is produced upon interaction of luciferase with luciferin, in the 
presence of oxygen. As previously mentioned, ulcerating tumours are necrotic 
and often hypoxic, resulting in reduced availability of oxygen and poor 
localisation of luciferin into the tumour due to poor blood supply. Measurement 
of subcutaneous tumours in mouse models with the usage of caliper is a 
widely used technique. It has the benefits of being low-cost and there is no 
requirement for anaesthetising the mice. Nevertheless, caliper measurements 
can be inaccurate due to a variety of reasons, including i) subjectivity; ii) 
inability to measure tumours of very small size, iii) difficulty of detecting small 
differences in tumour volume post treatment, iv) variability in tumour shape, 
v) thickness of the skin and vi) variability in measurements between different 
investigators411,412. For these reasons, I decided that it was necessary to 
establish a breast cancer xenograft model in which the tumour growth would 
be assessed with BLI imaging. 
For the above reasons, alternative xenografts models were established 
whereby T-47D and MDA-MB-468 cells were inoculated i.p., prior to treatment 
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with i.p. delivered T-cells. Although these models do not recapitulate the 
manner in which metastatic human breast cancer might be treated with CAR 
T-cell immunotherapy, they were used as convenient proof-of-concept models 
for the assessment of the in vivo efficacy of MUC1-specific CAR T-cells. While 
intravenous injection of CAR T-cells might be deemed more clinically relevant, 
previous members of our lab have reported that CAR T-cells administered 
using this route traffic poorly to the peritoneal cavity413.  
In the two in vivo therapeutic studies, NSG mice were inoculated i.p. 
with either 2x106 MDA-MB-468_ffluc cells or 0.5x106 T-47D_ffluc cells. As 
indicated by the results of the pilot study shown in section 5.2.3, mice injected 
with 2x106 and 5x106 MDA-MB-468_ffluc cells presented a similar pattern of 
tumour growth. Additionally, they presented better tumour distribution in 
comparison with mice inoculated with 0.5x106 cells, since tumour nodules 
were observed throughout the peritoneal cavity (data not shown). Given their 
similar behaviour, a cell dose of 2x106 MDA-MB-468_ffluc cells was selected 
to be used in the therapeutic study (rather than 5x106 cells) to reduce total 
tumour cell number that needed to be expanded for this study. In regard to T-
47D cells, the dose of 0.5x106 cells was chosen since a more stable BLI signal 
was observed over-time, when compared with the other three doses included 
in that pilot study.  
In the first therapeutic study, mice with established MDA-MB-468_ffluc 
tumours received 8x106 MUC1-specific CAR T-cells or non-transduced T-
cells. However, no tumour response was observed in any of the treated 
groups. This may be accounted for by the fact that mice already had high 
tumour burden when they received the treatment (day 32). This is indicated 
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by the fact that the study had to be terminated only 10 days post CAR T-cell 
injection, due to progressive disease. It should be noted that in the initial study 
design, it was planned to inject the CAR T-cells at day 12 post tumour 
inoculation. Nevertheless, technical issues led to a delay in the timing of 
treatment. It would be interesting to repeat the same experiment but, on this 
occasion, inject the MUC1-specific CAR T-cells in an earlier time point. Lack 
of response has been attributed to various reasons in other similar studies, 
one of them being poor localization of CAR T-cells243,414. This explanation 
seems unlikely in this case as MUC1-specific CAR T-cells were injected in the 
same locus (peritoneal cavity) as the engrafted tumour cells. Another possible 
explanation could be lack of T-cell persistence. This was not further 
investigated as the study had to be terminated urgently. 
In the second therapeutic study, mice inoculated with T-47D_ffluc 
received 12x106 MUC1-specific CAR T-cells or non-transduced cells. This 
model was chosen as it was important to investigate if the MUC1-specific CAR 
T-cells could demonstrate tumour regression in a less aggressive tumour 
model. Although no significant tumour regression was observed in any of the 
treatment groups, at least seven mice across the individual groups presented 
at least some degree of tumour regression post treatment with CAR T-cells. 
Notably, this was not observed in mice treated with non-transduced T-cells, 
indicating that the response was specific to treatment with MUC1 re-targeted 
CAR T-cells. T-cell persistence was evaluated upon termination of the study 
for two reasons. First, few mice showed long-term response post-treatment. 
Second, poor activity of CAR T-cells in vivo and in the clinical setting has been 
attributed in other studies to poor CAR T-cell persistence415–418. As shown in 
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Figure 5.12, viable human T-cells were detected in the peritoneal fluid 
obtained from most of the mice. This raises the possibility that the lack of 
response to CAR T-cells treatment was not due to poor CAR T-cell 
persistence. Notably, persistence did not seem to correlate with recognition of 
MUC1 by MUC1-specific CAR T-cells, as T-cells were also detected in the 
peritoneal cavity of mice treated with non-transduced T-cells. Non-specific 
persistence could be possibly attributed to alloreactivity and/or the profoundly 
immune compromised nature of the host mice. In support of this, it has been 
widely documented that NSG mice injected with human PBMCs commonly 
develop xenogeneic graft-versus-host disease (GvHD)419–421. Xenogeneic 
GvHD has been reported to develop upon recognition of host MHC class I/II 
by injected human PBMCs422. A limitation of the experiment presented in 
Figure 5.12 is that it is uncertain whether the T-cells detected in the peritoneal 
fluid are CAR-positive or non-transduced T-cells. Additionally, the absolute 
number of T-cells was not quantified. Therefore, no conclusive statement can 
be made regarding the possibility that lack of persistence of MUC1 re-targeted 
T-cells accounted for limited efficacy in this model. 
Another notable observation was the fact that no T-cells were detected 
in the spleens isolated from treated mice. This finding is in agreement with the 
results published by Pereira et al. who showed that CAR T-cells injected i.p. 
in SCID/Beige mice did not appear to migrate outside the peritoneal cavity413. 
However, these results do not agree with those published by Adusumilli et 
al.423. In this study, NSG mice bearing orthotopic mesothelioma tumours were 
treated with intra-pleural delivery of mesothelin-specific CAR T-cells (M28z). 
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After treatment, human T-cells were detected within the spleens of treated 
mice423. 
One other study has explored the in vivo cytotoxic activity of MUC1-
specific CAR T-cells in a breast cancer mouse model. Wilkie et al. reported 
significant delay in tumour progression using a MUC1-engineered MDA-MB-
435 xenograft model, following i.p. administration of a 3rd generation CAR with 
elongated hinge (HOX)295. It needs to be noted that MDA-MB-435 is now 
considered to be of melanoma origin424. Similar to the two therapeutic 
experiments undertaken in this PhD project, both tumour cells and CAR T-
cells were injected intraperitoneally. Furthermore, the tumour cells were 
engineered to over-express MUC1 by gene transfer, contrasting with the 
models used here in which endogenous TA-MUC1 was targeted.  Importantly, 
Wilkie et al. did not investigate further whether the hinge is responsible for the 
anti-tumour activity of the CAR observed in the in vivo experiment. For this 
reason, is unclear whether the hinge or the presence of two costimulatory 
molecules were responsible for tumour regression. In my study, HDF28z CAR 
T-cells did not present superior activity than TAB28z in neither of the two 
therapeutic experiments, suggesting that the incorporation of the hinge was 
not particularly beneficial. Thus, it would be interesting to investigate if addition 
of a second co-stimulatory domain in the TAB28z could potentially improve its 
anti-tumour activity. 
Finally, as indicated earlier, it is of great importance to be able to predict 
on-target off-tumour toxicities in pre-clinical in vivo studies. It has been 
reported by Spicer et al. that the murine protein of MUC1 presents 85% 
homology in the cytoplasmic and transmembrane regions with human MUC1 
 231 
protein425. Nevertheless, the homology in the tandem repeat domain is only 
34%, a fact that makes impossible the prediction of off-tumour toxicity using 
CAR T-cells that target immunodominant epitopes in this location425. A 
possible way to predict off-tumour toxicity would be to re-design the CAR 
molecule by replacement its components with the ones of murine origin and 
investigate activity in mice with an intact immune system. Another possible 
way of exploring the risk for of on-target off-tumour toxicity is by administrating 
CAR T-cells in a MUC1-transgenic model. Others have previously used 
transgenic mice for the same purpose235,426. For example, Wang et al. 
investigated the anti-tumour activity and the risk of off-tumour toxicity of HER-




The in vivo efficacy of TAB28z, H28z and HDF28z CAR T-cells was 
assessed in two individual mice models. MUC1-specific CAR T-cells failed to 
control tumour growth in NSG mice inoculated with MDA-MB-468 breast 
cancer cells. Nevertheless, the tumour burden was too high at the time-point 
of CAR T-cell injection which might have underestimated the therapeutic 
potential of anti-MUC1 CAR T-cells in this study. Assessment of in vivo activity 
of CAR T-cells was further performed using NSG mice engrafted with T-47D 
cells. Although no significant tumour reduction was observed, a few mice 
presented tumour reduction following treatment. This response was mostly 
observed in mice treated with either TAB28z and HDF28z CAR T-cells. Lack 
of overall response was not attribute to lack of T-cell persistence as T-cells 
were detected in the peritoneal fluid. Further in vivo studies should be 
performed in order to evaluate the therapeutic potential of CAR T-cells. 
Additionally, inclusion of an additional co-stimulatory molecule in the 




Chapter 6: Discussion 
6.1 Overview 
The aim of this PhD project was to develop a CAR T-cell immunotherapy 
approach for breast cancer. For this purpose, MUC1 was chosen as the target 
antigen due its overexpression in 90% of breast cancers124. Another special 
characteristic of MUC1 that enhances its attractiveness as a CAR T-cell target 
is the fact that it is aberrantly glycosylated in tumour cells138. In this project, 
the anti-tumour potential of a novel second generation MUC1-specific CAR 
named TAB28z was investigated in both the in vitro and in vivo setting. I also 
investigated whether the anti-tumour activity of TAB28z was superior when 
compared to two previously generated MUC1-specific CARs, named H28z 
and HDF28z295. As previously stated, these three MUC1-specific CARs 
contain a binding domain derived either from TAB004 or HMFG2. Previous 
studies have shown that both antibodies recognise tumour-associated 
MUC1284,287,320.   
A fundamental initial step in this project was to characterize this newly 
developed MUC1-specific CAR in vitro. While TAB004 and HMFG2 antibodies 
both recognise tumour-associated glycoforms of MUC1, the binding 
preference of TAB004 in this regard was not known. According to the results 
presented in Chapter 3, both TAB004-based and HMFG2-based CARs 
recognise all four TA glycoforms: e.g. MUC1 that is decorated with the T, ST, 
Tn or STn antigens.  
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Another significant step was to investigate whether TAB28z could be 
successfully expressed on the surface of activated human T-cells, isolated 
from healthy donors. This was validated using flow cytometry. The in vitro anti-
tumour activity of TAB28z was investigated using a panel of breast cancer cell 
lines that express a broad range of levels of cell surface MUC1. TAB28z-
engineered T-cells demonstrated significant anti-tumour activity against 
MUC1+++ and MUC1++ breast cancer cell lines, while minimal activity was 
observed against the cell line with low MUC1 surface expression.  The anti-
tumour activity of MUC1-specific CAR T-cells was accompanied by significant 
production of IFN-γ.  
In the course of these experiments, I observed that MUC1-specific CAR 
T-cells released IFN-γ constitutively, in the absence of interaction with tumour 
cells. This finding was unexpected and led to the hypothesis that MUC1 
expressed by activated T-cells could promote the activation of the CARs under 
study in this project. In support of this, I found that MUC1 expressed by 
activated T-cells was detectable using the HMFG2 antibody. This finding 
contrasts with previously published data which showed that T-cell associated 
MUC1 carried predominantly normal-associated glycoforms which were not 
detected using this antibody378.  
The effects of the continuous recognition of MUC1 during the in vitro 
CAR T-cell expansion period was further evidenced by the demonstration that 
all three signalling-intact MUC1-specific CAR T-cells underwent enrichment in 
culture, accompanied by a trend towards increased activation and exhaustion. 
Another significant effect of this background recognition was the reduced 
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number of cells present in these cultures, which may have resulted from 
fratricide or from activation-induced cell death.  
Despite these unexpected findings, I proceeded to investigate the 
efficacy of TAB28z in two distinct breast cancer xenograft models. A hint of 
anti-tumour activity was observed in mice with non-aggressive T-47D 
tumours. Nevertheless, neither TAB28z or the other two signalling signalling 
anti-MUC1 CARs were able to generate a potent anti-tumour response. This 
could be possibly partly attributed to the T-cell exhaustion phenotype that 
these CAR T-cell presented due to tonic signalling. 
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6.2 Future directions 
6.2.1 Ameliorating the effects of tonic signalling 
  Different strategies could be designed in order to attempt to overcome 
the effects of tonic signalling. In a previous study by Long et al. it has been 
shown that the detrimental effects of continuous signalling of CAR T-cells 
could be abrogated by replacing the CD28 co-stimulatory molecule of the CAR 
signalling domain with that of 4-1BB241.  
Another possible solution in order to restore T-cell function is the use of 
checkpoint inhibitors. As evident by the results presented in Chapter 4, 
signalling-intact MUC1-CAR T-cells presented a trend of upregulation of 
various exhaustion markers, such as PD-1. As previously mentioned in 
Section 1.3.4.3.1, the combination of CAR T-cells with checkpoint inhibitors 
have already been investigated in both the pre-clinical and clinical 
settings235,236,427. Two different types of experiments could be designed: 1) 
simultaneous treatment of breast cancer xenograft mice with both CAR T-cells 
and a checkpoint inhibitor such as pembrolizumab, and 2) in vitro treatment 
of CAR T-cells with a checkpoint inhibitor in order to reverse T-cell exhaustion, 
prior to their administration in mice with established breast cancer tumours. In 
support of the 2nd suggestion, K. Moon et al. have shown that mesothelin-
targeted CAR T-cells failed to result in tumour regression in mice due to T-cell 
exhaustion caused by the tumour microenvironment374. They further 
suggested that this effect is reversible as they managed to restore the activity 
of CAR TILs ex vivo by treating them with a PD-L1 inhibitor374.  
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6.2.2 Prevention of recognition of MUC1 expressed 
on activated T-cells by MUC1-specific CAR T-cells 
 The above suggestions are focused on managing T-cell exhaustion due 
to tonic signalling. Alternative strategies that warrant consideration entail the 
prevention of background recognition of MUC1 by the CAR T-cells during their 
in vitro expansion. One such approach would involve the prevention of binding 
of the scFv domain of the CAR to MUC1. This could be achieved in two distinct 
ways. One option entails the culture the CAR T-cells in the presence of the 
MUC1 24mer peptide. This would be expected to occupy the CAR’s binding 
domain, thus preventing to bind to MUC1 without cross-linking the CAR. 
Alternatively, the CAR T-cells could be cultured in the presence of either 
HMFG2 or TAB004. The added antibody would be expected to bind to MUC1 
expressed on T-cells, thus competing with the binding of the scFv. 
The latter approach could also be applied in the clinical setting in order 
to prevent on-target off-tumour toxicities. This idea suggests the pre-treatment 
of patients with a MUC1 antibody, in order to pre-occupy MUC1 expressed on 
activated T-cells. A similar strategy was followed in a phase I clinical trial for 
RCC patients where the efficacy of an anti-CAIX CAR was investigated. 
Previously, patients treated with CAIX-specific CAR T-cells presented severe 
liver tumour toxicity due to off-tumour recognition of CAIX-positive cells in the 
bile duct252. In an attempt to prevent this on-target off-tumour toxicity, Lamers 
and colleagues pre-treated a small number patients with an anti-CAIX 
monoclonal antibody, prior to the administration of CAIX-specific CAR T-
cells253. According to the results of the study, the pre-treatment prevented the 
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on-target toxicity, thus allowing for administration of higher CAR T-cell dose. 
It is noteworthy that, in this approach, the dose of administered antibody 
needs to be optimized in order to allow for blocking of the antigen expressed 
in normal tissues without shielding its detection in tumour cells. 
As previously mentioned, blocking the interaction of the anti-MUC1 CAR 
with MUC1 expressed on T-cells could be achieved by culturing the T-cells in 
the presence of either the MUC1 24mer peptide or a MUC1-specific antibody. 
Each of these strategies poses some limitations. The binding of MUC1 peptide 
to the scFv domain of the CAR could cause activation and in turn 
downregulation of the CAR receptor428. On the other hand, “masking” MUC1 
on activated T-cells by culturing the T-cells in the presence of MUC1 
antibodies has been previously reported to affect T-cell proliferation. Various 
studies have examined the role of MUC1 expressed on T-cells by culturing 
them in the presence of distinct MUC1 antibodies375,377,429. The results derived 
from these studies suggest the addition of antibody resulted in crosslinking of 
MUC1 and subsequently in inhibition of T-cell proliferation375,377,429.  
Another potential strategy of inhibiting the MUC1-CAR T-cell interaction 
during the in vitro T-cell expansion period is the ablation of MUC1 genes, for 
example using CRISPR/Cas9 technology. As previously mentioned in 
Chapter 1, this approach has already been used for the genetic engineering 
of CAR T-cells237,240. Additionally, this technology could be used in order to 
investigate further the role of MUC1 expressed on activated T-cells, since this 
remains unclear. As mentioned above, there is some evidence that MUC1 
regulates T-cell function by inhibiting T-cell proliferation and promoting T-cell 
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depletion430. Others have suggested that MUC1 might play a role in T-cell 
migration through its interaction with endothelial cells378.  
Expression of MUC1 in other immune subsets such as in γδ T-cells, 
natural killer (NK) cells or NK T-cells remains unknown. All three cell 
populations have been previously used as carriers of CAR molecules instead 
of using αβ T-cells431–434. Thus, it would be interesting to investigate whether 
MUC1 is detectable by HMFG2 or TAB004 in these cell populations and if not 
then they could be transduced with the MUC1-specific CARs.  
6.2.3 Prevention of severe adverse events in the 
clinical setting 
The recognition of MUC1 on activated T-cells does not only affect the 
functionality of the anti-MUC1 CAR T-cells but also poses a significant risk for 
on-target off-tumour toxicities. The effects of administrating these MUC1-
specific CAR T-cells into patients with an infection or an autoimmune disease 
could be detrimental. Additionally, it has been reported that HMFG2 reacts 
strongly with lactating breast and to a lesser extent with some other epithelial 
tissues such as normal resting breast tissue317,318,320. If this was going to be 
tested in a clinical trial, the necessity of integrating a control system within the 
MUC1-specific CAR T-cells is undeniable. As previously explained in Chapter 
1, different suicide systems and elimination switches could be applied and 
used in CAR T-cell immunotherapy in order to prevent or mitigate serious 
adverse events281,282,435. 
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6.2.4 Considerations regarding potency of MUC1-
specific CAR T-cells 
The lack of in vivo tumour regression following adoptive transfer of 
MUC1 re-targeted CAR T-cells could not only be attributable to tonic signalling 
but also to lack of CAR T-cell potency. As previously mentioned, it is difficult 
to target MUC1 with CAR T-cells due to its large extracellular domain which 
results in steric hindrance. The MUC1 extracellular domain is 200-500nm 
long, largely accounted for by the polymorphic VNTR region436. The 
recognition of an antigen/MHC by a T-cell receptor (TCR) leads to the immune 
synapse formation which subsequently results to T-cell activation437. The 
length of the immunological synapse (i.e the distance between the plasma 
membrane of T-cell and the antigen presenting cell (APC)) is approximately 
15 nm (Figure 6.1)438.  
According to the kinetic segregation model, some non-specific kinase 
phosphorylation events are observed in resting T-cells which would result in 
low levels of T-cell activation437,439. CD148 and CD45 are large phosphatases 
that regulate immune responses. These non-specific phosphorylation events 
are inhibited by the CD148 and CD45 as they block kinase activation by 
causing de-phosphorylation440. Upon specific T-cell-antigen (APC) interaction 
the immunological synapse is formed. At this point, CD45 and CD148 are 
excluded from the synapse due to their large extracellular domain and thus 
there is no inhibition of the specific immune response440. Nevertheless, the 
large extracellular domain of MUC1 could hinder the formation of close-
contact regions, when engaged by a CAR. This could subsequently permit 
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access to inhibitory phosphatases, leading to sub-optimal T-cell activation and 
preventing the formation of a close contact between T-cell and target cell. 
Based on this concept, one could consider that MUC1 may be too large to be 
targeted efficiently using a CAR-engineered T-cells (Figure 6.1). 
 
Figure 6.1: Steric hindrance due to the large extracellular MUC1 domain. In a normal MHC-
interaction, the distance between a T-cell and an APC is ~15nm long. In the case where 
MUC1 is targeted by a CAR this distance is much bigger due to the large MUC1 extracellular 
domain. 
Despite these considerations, others have shown that targeting MUC1 
is possible with CAR T-cells. Nevertheless, in none of these studies the 
researchers suggested similar issues with tonic signalling. In the study by 
Wilkie et al., the HMFG2-based CAR T-cells were expanded in vitro for a much 
shorter period of time (personal communication), thus making it impossible to 
make these observations295. Posey et al. used a scFv derived from the 5E5 
antibody337. As previously shown in chapter 4, this antibody did not detect 

















The low potency due to MUC1 steric inhabitation in combination with the 
effects of tonic signalling could have resulted to the lack of anti-tumour activity 
in vivo (Chapter 5).  
Throughout this project, a CAR with an elongated spacer (HDF28z) was 
used in order to investigate if this will improve accessibility of the CAR to the 
MUC1 ectodomain295. Nevertheless, this did not result in improved T-cell 
activity such neither in the vitro or in vivo experiments presented. Other 
researchers have designed strategies in order to improve the anti-tumour 
activity of CAR T-cells. These include the targeted integration of the CAR 
transgene to the TRAC locus and co-expression of a CAR with the IL-17R  
cytokine receptor and they could be combined with the MUC1-
immunotherapeutic approach presented herein240,242. 
6.2.5 Further comments  
An important limitation of this study is that the surface expression of 
MUC1, in breast cancer cell lines and activated T-cells was only investigated 
using the HMFG2 antibody. Further studies need to be conducted whereby 
surface expression MUC1 in both settings is also investigated using the 
TAB004 antibody, allowing comparison with HMFG2. This was not done 
during this PhD project due to restricted access to TAB004. Nevertheless, the 
two antibodies seem to have similar binding preferences as indicated by their 
broadly similar binding profile to distinct TA glycoforms of MUC1. Additionally, 
both TAB004-based and HMFG2-based CARs are readily detectable by flow 
cytometry following incubation with a biotinylated VNTR-derived 24mer MUC1 
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peptide284,441. Both the TAB004-based and HMFG2-based CAR T-cells used 
in this project presented a similar pattern of background production of IFN-γ, 
CAR T-cell enrichment, reduced T-cell expansion and a trend towards 
increased T-cell activation and exhaustion. These observations strongly 
suggest that MUC1 expressed on T-cells is detectable by the TAB004 
antibody in addition to HMFG2. 
Another concern related to a MUC1-specific immunotherapeutic 
approach is the potential ability of the infused CAR T-cells to bind circulating 
(tumour-derived) MUC1. This could prevent the CAR T-cells from engaging 
MUC1 in the tumour site. Nevertheless, it has been previously shown that 
radiolabelled MUC1 antibodies effectively trafficked into the tumour site in 
patients with MUC1-expressing malignancies such as breast, ovarian and 




In summary, TAB28z CAR T-cells presented significant anti-tumour 
activity in vitro, which unfortunately was not maintained when evaluated in the 
in vivo setting. This novel CAR did not present superior functionality when 
compared to H28z and HDF28z CAR T-cells. An important finding of this PhD 
project is that MUC1 expressed on T-cells was detectable using the HMFG2 
antibody, suggesting that is decorated with core-1 glycans. Recognition of 
MUC1 by MUC1-specific CAR T-cells during the in vitro expansion period led 
to tonic signalling which could have possibly contributed to the lack of efficacy 
in the breast cancer xenograft models used here. Different strategies could be 
designed in order to augment the results of this background recognition of 
MUC1 or to prevent it happening in the first place. Nevertheless, even if we 
prevent T-cell exhaustion, the risk of depletion of MUC1-positive T-cells by 
CAR T-cells administered to patients still exists. One possible solution would 
be to pre-treat patients with HMFG2 or TAB004 antibody in order to mask 
MUC1 epitopes expressed on T-cells. As it is unclear if this is going to be 
successful, administration of MUC1-specific CAR T-cells into patients should 
only take place only in combination with a CAR T-cell suicide system/ 
elimination switch. The results presented in this PhD project highlight one of 
the major obstacles which characterises CAR T-cell immunotherapy, namely 
the development of a safe and yet potent CAR T-cell immunotherapeutic 
approach directed against a tumour selective target found in solid tumours 
such as breast cancer.  
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CAR T-cell transduction efficiency by using the PG13-packaging cells 
versus the HEK 293T VECs 
 
Supplementary Figure 1: T-cell transduction efficiency by using PG-13 or HEK 293T VEC 
cells. Isolated PBMCs from healthy volunteers were isolated and activated 48h afterwards 
with CD3/CD28 paramagnetic beads. At 48h post T-cell activation, cells were transduced to 
express either the TAB28z, H28z, HDF28z or HDFTr CAR. For the purpose of T-cell 
transduction viral supernanant from either PG-13 or HEK 293T VEC retroviral packaging cells 
was used which carry the CAR transgene. At day 5 post transduction, the CAR T-cell 
transduction efficiency was evaluated with flow cytometry. Statistical analysis was performed 









































p= < 0.01 




1. Torre, L. A. et al. Global Cancer Statistics, 2012. CA a cancer J. Clin. 65, 87–108 
(2015). 
2. Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and 
major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015). 
3. Cancer Research UK. The Twenty Most Common Cancers, 2014. Cancer Research 
UK statistics. 
4. Cancer Research UK. The 20 Most Common Causes of Cancer Death in 2014, Cancer 
Research UK statistics. 
5. Cancer Research UK. Breast cancer mortality statistics | Cancer Research UK. 
Available at: http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/breast-cancer/mortality#heading-Two. (Accessed: 
17th September 2017) 
6. Cancer Research UK. Age-specific Incidence Rates of Breast Bancer , Cancer 
Research UK statistics. 
7. Singletary, S. E. Rating the Risk Factors for Breast Cancer. Ann. Surg. 237, 474–482 
(2003). 
8. Antoniou, A. et al. Average Risks of Breast and Ovarian Cancer Associated with 
BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: 
A Combined Analysis of 22 Studies. Am. J. Hum. Genet 72, 1117–1130 (2003). 
9. Chlebowski, R. T. et al. Ethnicity and Breast Cancer: Factors Influencing Differences 
in Incidence and Outcome. JNCI J. Natl. Cancer Inst. 97, 439–448 (2005). 
10. Smigal, C. et al. Trends in Breast Cancer by Race and Ethnicity: Update 2006. CA. 
Cancer J. Clin. 56, 168–183 (2006). 
11. Trichopoulos, D., MacMahon, B. & Cole, P. Menopause and breast cancer risk. J. Natl. 
Cancer Inst. 48, 605–13 (1972). 
12. Brinton, L. A., Schairer, C., Hoover, R. N. & Fraumeni, J. F. Menstrual Factors and 
Risk of Breast Cancer. Cancer Invest. 6, 245–254 (1988). 
13. Brinton, L. A., Hoover, R. & Fraumeni, J. F. Reproductive factors in the aetiology of 
breast cancer. Br. J. Cancer 47, 757–762 (1983). 
14. White, E. Projected changes in breast cancer incidence due to the trend toward 
delayed childbearing. Am. J. Public Health 77, 495–7 (1987). 
15. Ellison, R. C., Zhang, Y., McLennan, C. E. & Rothman, K. J. Exploring the relation of 
alcohol consumption to risk of breast cancer. Am. J. Epidemiol. 154, 740–7 (2001). 
16. Tretli, S. Height and weight in relation to breast cancer morbidity and mortality. A 
prospective study of 570,000 women in Norway. Int. J. Cancer 44, 23–30 (1989). 
 266 
17. Lahmann, P. H. et al. Long-term weight change and breast cancer risk: the European 
prospective investigation into cancer and nutrition (EPIC). Br. J. Cancer 93, 582–9 
(2005). 
18. Ng, A. K. & Travis, L. B. Radiation therapy and breast cancer risk. J. Natl. Compr. 
Canc. Netw. 7, 1121–8 (2009). 
19. Boice, J. D., Preston, D., Davis, F. G. & Monson, R. R. Frequent chest X-ray 
fluoroscopy and breast cancer incidence among tuberculosis patients in 
Massachusetts. Radiat. Res. 125, 214–22 (1991). 
20. Thune, I., Brenn, T., Lund, E. & Gaard, M. Physical activity and the risk of breast 
cancer. N. Engl. J. Med. 336, 1269–1275 (1997). 
21. Calle, E. E. et al. Breast cancer and hormone replacement therapy: Collaborative 
reanalysis of data from 51 epidemiological studies of 52,705 women with breast 
cancer and 108,411 women without breast cancer. Lancet 350, 1047–1059 (1997). 
22. Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M. & Allan, J. D. 
Postmenopausal Hormone Replacement Therapy. JAMA 288, 872 (2002). 
23. Beaber, E. F. et al. Recent oral contraceptive use by formulation and breast cancer 
risk among women 20 to 49 years of age. Cancer Res. 74, 4078–4089 (2014). 
24. Dupont, W. D. et al. Breast cancer risk associated with proliferative breast disease 
and atypical hyperplasia. Cancer 71, 1258–65 (1993). 
25. Maxwell, K. N. & Domchek, S. M. Familial breast cancer risk. Curr. Breast Cancer 
Rep. 5, 170–182 (2013). 
26. Reis-Filho, J. S. & Pusztai, L. Gene expression profiling in breast cancer: 
Classification, prognostication, and prediction. Lancet 378, 1812–1823 (2011). 
27. Weigelt, B. & Reis-Filho, J. S. Histological and molecular types of breast cancer: is 
there a unifying taxonomy? Nat. Rev. Clin. Oncol. 6, 718–730 (2009). 
28. Tavassoli, F. a et al. Intraductal proliferative lesions. World Heal. Organ. Classif. 
Tumours. Pathol. Genet. Tumours Breast Female Genit. Organs. 63–74 (2003). 
29. Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. 
Med. 360, 790–800 (2009). 
30. Weigelt, B., Baehner, F. L. & Reis-Filho, J. S. The contribution of gene expression 
profiling to breast cancer classification, prognostication and prediction: a retrospective 
of the last decade. J. Pathol. 220, 263–80 (2010). 
31. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 
(2000). 
32. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98, 10869–10874 
(2001). 
33. Weigelt, B. et al. Molecular portraits and 70-gene prognosis signature are preserved 
throughout the metastatic process of breast cancer. Cancer Res. 65, 9155–8 (2005). 
 267 
34. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene 
expression data sets. Proc. Natl. Acad. Sci. 100, 8418–8423 (2003). 
35. Carey, L. A. et al. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast 
Cancer Study. JAMA 295, 2492 (2006). 
36. Nielsen, T. O. et al. A comparison of PAM50 intrinsic subtyping with 
immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen 
receptor-positive breast cancer. Clin. Cancer Res. 16, 5222–5232 (2010). 
37. Rouzier, R. et al. Breast cancer molecular subtypes respond differently to preoperative 
chemotherapy. Clin. Cancer Res. 11, 5678–5685 (2005). 
38. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic 
subtypes. J. Clin. Oncol. 27, 1160–7 (2009). 
39. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive 
analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, 
and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a 
population-based study from the California cancer Registry. Cancer 109, 1721–8 
(2007). 
40. Eroles, P., Bosch, A., Alejandro Pérez-Fidalgo, J. & Lluch, A. Molecular biology in 
breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat. Rev. 38, 698–
707 (2012). 
41. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-
negative breast cancer. N. Engl. J. Med. 351, 2817–26 (2004). 
42. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in 
breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002). 
43. Fan, C. et al. Concordance among gene-expression-based predictors for breast 
cancer. N. Engl. J. Med. 355, 560–9 (2006). 
44. National Institute for Health and Care Excellence (NICE). Early and locally advanced 
breast cancer overview - NICE Pathways. Available at: 
https://pathways.nice.org.uk/pathways/early-and-locally-advanced-breast-cancer. 
(Accessed: 4th September 2017) 
45. National Institute for Health and Care Excellence (NICE). Advanced breast cancer 
overview - NICE Pathways. Available at: 
https://pathways.nice.org.uk/pathways/advanced-breast-cancer. (Accessed: 4th 
September 2017) 
46. Kapteijn, B. A. et al. Identification and biopsy of the sentinel lymph node in breast 
cancer. Eur. J. Surg. Oncol. 24, 427–30 (1998). 
47. Turner, R. R., Ollila, D. W., Krasne, D. L. & Giuliano, A. E. Histopathologic validation 
of the sentinel lymph node hypothesis for breast carcinoma. Ann. Surg. 226, 271-6-8 
(1997). 
48. Krag, D. N., Weaver, D. L., Alex, J. C. & Fairbank, J. T. Surgical resection and 
 268 
radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. 
Surg. Oncol. 2, 335–9; discussion 340 (1993). 
49. Alex, J. C. & Krag, D. N. Gamma-probe guided localization of lymph nodes. Surg. 
Oncol. 2, 137–43 (1993). 
50. Ahmed, M., Purushotham, A. & Douek, M. Novel techniques for sentinel lymph node 
biopsy in breast cancer: a systematic review. Lancet Oncol. 15, e351–e362 (2014). 
51. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 
646–674 (2011). 
52. Zhang, H., Tombline, G. & Weber, B. L. BRCA1, BRCA2, and DNA Damage 
Response: Collision or Collusion? Cell 92, 433–436 (1998). 
53. Easton, D. F., Ford, D. & Bishop, D. T. Breast and ovarian cancer incidence in BRCA1-
mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56, 265–
71 (1995). 
54. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a 
therapeutic strategy. Nature 434, 917–21 (2005). 
55. Mateo, J. et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N. 
Engl. J. Med. 373, 1697–1708 (2015). 
56. Ledermann, J. A. et al. Overall survival in patients with platinum-sensitive recurrent 
serous ovarian cancer receiving olaparib maintenance monotherapy: an updated 
analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet 
Oncol. 17, 1579–1589 (2016). 
57. Ledermann, J. et al. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed 
Ovarian Cancer. N. Engl. J. Med. 366, 1382–1392 (2012). 
58. Fong, P. C. et al. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA 
Mutation Carriers. N. Engl. J. Med. 361, 123–134 (2009). 
59. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of 
poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005). 
60. Dobzhansky, T. Genetics of Natural Populations. Xiii. Recombination and Variability 
in Populations of Drosophila Pseudoobscura. Genetics 31, 269–290 (1946). 
61. Ashworth, A., Lord, C. J. & Reis-Filho, J. S. Genetic interactions in cancer progression 
and treatment. Cell 145, 30–38 (2011). 
62. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with 
amplification of the HER-2/neu oncogene. Science 235, 177–82 (1987). 
63. De Laurentiis, M. et al. A meta-analysis on the interaction between HER-2 expression 
and response to endocrine treatment in advanced breast cancer. Clin. Cancer Res. 
11, 4741–8 (2005). 
64. Harris, C. A., Ward, R. L., Dobbins, T. A., Drew, A. K. & Pearson, S. The efficacy of 
HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann. Oncol. 22, 
1308–17 (2011). 
 269 
65. Phillips, G. D. L. et al. Targeting HER2-Positive Breast Cancer with Trastuzumab-
DM1, an Antibody–Cytotoxic Drug Conjugate. Cancer Res 68, 9280–90 (2008). 
66. Junttila, T. T., Guangmin Li, B., Kathryn Parsons, B., Gail Lewis Phillips, B. & Mark 
Sliwkowski, B. X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of 
trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. 
doi:10.1007/s10549-010-1090-x 
67. Verma, S. et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. 
n engl j med 36719367, 1783–91 (2012). 
68. National Cancer Institute (NIH). FDA Approval for Ado-Trastuzumab Emtansine - 
National Cancer Institute. Available at: https://www.cancer.gov/about-
cancer/treatment/drugs/fda-ado-trastuzumab-emtansine. (Accessed: 22nd 
September 2017) 
69. Rusnak, D. W. et al. The effects of the novel, reversible epidermal growth factor 
receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal 
and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1, 85–94 (2001). 
70. Wood, E. R. et al. A unique structure for epidermal growth factor receptor bound to 
GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, 
and receptor activity in tumor cells. Cancer Res. 64, 6652–6659 (2004). 
71. National Cancer Institute (NIH). FDA Approval for Lapatinib Ditosylate - National 
Cancer Institute. Available at: https://www.cancer.gov/about-
cancer/treatment/drugs/fda-lapatinib. (Accessed: 20th September 2017) 
72. Cameron, D. et al. A phase III randomized comparison of lapatinib plus capecitabine 
versus capecitabine alone in women with advanced breast cancer that has progressed 
on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 
112, 533–543 (2008). 
73. Schwartzberg, L. S. et al. Lapatinib plus Letrozole as First-Line Therapy for HER-2+ 
Hormone Receptor-Positive Metastatic Breast Cancer. Oncologist 15, 122–129 
(2010). 
74. Miller, K. et al. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic 
Breast Cancer. 26, (2007). 
75. National Cancer Institute (NIH). FDA Approval for Bevacizumab - National Cancer 
Institute. National Cancer Institute (2013). Available at: https://www.cancer.gov/about-
cancer/treatment/drugs/fda-bevacizumab. (Accessed: 30th September 2017) 
76. Gianni, L. et al. AVEREL: A randomized phase III trial evaluating bevacizumab in 
combination with docetaxel and trastuzumab as first-line therapy for her2-positive 
locally recurrent/metastatic breast cancer. J. Clin. Oncol. 31, 1719–1725 (2013). 
77. Miller, K. D. et al. Randomized phase III trial of capecitabine compared with 
bevacizumab plus capecitabine in patients with previously treated metastatic breast 
cancer. J. Clin. Oncol. 23, 792–799 (2005). 
 270 
78. U.S Food and Drug Administration. Drug Safety and Availability - Avastin 
(bevacizumab) Information. Available at: 
https://www.fda.gov/Drugs/DrugSafety/ucm193900.htm. (Accessed: 30th September 
2017) 
79. Muenst, S. et al. Expression of programmed death ligand 1 (PD-L1) is associated with 
poor prognosis in human breast cancer. 146, 15–24 (2014). 
80. Sabatier, R. et al. Prognostic and predictive value of PDL1 expression in breast 
cancer. Oncotarget 6, (2014). 
81. Ghebeh, H. et al. The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed 
in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important 
High-Risk Prognostic Factors. Neoplasia 8, 190–198 (2006). 
82. Mittendorf, E. A. et al. PD-L1 expression in triple-negative breast cancer. Cancer 
Immunol. Res. 2, 361–70 (2014). 
83. Soliman, H., Khalil, F. & Antonia, S. PD-L1 expression is increased in a subset of basal 
type breast cancer cells. PLoS One 9, (2014). 
84. Rugo, H. et al. Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-
3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-
negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res. 76, S5-7-
S5-7 (2016). 
85. Emens, L. A. et al. Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical 
activity in patients with metastatic triple-negative breast cancer. Cancer Res. 75, PD1-
6-PD1-6 (2015). 
86. Hoffmann-La Roche. A Study of Atezolizumab in Combination With Nab-Paclitaxel 
Compared With Placebo With Nab-Paclitaxel for Participants With Previously 
Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) - Full Text View 
- ClinicalTrials.gov. Available at: https://clinicaltrials.gov/show/NCT02425891. 
(Accessed: 22nd September 2017) 
87. Genentech, I. A Study of Atezolizumab Administered in Combination With 
Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or 
Metastatic Solid Tumors - Full Text View - ClinicalTrials.gov. Available at: 
https://clinicaltrials.gov/show/NCT01633970. (Accessed: 22nd September 2017) 
88. Nanda, R. et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast 
Cancer: Phase Ib KEYNOTE-012 Study. J. Clin. Oncol. 34, 2460–7 (2016). 
89. Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) Monotherapy for 
Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086). 
clinicaltrials.gov 2015–2018 (2015). 
90. Vonderheide, R. H. et al. Tremelimumab in Combination with Exemestane in Patients 
with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible 
Costimulator Expression on Patient T Cells. doi:10.1158/1078-0432.CCR-10-0505 
 271 
91. Cesar Augusto Santa-Maria, N. U. MEDI4736 and Tremelimumab in Treating Patients 
With Metastatic HER2 Negative Breast Cancer - Full Text View - ClinicalTrials.gov. 
Available at: https://clinicaltrials.gov/ct2/show/NCT02536794. (Accessed: 23rd 
September 2017) 
92. clinicaltrials.gov. Search of: chimeric antigen receptors | Breast Cancer - List Results 
- ClinicalTrials.gov. Available at: 
https://clinicaltrials.gov/ct2/results?cond=Breast+Cancer+&term=chimeric+antigen+r
eceptors&cntry1=&state1=&recrs=#wrapper. (Accessed: 23rd September 2017) 
93. Hollingsworth, M. A. & Swanson, B. J. Mucins in cancer: protection and control of the 
cell surface. Nat. Rev. Cancer 4, 45–60 (2004). 
94. Kufe, D. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9, 874–
885 (2009). 
95. Gendler, S., Taylor-Papadimitriou, J., Duhig, T., Rothbard, J. & Burchell, J. A highly 
immunogenic region of a human polymorphic epithelial mucin expressed by 
carcinomas is made up of tandem repeats. J. Biol. Chem. 263, 12820–3 (1988). 
96. Asker, N., Axelsson, M. A., Olofsson, S. O. & Hansson, G. C. Dimerization of the 
human MUC2 mucin in the endoplasmic reticulum is followed by a N-glycosylation-
dependent transfer of the mono- and dimers to the Golgi apparatus. J. Biol. Chem. 
273, 18857–63 (1998). 
97. Gum, J. R., Hicks, J. W., Toribara, N. W., Siddiki, B. & Kim, Y. S. Molecular cloning of 
human intestinal mucin (MUC2) cDNA. Identification of the amino terminus and overall 
sequence similarity to prepro-von Willebrand factor. J. Biol. Chem. 269, 2440–2446 
(1994). 
98. Godl, K. et al. The N terminus of the MUC2 mucin forms trimers that are held together 
within a trypsin-resistant core fragment. J. Biol. Chem. 277, 47248–56 (2002). 
99. Verdugo, P., Aitken, M., Langley, L. & Villalon, M. J. Molecular mechanism of product 
storage and release in mucin secretion. II. The role of extracellular Ca++. Biorheology 
24, 625–33 (1987). 
100. Kesimer, M., Makhov, A. M., Griffith, J. D., Verdugo, P. & Sheehan, J. K. Unpacking a 
gel-forming mucin: a view of MUC5B organization after granular release. Am. J. 
Physiol. - Lung Cell. Mol. Physiol. 298, (2009). 
101. Singh, R. & Bandyopadhyay, D. MUC1: A target molecule for cancer therapy. Cancer 
Biol. Ther. 6, 481–486 (2014). 
102. Nath, S. & Mukherjee, P. MUC1: A multifaceted oncoprotein with a key role in cancer 
progression. Trends in Molecular Medicine 20, 332–342 (2014). 
103. Ligtenbergs, M. J. L. et al. Cell-associated Episialin Is a Complex Containing Two 
Proteins Derived from a Common Precursor. J. Biol. Chem. 267, (1992). 
104. Levitin, F. et al. The MUC1 SEA module is a self-cleaving domain. J. Biol. Chem. 280, 
33374–33386 (2005). 
 272 
105. Gendler, S. J. et al. Molecular cloning and expression of human tumor-associated 
polymorphic epithelial mucin. J. Biol. Chem. 265, 15286–93 (1990). 
106. Müller, S. et al. High density O-glycosylation on tandem repeat peptide from secretory 
MUC1 of T47D breast cancer cells. J. Biol. Chem. 274, 18165–72 (1999). 
107. Lan, M. S., Batra, S. K., Qi, W. N., Metzgar, R. S. & Hollingsworth, M. A. Cloning and 
sequencing of a human pancreatic tumor mucin cDNA. J. Biol. Chem. 265, 15294–
15299 (1990). 
108. Hanisch, F. G. & Müller, S. MUC1: the polymorphic appearance of a human mucin. 
Glycobiology 10, 439–449 (2000). 
109. Litvinov, S. V. & Hilkens, J. The epithelial sialomucin, episialin, is sialylated during 
recycling. J. Biol. Chem. 268, 21364–21371 (1993). 
110. Thathiah, A., Blobel, C. P. & Carson, D. D. Tumor necrosis factor-α converting 
enzyme/ADAM 17 mediates MUC1 shedding. J. Biol. Chem. 278, 3386–3394 (2003). 
111. Thathiah, A. & Carson, D. D. MT1-MMP mediates MUC1 shedding independent of 
TACE/ADAM17. Biochem. J 382, 363–373 (2004). 
112. Kufe, D. MUC1-C oncoprotein as a target in breast cancer: activation of signaling 
pathways and therapeutic approaches. Oncogene 32, 1073–1081 (2012). 
113. Li, Y., Liu, D., Chen, D., Kharbanda, S. & Kufe, D. Human DF3/MUC1 carcinoma-
associated protein functions as an oncogene. Oncogene 22, 6107–6110 (2003). 
114. Huang, L. et al. MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3B–Mediated 
Phosphorylation and Degradation of B-Catenin. Cancer Res 65, 10413–22 (2005). 
115. Schroeder, J. A. et al. MUC1 overexpression results in mammary gland tumorigenesis 
and prolonged alveolar differentiation. Oncogene 23, 5739–5747 (2004). 
116. Kardon, R. et al. Bacterial conjunctivitis in Muc1 null mice. Invest. Ophthalmol. Vis. 
Sci. 40, 1328–35 (1999). 
117. McAuley, J. L. et al. MUC1 cell surface mucin is a critical element of the mucosal 
barrier to infection. J. Clin. Invest. 117, 2313–24 (2007). 
118. Desouza, M. M. et al. MUC1/episialin: a critical barrier in the female reproductive tract. 
J. Reprod. Immunol. 45, 127–158 (1999). 
119. Lillehoj, E. P., Kim, H., Chun, E. Y., Kim, K. C. & Chul, K. Pseudomonas aeruginosa 
stimulates phosphorylation of the airway epithelial membrane glycoprotein Muc1 and 
activates MAP kinase. 
120. Finn, O. J., Beatty, P. L., Plevy, S. E. & Sepulveda, A. R. Cutting Edge: Transgenic 
Expression of Cutting Edge: Transgenic Expression of Human MUC1 in IL-10 ؊/؊ 
Mice Accelerates Inflammatory Bowel Disease and Progression to Colon Cancer 1. J 
Immunol Ref. 179, 735–739 (2007). 
121. Ligtenberg, M. J. L., Buijs, F., Vos, H. L. & Milkens2, J. Suppression of Cellular 
Aggregation by High Levels of Episialin. CANCER Res. 52, 2318–2324 (1992). 
122. Wesseling, J., Van Der Valk, S. W. & Hilkens, J. A Mechanism for Inhibition of E-
 273 
Cadherin-mediated Cell-Cell Adhesion by the Membrane-associated Mucin 
Episialin/MUC1. Mol. Biol. Cell 7, 565–577 (1996). 
123. Pimental, R. A., Julian, J., Gendler, S. J. & Carson, D. D. Synthesis and Intracellular 
Trafficking of Muc-1 and Mucins by Polarized Mouse Uterine Epithelial Cells*. 
124. Zaretsky, J. Z. et al. Expression of genes coding for pS2, c-erbB2, estrogen receptor 
and the H23 breast tumor-associated antigen. A comparative analysis in breast 
cancer. FEBS Lett. 265, 46–50 (1990). 
125. Hinoda, Y. et al. Increased expression of MUC1 in advanced pancreatic cancer. J. 
Gastroenterol. 38, 1162–6 (2003). 
126. Utsunomiya, T. et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas: 
its relationship with the prognosis of the patients. Clin. Cancer Res. 4, 2605–14 (1998). 
127. Dong, Y. et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. 
J. Pathol. 183, 311–7 (1997). 
128. Takahashi, T. et al. Expression of MUC1 on myeloma cells and induction of HLA-
unrestricted CTL against MUC1 from a multiple myeloma patient. J. Immunol. 153, 
2102–9 (1994). 
129. Dyomin, V. G. et al. MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) 
translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 95, 
2666–71 (2000). 
130. Thompson, F. et al. Clonal chromosome abnormalities in human breast carcinomas. 
I. Twenty-eight cases with primary disease. Genes. Chromosomes Cancer 7, 185–93 
(1993). 
131. Bièche, I. & Lidereau, R. A gene dosage effect is responsible for high overexpression 
of the MUC1 gene observed in human breast tumors. Cancer Genet. Cytogenet. 98, 
75–80 (1997). 
132. Lacunza, E. et al. MUC1 oncogene amplification correlates with protein 
overexpression in invasive breast carcinoma cells. Cancer Genet. Cytogenet. 201, 
102–110 (2010). 
133. Zaretsky, J. Z. et al. Analysis of the promoter of the MUC1 gene overexpressed in 
breast cancer. FEBS Lett. 461, 189–195 (1999). 
134. Lagow, E. L. & Carson, D. D. Synergistic stimulation of MUC1 expression in normal 
breast epithelia and breast cancer cells by interferon-gamma and tumor necrosis 
factor-alpha. J. Cell. Biochem. 86, 759–772 (2002). 
135. Iorio, M. V et al. MicroRNA gene expression deregulation in human breast cancer. 
Cancer Res. 65, 7065–7070 (2005). 
136. Rajabi, H. et al. Mucin 1 oncoprotein expression is suppressed by the miR-125b 
oncomir. Genes and Cancer 1, 62–68 (2010). 
137. Yamada, N. et al. MUC1 expression is regulated by DNA methylation and histone H3 
lysine 9 modification in cancer cells. Cancer Res. 68, 2708–2716 (2008). 
 274 
138. Dalziel, M. et al. The relative activities of the C2GnT1 and ST3Gal-I 
glycosyltransferases determine O-glycan structure and expression of a tumor-
associated epitope on MUC1. J. Biol. Chem. 276, 11007–15 (2001). 
139. Brockhausen, I. & Yang, J. Mechanisms underlying aberrant glycosylation of MUC1 
mucin in breast cancer cells. Eur. J. … 617, 607–617 (1995). 
140. Burchell, J. et al. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast 
carcinomas. Glycobiology 9, 1307–11 (1999). 
141. Picco, G. et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis. 
Glycobiology 20, 1241–1250 (2010). 
142. Altschuler, Y. et al. Clathrin-mediated Endocytosis of MUC1 Is Modulated by Its 
Glycosylation State. Mol. Biol. Cell 11, 819–831 (2000). 
143. Kufe, D. et al. Differential reactivity of a novel monoclonal antibody (DF3) with human 
malignant versus benign breast tumors. Hybridoma 3, 223–32 (1984). 
144. Ramasamy, S. et al. The MUC1 and galectin-3 oncoproteins function in a microRNA-
dependent regulatory loop. Mol. Cell 27, 992–1004 (2007). 
145. Bitler, B. G., Goverdhan, A. & Schroeder, J. A. MUC1 regulates nuclear localization 
and function of the epidermal growth factor receptor. J. Cell Sci. 123, 1716–23 (2010). 
146. Pochampalli, M., El Bejjani, R. & Schroeder, J. MUC1 is a novel regulator of ErbB1 
receptor trafficking. Oncogene 26, 1693–1701 (2007). 
147. Sahraei, M. et al. MUC1 regulates PDGFA expression during pancreatic cancer 
progression. Oncogene 31, (2012). 
148. Pandey, P., Kharbanda, S. & Kufe, D. Association of the DF3/MUC1 breast cancer 
antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res. 55, 4000–3 (1995). 
149. Kitamoto, S. et al. MUC1 enhances hypoxia-driven angiogenesis through the 
regulation of multiple proangiogenic factors. Oncogene 32, (2012). 
150. Beatson, R. et al. MUC1 modulates the tumor immune microenvironment through the 
engagement of Siglec-9. Nat. Immunol. 17, 1273–1281 (2017). 
151. Lüttges, J., Feyerabend, B., Buchelt, T., Pacena, M. & Klöppel, G. The mucin profile 
of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am. J. Surg. 
Pathol. 26, 466–71 (2002). 
152. Nakamori, S., Ota, D. M., Cleary, K. R., Shirotani, K. & Irimura, T. MUC1 mucin 
expression as a marker of progression and metastasis of human colorectal carcinoma. 
Gastroenterology 106, 353–61 (1994). 
153. Rahn, J. J., Dabbagh, L., Pasdar, M. & Hugh, J. C. The importance of MUC1 cellular 
localization in patients with breast carcinoma: an immunohistologic study of 71 
patients and review of the literature. Cancer 91, 1973–82 (2001). 
154. Pitroda, S. P., Khodarev, N. N., Beckett, M. A., Kufe, D. W. & Weichselbaum, R. R. 
MUC1-induced alterations in a lipid metabolic gene network predict response of 
human breast cancers to tamoxifen treatment. Proc. Natl. Acad. Sci. U. S. A. 106, 
 275 
5837–41 (2009). 
155. Safi, F., Kohler, I., Röttinger, E. & Beger, H. The value of the tumor marker CA 15-3 
in diagnosing and monitoring breast cancer. A comparative study with 
carcinoembryonic antigen. Cancer 68, 574–82 (1991). 
156. Steinberg, W. The clinical utility of the CA 19-9 tumor-associated antigen. Am. J. 
Gastroenterol. 85, 350–5 (1990). 
157. Winter, J. M. et al. A Novel Survival-Based Tissue Microarray of Pancreatic Cancer 
Validates MUC1 and Mesothelin as Biomarkers. PLoS One 7, e40157 (2012). 
158. Rivalland, G., Loveland, B. & Mitchell, P. Update on Mucin-1 immunotherapy in 
cancer: a clinical perspective. Expert Opin. Biol. Ther. 15, 1773–1787 (2015). 
159. Barnd, D. L., Lan, M. S., Metzgar, R. S. & Finn, O. J. Specific, major histocompatibility 
complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T 
cells. Proc. Natl. Acad. Sci. U. S. A. 86, 7159–63 (1989). 
160. Jerome, K. R. et al. Cytotoxic T-lymphocytes derived from patients with breast 
adenocarcinoma recognize an epitope present on the protein core of a mucin molecule 
preferentially expressed by malignant cells. Cancer Res. 51, 2908–16 (1991). 
161. Hiltbold, E. M. et al. The mechanism of unresponsiveness to circulating tumor antigen 
MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. 
165, 3730–3741 (2000). 
162. Melero, I. et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. 
Rev. Clin. Oncol. 11, 509–24 (2014). 
163. Hossain, M. K. & Wall, K. A. Immunological Evaluation of Recent MUC1 Glycopeptide 
Cancer Vaccines. Vaccines 4, 1–13 (2016). 
164. Cai, H. et al. Synthesis of Tn/T Antigen MUC1 Glycopeptide BSA Conjugates and 
Their Evaluation as Vaccines. European J. Org. Chem. 2011, 3685–3689 (2011). 
165. Kim, S. K. et al. Comparison of the effect of different immunological adjuvants on the 
antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH 
conjugate cancer vaccines. Vaccine 18, 597–603 (1999). 
166. Kaiser, A. et al. A synthetic vaccine consisting of a tumor-associated sialyl-T NMUC1 
tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly 
selective immune response. Angew. Chemie - Int. Ed. 48, 7551–7555 (2009). 
167. Palitzsch, B. et al. A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal 
Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables 
the Diagnosis of Human Pancreatic Cancer. Angew. Chemie Int. Ed. 55, 2894–2898 
(2016). 
168. Apostolopoulos, V., Pietersz, G. A. & Mckenzie, I. F. C. Cell-mediated immune 
responses to MUCl fusion protein coupled to mannan. 14, 930–938 (1996). 
169. Apostolopoulos, V. & Thalhammer, T. Targeting antigens to dendritic cell receptors for 
vaccine development. J. drug … 2013, (2013). 
 276 
170. Vassilaros, S. et al. Up to 15-year clinical follow-up of a pilot Phase III immunotherapy 
study in stage II breast cancer patients using oxidized mannan-MUC1. 
Immunotherapy 5, 1177–82 (2013). 
171. Apostolopoulos, V. et al. Pilot phase III immunotherapy study in early-stage breast 
cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer 
Res. 8, R27 (2006). 
172. Karanikas, V. et al. Mannan Mucin-1 Peptide Immunization: Influence of 
Cyclophosphamide and the Route of Injection. J. Immunother. (1991). 24, 172–183 
(2001). 
173. Samuel, J. et al. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-
based vaccine. Int. J. Cancer 75, 295–302 (1998). 
174. Butts, C. et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for 
stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 
trial. Lancet Oncol. 15, 59–68 (2014). 
175. Mitchell, P. et al. Tecemotide in unresectable stage III non-small-cell lung cancer in 
the phase III START study: updated overall survival and biomarker analyses. Ann. 
Oncol. 26, 1134–1142 (2015). 
176. Dreicer, R. et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA 
doubling time in patients with prostate cancer with biochemical failure. Invest. New 
Drugs 27, 379–386 (2009). 
177. Arriola, E. & Ottensmeier, C. TG4010: a vaccine with a therapeutic role in cancer. 
Immunotherapy 8, 511–519 (2016). 
178. Lohmueller, J. J. et al. Antibodies elicited by the first non-viral prophylactic cancer 
vaccine show tumor-specificity and immunotherapeutic potential. Sci. Rep. 6, 31740 
(2016). 
179. Lohmueller, J. & Finn, O. J. Current modalities in cancer immunotherapy: 
Immunomodulatory antibodies, CARs and vaccines. Pharmacology and Therapeutics 
(2017). doi:10.1016/j.pharmthera.2017.03.008 
180. Ibrahim, N. K. et al. Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody 
AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast 
Cancer. Clin. Cancer Res. 17, (2011). 
181. Hird, V. et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. 
Br. J. Cancer 68, 403–6 (1993). 
182. Verheijen, R. H. et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled 
HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a 
surgically defined complete remission. J. Clin. Oncol. 24, 571–8 (2006). 
183. Oei, A. L. et al. Decreased intraperitoneal disease recurrence in epithelial ovarian 
cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-
labeled murine HMFG1 without improvement in overall survival. Int. J. Cancer 120, 
 277 
2710–2714 (2007). 
184. Ocean, A. J. et al. Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan 
and low-dose gemcitabine is active in advanced pancreatic cancer. Cancer 118, 
5497–5506 (2012). 
185. Moreno, M. et al. High level of MUC1 in serum of ovarian and breast cancer patients 
inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). 
doi:10.1016/j.canlet.2007.06.016 
186. Marincola, F. M. et al. Loss of HLA haplotype and B locus down-regulation in 
melanoma cell lines. J. Immunol. 153, 1225–37 (1994). 
187. Koopman, L. A., Corver, W. E., Van Der Slik, A. R., Giphart, M. J. & Fleuren, G. J. 
Multiple Genetic Alterations Cause Frequent and Heterogeneous Human 
Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer. J. Exp. Med 
191, 961–975 (2000). 
188. Cabrera, T. et al. High Frequency of Altered HLA Class I Phenotypes in Laryngeal 
Carcinomas. Hum. Immunol. 61, 499–506 (2000). 
189. Cabrera, T. et al. High frequency of altered HLA class I phenotypes in invasive 
colorectal carcinomas. Tissue Antigens 114–123 (1998). 
190. Cabrera, T. et al. High frequency of altered HLA class I phenotypes in invasive breast 
carcinomas. Hum. Immunol. 50, 127–134 (1996). 
191. Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell 144, 
646–674 (2011). 
192. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage 
polarization: tumor-associated macrophages as a paradigm for polarized M2 
mononuclear phagocytes. TRENDS Immunol. 23, (2002). 
193. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 
6, 295–307 (2006). 
194. Ostrand-Rosenberg, S. & Sinha, P. Inflammation and Cancer Myeloid-Derived 
Suppressor Cells: Linking Myeloid-Derived Suppressor Cells: Linking Inflammation 
and Cancer 1. J Immunol Ref. 18218284499, 4499–4506 (2009). 
195. Pickup, M., Novitskiy, S. & Moses, H. L. The roles of TGFβ in the tumour 
microenvironment. Nat. Publ. Gr. 13, (2013). 
196. Robert, C. et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic 
Melanoma. N Engl J Med 364, 2517–26 (2011). 
197. Hodi, F. S. et al. Improved Survival with Ipilimumab in Patients with Metastatic 
Melanoma. n engl j med 3638363, 711–23 (2010). 
198. National Cancer Institute (NIH). FDA Approval for Ipilimumab - National Cancer 
Institute. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/fda-
ipilimumab. (Accessed: 24th September 2017) 
199. U.S Food and Drug Administration. FDA approves Yervoy to reduce the risk of 
 278 
melanoma returning after surgery. Available at: 
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469944.htm. 
(Accessed: 24th September 2017) 
200. Keytruda (pembrolizumab) FDA Approval History - Drugs.com. Available at: 
https://www.drugs.com/history/keytruda.html. (Accessed: 24th September 2017) 
201. Opdivo (nivolumab) FDA Approval History - Drugs.com. Available at: 
https://www.drugs.com/history/opdivo.html. (Accessed: 24th September 2017) 
202. U.S Food and Drug Administration. FDA approves first cancer treatment for any solid 
tumor with a specific genetic feature. (2017). Available at: 
https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htm. 
(Accessed: 24th September 2017) 
203. Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the 
immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. 
J. Med. 319, 1676–80 (1988). 
204. List results of engineered TCRs - ClinicalTrials.gov. clinicaltrials.gov Available at: 
https://clinicaltrials.gov/ct2/results?cond=&term=engineered+TCRs&cntry1=&state1=
&recrs=. (Accessed: 7th October 2017) 
205. Adaptimmune. Press Release :: Investors :: Adaptimmune. Available at: 
http://ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-
newsArticle&ID=2175118. (Accessed: 7th October 2017) 
206. Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates 
cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 
535–46 (2009). 
207. Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-
A3 TCR gene therapy. J. Immunother. 36, 133–51 (2013). 
208. Porter, D. L. et al. Chimeric Antigen Receptor Modified T Cells Directed Against CD19 
(CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In 
Relapsed, Refractory CLL. in 55th ASH Annual Meeting and Exposition (2013). 
209. Porter, D. L. et al. Randomized, Phase II Dose Optimization Study Of Chimeric Antigen 
Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With 
Relapsed, Refractory CLL. in 55th ASH Annual Meeting and Exposition (2013). 
210. Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Karpenter, R. O. & Yang, J. C. 
Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma 
With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric 
Antigen Receptor. in 55th ASH Annual Meeting and Exposition (2013). 
211. Maude, S. L. et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in 
Leukemia. N. Engl. J. Med. 371, 1507–1517 (2014). 
212. Gross, G., Eshhar, Z. & Waks, T. Expression of immunoglobulin-T-cell receptor 
chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. 
 279 
Acad. Sci. U. S. A. 86, 10024–8 (1989). 
213. Eshhar, Z. & Gross, G. Chimeric T cell receptor which incorporates the anti-tumour 
specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system 
for immunotherapeutical approach. Br. J. Cancer. Suppl. 10, 27–9 (1990). 
214. Guest, R. et al. TheRoleofExtracellularSpacerRegionsinthe 
OptimalDesignofChimericImmuneReceptors 
EvaluationofFourDifferentscFvsandAntigens. J. Immunother. (1991). 28, (2005). 
215. Gong, M. C. et al. Cancer patient T cells genetically targeted to prostate-specific 
membrane antigen specifically lyse prostate cancer cells and release cytokines in 
response to prostate-specific membrane antigen. Neoplasia 1, 123–7 (1999). 
216. Maher, J., Brentjens, R. J., Gunset, G., Rivière, I. & Sadelain, M. Human T-lymphocyte 
cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. 
Nat. Biotechnol. 20, 70–5 (2002). 
217. Zhao, Y. et al. A herceptin-based chimeric antigen receptor with modified signaling 
domains leads to enhanced survival of transduced T lymphocytes and antitumor 
activity. J. Immunol. 183, 5563–74 (2009). 
218. U.S Food & Drug Administration. Approved Drugs - FDA approves tisagenlecleucel 
for B-cell ALL and tocilizumab for cytokine release syndrome. (Center for Drug 
Evaluation and Research). 
219. U.S Food & Drug Administration. KYMRIAH Prescribing information. 
220. Maude, S. L., Barrett, D., Teachey, D. T. & Grupp, S. A. Managing Cytokine Release 
Syndrome Associated With Novel T Cell-Engaging Therapies. 
doi:10.1097/PPO.0000000000000035 
221. Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T 
cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112–
20 (2014). 
222. Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-
positive T cells in patients with neuroblastoma. Blood 118, 6050–6 (2011). 
223. van Schalkwyk, M. C. I. et al. Design of a phase I clinical trial to evaluate intratumoral 
delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or 
recurrent head and neck cancer. Hum. Gene Ther. Clin. Dev. 24, 134–42 (2013). 
224. Noy, R. & Pollard, J. W. Tumor-Associated Macrophages: From Mechanisms to 
Therapy. Immunity 41, 49–61 (2014). 
225. Olumi, A. F. et al. Carcinoma-associated Fibroblasts Direct Tumor Progression of 
Initiated Human Prostatic Epithelium. CANCER Res. 59, 5002–5011 (1999). 
226. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the 
immune system. Nat. Rev. Immunol. 9, 162–174 (2009). 
227. Powell, D. R. & Huttenlocher, A. Neutrophils in the Tumor Microenvironment. Trends 
Immunol. 37, 41–52 (2016). 
 280 
228. Sica, A. et al. Autocrine Production of IL-10 Mediates Defective IL-12 Production and 
NF- B Activation in Tumor-Associated Macrophages. J. Immunol. 164, 762–767 
(2000). 
229. Biswas, S. K. et al. A distinct and unique transcriptional program expressed by tumor-
associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation). 
Blood 107, 2112–2122 (2006). 
230. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters 
immune privilege and predicts reduced survival. Nat. Med. 10, 942–949 (2004). 
231. Liu, J. et al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and 
promote the development of colorectal cancer via enhancing CCL20 production in 
mice. PLoS One 6, (2011). 
232. Rodriguez, P. C. et al. L-Arginine Consumption by Macrophages Modulates the 
Expression of CD3 Chain in T Lymphocytes. J. Immunol. 171, 1232–1239 (2003). 
233. Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate 
systemic tumors without need for prior conditioning. Blood 119, 4133–4141 (2012). 
234. Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D. & Brentjens, R. J. Armored CAR 
T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. 
Rep. 7, 10541 (2017). 
235. John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of 
established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636–5646 (2013). 
236. Chong, E. A. et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-
modified T cells: Refueling the CAR. Blood 129, 1039–1041 (2017). 
237. Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to 
PD1 inhibition. Clin. Cancer Res. 23, 2255–2266 (2017). 
238. Lim, W. A. & June, C. H. The Principles of Engineering Immune Cells to Treat Cancer. 
Cell 168, 724–740 (2017). 
239. Kawalekar, O. U. et al. Distinct Signaling of Coreceptors Regulates Specific 
Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity 
44, 380–390 (2016). 
240. Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances 
tumour rejection. Nature 543, 113–117 (2017). 
241. Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic 
signaling of chimeric antigen receptors. Nat. Med. 1–13 (2015). doi:10.1038/nm.3838 
242. Shum, T. et al. Constitutive signaling from an engineered IL-7 receptor promotes 
durable tumor elimination by tumor redirected T-cells. Cancer Discov. CD-17-0538 
(2017). doi:10.1158/2159-8290.CD-17-0538 
243. Craddock, J. A. et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T 
cells by expression of the chemokine receptor CCR2b. J. Immunother. 33, 780–8 
(2010). 
 281 
244. Moon, E. K. et al. Expression of a functional CCR2 receptor enhances tumor 
localization and tumor eradication by retargeted human T cells expressing a 
mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17, 4719–4730 
(2011). 
245. Di Stasi, A. et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor 
targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor 
model. Blood 113, 6392–6402 (2009). 
246. Scheuermann, R. H. & Racila, E. CD19 antigen in leukemia and lymphoma diagnosis 
and immunotherapy. Leuk. Lymphoma 18, 385–397 (1995). 
247. Uckun, F. M. et al. Detailed Studies on Expression and Function of CD19 Surface 
Determinant by Using B43 Monoclonal Antibody and the Clinical Potential of Anti-
CD19 Immunotoxins. Blood 71, 
248. Kochenderfer, J. N. et al. B--cell depletion and remissions of malignancy along with 
cytokine- associated toxicity in a clinical trial of anti-CD19 chimeric-antigen- receptor–
transduced T cells. Blood 119, 2709–2720 (2012). 
249. Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma 
in a patient treated with autologous T cells genetically engineered to recognize CD19. 
Blood 116, 4099–4102 (2010). 
250. Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P. & Rosenberg, S. A. Adoptive 
transfer of syngeneic T cells transduced with a chimeric antigen receptor that 
recognizes murine CD19 can eradicate lymphoma and normal B cells. 116, 3875–
3886 (2010). 
251. Quartier, P. et al. Early and prolonged intravenous immunoglobulin replacement 
therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J. 
Pediatr. 134, 589–96 (1999). 
252. Lamers, C. H. J. et al. Treatment of metastatic renal cell carcinoma with autologous 
T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical 
experience. J. Clin. Oncol. 24, e20-2 (2006). 
253. Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-
engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 
21, 904–912 (2013). 
254. Yan, M. et al. HER2 expression status in diverse cancers: review of results from 
37,992 patients. Cancer Metastasis Rev. 34, 157–64 (2015). 
255. Press, M. F., Cordon-Cardo, C. & Slamon, D. J. Expression of the HER-2/neu proto-
oncogene in normal human adult and fetal tissues. Oncogene 5, 953–62 (1990). 
256. Morgan, R. A. et al. Case report of a serious adverse event following the administration 
of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 
18, 843–51 (2010). 
257. Ahmed, N. et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific 
 282 
Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive 
Sarcoma. J. Clin. Oncol. 33, 1688–96 (2015). 
258. Ahmed, N. et al. Immunotherapy for Osteosarcoma: Genetic Modification of T cells 
Overcomes Low Levels of Tumor Antigen Expression. Mol. Ther. 17, 1779–1787 
(2009). 
259. Hammarstrom. The carcinoembryonic anigen (CEA) family: structures, suggested 
functions and expression in normal and malignant tissues. Semin. CANCER BI 
OLOGY 9, (1999). 
260. Parkhurst, M. R. et al. Characterization of genetically modified T-cell receptors that 
recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal 
cancer cells. Clin. Cancer Res. 15, 169–80 (2009). 
261. Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate 
regression of metastatic colorectal cancer but induce severe transient colitis. Mol. 
Ther. 19, 620–6 (2011). 
262. Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-
cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048–2060 (2013). 
263. Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen 
receptor cause remissions of multiple myeloma. Blood 128, 1688–1700 (2016). 
264. Dutour,  a et al. In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-
Expressing EBV-CTL against CD33 Acute Myeloid Leukemia. Adv. Hematol. 2012, 
683065 (2012). 
265. Pizzitola, I. et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently 
target primary acute myeloid leukemia cells in vivo. Leukemia 1–10 (2014). 
doi:10.1038/leu.2014.62 
266. Mardiros, A. et al. T cells expressing CD123-specific chimeric antigen receptors 
exhibit specific cytolytic effector functions and antitumor effects against human acute 
myeloid leukemia. Blood 122, 3138–3148 (2013). 
267. Wang, Q. et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells 
in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23, 
184–91 (2015). 
268. Cellectis. Cellectis Reports Clinical Hold of UCART123 Studies | Cellectis. Available 
at: http://www.cellectis.com/en/press/cellectis-reports-clinical-hold-of-ucart123-
studies/. (Accessed: 1st October 2017) 
269. Wilkie, S. et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric 
antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 
32, 1059–70 (2012). 
270. Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. 
Combinatorial antigen recognition with balanced signaling promotes selective tumor 
eradication by engineered T cells. Nat. Biotechnol. 31, 71–5 (2013). 
 283 
271. Lanitis, E. et al. Chimeric Antigen Receptor T Cells with Dissociated Signaling 
Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In 
Vivo. Cancer Immunol. Res. 1, 43–53 (2013). 
272. Roybal, K. T. et al. Precision Tumor Recognition by T Cells with Combinatorial 
Antigen-Sensing Circuits. Cell 164, 770–779 (2016). 
273. Morsut, L. et al. Engineering Customized Cell Sensing and Response Behaviors Using 
Synthetic Notch Receptors. Cell 780–791 (2016). doi:10.1016/j.cell.2016.01.012 
274. Roybal, K. T. et al. Engineering T Cells with Customized Therapeutic Response 
Programs Using Synthetic Notch Receptors. Cell 167, 419–432 (2016). 
275. Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory 
chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. 
Transl. Med. 5, 215ra172 (2013). 
276. Fitzgerald, J. C. et al. Cytokine Release Syndrome After Chimeric Antigen Receptor 
T Cell Therapy for Acute Lymphoblastic Leukemia. Crit. Care Med. 45, e124–e131 
(2017). 
277. Prudent, V. & Breitbart, W. S. Chimeric antigen receptor T-cell neuropsychiatric 
toxicity in acute lymphoblastic leukemia. doi:10.1017/S147895151600095X 
278. Davila, M. L., Kloss, C. C., Gunset, G. & Sadelain, M. CD19 CAR-Targeted T Cells 
Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse 
Model of B Cell Acute Lymphoblastic Leukemia. PLoS One 8, (2013). 
279. Juno Therapeutics. News Release | Juno Therapeutics. Available at: 
http://ir.junotherapeutics.com/phoenix.zhtml?c=253828&p=irol-
newsArticle&ID=2250772. (Accessed: 26th September 2017) 
280. Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N 
Engl J Med 365, 1673–1683 (2011). 
281. Zhou, X. et al. Inducible caspase-9 suicide gene controls adverse effects from 
alloreplete T cells after haploidentical stem cell transplantation. Blood 125, 4103–4113 
(2015). 
282. Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J. & Lim, W. A. Remote control of 
therapeutic T cells through a small molecule-gated chimeric receptor. Science (80-. ). 
350, aab4077-aab4077 (2015). 
283. Cheever, M. a et al. The prioritization of cancer antigens: a national cancer institute 
pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323–
37 (2009). 
284. Curry, J. M. et al. The use of a novel MUC1 antibody to identify cancer stem cells and 
circulating MUC1 in mice and patients with pancreatic cancer. J. Surg. Oncol. (2013). 
doi:10.1002/jso.23316 
285. Moore, L. J. et al. Antibody-Guided In Vivo Imaging for Early Detection of Mammary 
Gland Tumors. Transl. Oncol. 9, 295–305 (2016). 
 284 
286. OncoTAb. About OncoTAb - OncoTAb. Available at: https://www.oncotab.com/about/. 
(Accessed: 12th September 2017) 
287. Taylor-Papadimitriou~, J. et al. Monoclonal Antibodies To Epithelium-Specific 
Components of the Human Milk Fat Globule Membrane: Production and Reaction With 
Cells in Culture. Int. J. Cancer 28, 17–21 (1981). 
288. Burchell, J. Detection of the tumour-associated antigens recognized by the 
monoclonal antibodies HMFG-1 and HMFG-2 in serum from patients with breast 
cancer. Int. J. Cancer 768, 763–768 (1984). 
289. Epenetos, A. A., Canti, G., Curling, M., Bodmer, W. F. & Taylor-Papadimitriou, J. Use 
of two epithelium-specific monoclonal antibodies for diagnosis in serous effusions. 
Lancet 1004–1006 (1982). 
290. Abramenko, I. V., Gluzman, D. F., Sklyarenko, L. M., Pisnyachevskaya, G. V. & 
Pinchouk, V. G. Immunocytochemical staining of cells in 153 pleural effusions with a 
panel of monoclonal antibodies and lectins. Anticancer Res. 11, 629–634 (1991). 
291. Epenetos, A. A. et al. TARGETING OF IODINE-123-LABELLED TUMOUR-
ASSOCIATED MONOCLONAL ANTIBODIES TO OVARIAN, BREAST, AND 
GASTROINTESTINAL TUMOURS. Lancet 320, 999–1004 (1982). 
292. Epenetos, A. A. et al. 123I radioiodinated antibody imaging of occult ovarian cancer. 
Cancer 55, 984–987 (1985). 
293. Riviere, I., Brose, K. & Mulligan, R. C. Effects of retroviral vector design on expression 
of human adenosine deaminase in murine bone marrow transplant recipients 
engrafted with genetically modified cells. Proc. Natl. Acad. Sci. 92, 6733–6737 (1995). 
294. Brewin, J. et al. Generation of EBV-specific cytotoxic T cells that are resistant to 
calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative 
disease. 114, 4792–4803 (2009). 
295. Wilkie, S. et al. Retargeting of human T cells to tumor-associated MUC1: the evolution 
of a chimeric antigen receptor. J. Immunol. 180, 4901–9 (2008). 
296. Whilding, L. M. et al. Targeting of Aberrant ??v??6 Integrin Expression in Solid Tumors 
Using Chimeric Antigen Receptor-Engineered T Cells. Mol. Ther. 25, 259–273 (2017). 
297. Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally. 
Cancer Cell 10, 515–527 (2009). 
298. Kenny, P. A. et al. The morphologies of breast cancer cell lines in three-dimensional 
assays correlate with their profiles of gene expression. Mol. Oncol. 1, 84–96 (2007). 
299. Roy, C. et al. An analytical study of the dimerization of in vitro generated RNA of 
Moloney murine leukemia virus MoMuLV. Nucleic Acids Res. 18, 7287–92 (1990). 
300. Coffin, J. M., Hughes, S. H. & Varmus, H. E. Retroviruses. Retroviruses (Cold Spring 
Harbor Laboratory Press, 1997). 
301. Nisole, S. et al. Early steps of retrovirus replicative cycle. Retrovirology 1, 9 (2004). 
302. Roe, T., Reynolds, T. C., Yu, G. & Brown, P. O. Integration of murine leukemia virus 
 285 
DNA depends on mitosis. EMBO J. 12, 2099–108 (1993). 
303. Stake, M. S., Bann, D. V, Kaddis, R. J. & Parent, L. J. Nuclear trafficking of retroviral 
RNAs and Gag proteins during late steps of replication. Viruses 5, 2767–95 (2013). 
304. Ory, D. S., Neugeborent, B. A. & Mulligantt, R. C. A stable human-derived packaging 
cell line for production of high titer retrovirus / vesicular stomatitis virus G pseudotypes. 
93, 11400–11406 (1996). 
305. Miller, A., Garcia, J. & Suhr, N. Von. Construction and properties of retrovirus 
packaging cells based on gibbon ape leukemia virus. J. … 65, 2220–2224 (1991). 
306. Persons, D. a, Mehaffey, M. G., Kaleko, M., Nienhuis,  a W. & Vanin, E. F. An improved 
method for generating retroviral producer clones for vectors lacking a selectable 
marker gene. Blood Cells. Mol. Dis. 24, 167–82 (1998). 
307. Ghani, K. & Wang, X. Efficient human hematopoietic cell transduction using RD114-
and GALV-pseudotyped retroviral vectors produced in suspension and serum-free 
media. Hum. gene … 974, 966–974 (2009). 
308. Parente-Pereira, A. C., Wilkie, S., Van der Stegen, S. J. C., Davies, D. M. & Maher, J. 
Use of retroviral-mediated gene transfer to deliver and test function of chimeric antigen 
receptors in human T-cells. J. Biol. Methods 1, 7 (2014). 
309. Kingsley, D. M., Kozarsky, K. F., Hobbie, L. & Krieger, M. Reversible Defects in O-
Linked Glycosylation and LDL Receptor Expression in a UDP-GaWDP-GalNAc 4-
Epimerase Deficient Mutant. Cell 44, 749–759 (1966). 
310. Bäckström, M. et al. Recombinant MUC1 mucin with a breast cancer-like O-
glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem. J. 
376, 677–86 (2003). 
311. Link, T. et al. Bioprocess development for the production of a recombinant MUC1 
fusion protein expressed by CHO-K1 cells in protein-free medium. J. Biotechnol. 110, 
51–62 (2004). 
312. Beatson, R. et al. The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and 
sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL. 
PLoS One 10, e0125994 (2015). 
313. Louis, K. S. & Siegel, A. C. Cell Viability Analysis Using Trypan Blue: Manual and 
Automated Methods. in 7–12 (2011). doi:10.1007/978-1-61779-108-6_2 
314. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to 
proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63 (1983). 
315. Riss, T. L. et al. Cell Viability Assays. Assay Guidance Manual (Eli Lilly & Company 
and the National Center for Advancing Translational Sciences, 2004). 
316. Taylor-Papadimitriou, J. et al. Monoclonal antibodies to epithelium-specific 
components of the human milk fat globule membrane: production and reaction with 
cells in culture. Int. J. cancer 28, 17–21 (1981). 
317. Arklie, J., Taylor-Papadimitriou, J., Bodmer, W., Egan, M. & Millis, R. Differentiation 
 286 
antigens expressed by epithelial cells in the lactating breast are also detectable in 
breast cancers. Int. J. Cancer 28, 23–29 (1981). 
318. Burchell, J. Detection of the tumour-associated antigens recognized by the 
monoclonal antibodies HMFG-1 and HMFG-2 in serum from patients with breast 
cancer. Int. J. Cancer 768, 763–768 (1984). 
319. Burchell, J., Durbin, H. & Taylor-Papadimitriou, J. Complexity of expression of 
antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, 
in normal and malignant human mammary epithelial cells. J. Immunol. 131, 508–13 
(1983). 
320. Burchell, J. et al. Development and Characterization of Breast Cancer Reactive 
Monoclonal Antibodies Directed to the Core Protein of the Human Milk Mucin. Cancer 
Res. 5476–5482 (1987). 
321. Sørensen, A. L. et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 
glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override 
tolerance. Glycobiology 16, 96–107 (2006). 
322. Beverley, P. C. L. & Callard, R. E. Distinctive functional characteristics of human „T” 
lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. Eur. J. 
Immunol. 11, 329–334 (1981). 
323. Evans, R. L. et al. Thymus-dependent membrane antigens in man: Inhibition of cell-
mediated lympholysis by monoclonal antibodies to TH2 antigen. Immunology 78, 544–
548 (1981). 
324. Smith, S. H., Brown, M. H., Rowe, D., Callard, R. E. & Beverley, P. C. L. Functional 
subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1. 
Immunology 58, 63–70 (1986). 
325. May, K. F. et al. Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion 
and immunity in a hu-PBL-SCID model: a new method for preclinical screening of 
costimulatory monoclonal antibodies. Blood 105, 1114–20 (2005). 
326. the BD LSR Fortessa cytometer. Available at: 
http://www.bdbiosciences.com/ds/is/tds/23-9141.pdf. (Accessed: 9th July 2017) 
327. Leonard D. Shultz, Bonnie L. Lyons, Lisa M. Burzenski, Bruce Gott, Xiaohua Chen, 
Stanley Chaleff, Malak Kotb, Stephen D. Gillies, Marie King, Julie Mangada, D. L. & 
Handgretinger, G. and R. Human Lymphoid and Myeloid Cell Development in 
NOD/LtSz-scid IL2R null Mice Engrafted with Mobilized Human Hemopoietic Stem 
Cells. J. Immunol. 174, 6477–6489 (2005). 
328. The Jackson Laboratory. NOD scid gamma (NSG). Available at: 
https://www.jax.org/strain/005557. (Accessed: 10th July 2017) 
329. Shaner, N. C. et al. Improved monomeric red, orange and yellow fluorescent proteins 
derived from Discosoma sp. red fluorescent protein. Nat. Biotechnol. 22, 1567–1572 
(2004). 
 287 
330. Donnelly, M. L. L. et al. Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ 
mechanism indicates not a proteolytic reaction, but a novel translational effect: A 
putative ribosomal ‘skip’. J. Gen. Virol. 82, 1013–1025 (2001). 
331. Tomayko, M. M. & Reynolds, C. P. Determination of subcutaneous tumor size in 
athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148–54 (1989). 
332. Kimura, T. & Finn, O. J. MUC1 immunotherapy is here to stay. Expert Opin. Biol. Ther. 
13, 35–49 (2013). 
333. Roulois, D., Grégoire, M. & Fonteneau, J. F. J. MUC1-specific cytotoxic T lymphocytes 
in cancer therapy: induction and challenge. Biomed Res. Int. 2013, 871936 (2012). 
334. Kondo, H. et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-
pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 28, 379–387 
(2008). 
335. Maher, J. & Wilkie, S. CAR mechanics: driving T cells into the MUC of cancer. Cancer 
Res. 69, 4559–62 (2009). 
336. Posey, A. D., Clausen, H. & June, C. H. Distinguishing Truncated and Normal MUC1 
Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to 
Safety. Immunity 45, 947–948 (2016). 
337. Posey, A. D. et al. Engineered CAR T Cells Targeting the Cancer-Associated Tn-
Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity 44, 
1444–1454 (2016). 
338. You, F. et al. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal 
vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen 
receptor transduced T cells. Sci. China 59, 386–397 (2016). 
339. PersonGen BioTherapeutics (Suzhou) Co., L. CAR-T Cell Immunotherapy in MUC1 
Positive Solid Tumor - Full Text View - ClinicalTrials.gov. Available at: 
https://clinicaltrials.gov/ct2/show/NCT02617134?term=muc1+chimeric+antigen+rece
ptors&rank=2. (Accessed: 5th August 2017) 
340. PersonGen BioTherapeutics (Suzhou) Co., L. Phase I/II Study of Anti-Mucin1 (MUC1) 
CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor - Full Text 
View - ClinicalTrials.gov. Available at: 
https://clinicaltrials.gov/ct2/show/NCT02587689?term=muc1+chimeric+antigen+rece
ptors&rank=4. (Accessed: 5th August 2017) 
341. PersonGen BioTherapeutics (Suzhou) Co., L. CAR-pNK Cell Immunotherapy in MUC1 
Positive Relapsed or Refractory Solid Tumor. Available at: 
https://clinicaltrials.gov/ct2/show/NCT02839954?term=muc1+chimeric+antigen+rece
ptors&rank=1. (Accessed: 5th August 2017) 
342. Shanghai Cell Therapy Research Institute. CTLA-4 and PD-1 Antibodies Expressing 
MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor - Full Text View - 
ClinicalTrials.gov. Available at: 
 288 
https://clinicaltrials.gov/ct2/show/NCT03179007?term=muc1+chimeric+antigen+rece
ptors&rank=3. (Accessed: 5th August 2017) 
343. Taylor-Papadimitriou, J., Burchell, J., Miles, D. . W. & Dalziel, M. MUC1 and cancer. 
Biochim. Biophys. Acta - Mol. Basis Dis. 1455, 301–313 (1999). 
344. Walsh, M. D., Luckie, S. M., Cummings, M. C., Antalis, T. M. & McGuckin, M. a. 
Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and 
in vitro. Breast Cancer Res. Treat. 58, 255–266 (1999). 
345. Bear, A. S. et al. Replication-Competent Retroviruses in Gene-Modified T Cells Used 
in Clinical Trials: Is It Time to Revise the Testing Requirements? 20, (2012). 
346. Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric 
antigen receptor T cells. Sci. Transl. Med. 4, 132ra53 (2012). 
347. Pinku Mukherjee. Tumor specific antibodies and uses therefor. (2010). 
348. Sorensen, A. L. et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 
glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override 
tolerance. Glycobiology 16, 96–107 (2005). 
349. Ruella, M. et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after 
CD19-directed immunotherapies. J. Clin. Invest. 126, 3814–3826 (2016). 
350. Brunner, K. T., Mauel, J., Cerottini, J.-C. & Chapuis, B. Quantitative Assay of the Lytic 
Action of Immune Lymphoid Cells on 5&quot;Cr-Labelled Allogeneic Target Cells In 
vitro; Inhibition by Isoantibody and by Drugs. Immunology 14, (1968). 
351. Gertner-dardenne, J. Standard 4-hours Chromium-51 (51Cr) Release Assay. BIO-
PROTOCOL 2, (2012). 
352. Korzeniewski, C. & Callewaert, D. M. An enzyme-release assay for natural 
cytotoxicity. J. Immunol. Methods 64, 313–320 (1983). 
353. Decker, T. & Lohmann-Matthes, M. L. A quick and simple method for the quantitation 
of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor 
necrosis factor (TNF) activity. J. Immunol. Methods 115, 61–69 (1988). 
354. Corporation, P. CytoTox 96(R) Non-Radioactive Cytotoxicity Assay Technical Bulletin 
TB163. 608–277 
355. Coombe, D. R., Nakhoul, A.-M., Stevenson, S. M., Peroni, S. E. & Sanderson, C. J. 
Expressed luciferase viability assay (ELVA) for the measurement of cell growth and 
viability. J. Immunol. Methods 215, 145–150 (1998). 
356. Karimi, M. A. et al. Measuring cytotoxicity by bioluminescence imaging outperforms 
the standard chromium-51 release assay. PLoS One 9, e89357 (2014). 
357. Nakagawa, Y., Watari, E., Shimizu, M. & Takahashi, H. One-step simple assay to 
determine antigen-specific cytotoxic activities by single-color flow cytometry. Biomed. 
Res. 32, 159–166 (2011). 
358. Qin, L. et al. Incorporation of a hinge domain improves the expansion of chimeric 
antigen receptor T cells. doi:10.1186/s13045-017-0437-8 
 289 
359. Hudecek, M. et al. The non-signaling extracellular spacer domain of chimeric antigen 
receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125–135 
(2014). 
360. Hombach, A., Hombach, A. & Abken, H. Adoptive immunotherapy with genetically 
engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular 
moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended 
initiation of an innate immune response. Gene Ther. 17, 1206–121391 (2010). 
361. Frigault, M. J. et al. Identification of chimeric antigen receptors that mediate 
constitutive or inducible proliferation of T cells. Cancer Immunol. Res. 3, 356–367 
(2015). 
362. Murphy, K. & Weaver, K. Janeway’s Immunobiology. (Garland Science). 
363. Anderson, M. S. et al. Projection of an immunological self shadow within the thymus 
by the aire protein. Science 298, 1395–401 (2002). 
364. Moran, A. E. et al. T cell receptor signal strength in Treg and iNKT cell development 
demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208, 1279–89 
(2011). 
365. Liu, G. Y. et al. Low Avidity Recognition of Self-Antigen by T Cells Permits Escape 
from Central Tolerance. Immunity 3, 407–415 (1995). 
366. Redmond, W. L. & Sherman, L. A. Review Peripheral Tolerance of CD8 T 
Lymphocytes. Immunity 22, 275–284 (2005). 
367. Ohashi, P. S. et al. Ablation of ‘tolerance’ and induction of diabetes by virus infec- tion 
in viral antigen transgenic mice. Cell 65, 305–317 (1991). 
368. Mueller, D. L. Mechanisms maintaining peripheral tolerance. Nature Immunology 11, 
21–27 (2010). 
369. Hernandez, J., Aung, S., Redmond, W. L. & Sherman, L. A. Phenotypic and functional 
analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-
presentation of self-antigen. J. Exp. Med. 194, 707–17 (2001). 
370. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under 
steady state conditions in vivo. J. Exp. Med. 194, 769–79 (2001). 
371. Rocha, B., Grandien, A. & Freitas, A. A. Anergy and exhaustion are independent 
mechanisms of peripheral T cell tolerance. J. Exp. Med. 181, 993–1003 (1995). 
372. Mamalaki, C. et al. T cell deletion follows chronic antigen specific T cell activation in 
vivo. Int. Immunol. 5, 1285–92 (1993). 
373. Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function 
of induced regulatory T cells. J. Exp. Med. 206, 3015–29 (2009). 
374. Moon, E. K. et al. Multifactorial T-cell hypofunction that is reversible can limit the 
efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin. 
Cancer Res. 20, 4262–4273 (2014). 
375. Agrawal, B. & Longenecker, B. M. MUC1 mucin-mediated regulation of human T cells. 
 290 
Int. Immunol. 17, 391–399 (2005). 
376. Chang, J. F., Zhao, H. L., Phillips, J. & Greenburg, G. The epithelial mucin, MUC1, is 
expressed on resting T lymphocytes and can function as a negative regulator of T cell 
activation. Cell. Immunol. 201, 83–88 (2000). 
377. Agrawal, B., Krantz, M. J., Parker, J. & Longenecker, B. M. Expression of MUC1 mucin 
on activated human T cells: implications for a role of MUC1 in normal immune 
regulation. Cancer Res. 58, 4079–81 (1998). 
378. Correa, I. et al. Form and pattern of MUC1 expression on T cells activated in vivo or 
in vitro suggests a function in T-cell migration. Immunology 108, 32–41 (2003). 
379. Simms, P. E. & Ellis, T. M. Utility of flow cytometric detection of CD69 expression as 
a rapid method for determining poly- and oligoclonal lymphocyte activation. Clin. 
Diagn. Lab. Immunol. 3, 301–4 (1996). 
380. Tarp, M. A. et al. Identification of a novel cancer-specific immunodominant 
glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17, 197–209 (2006). 
381. Fattorossi, A. et al. Constitutive and Inducible Expression of the Epithelial Antigen 
MUC1 (CD227) in Human T Cells. Exp. Cell Res. 280, 107–118 (2002). 
382. Green, D. R., Droin, N. & Pinkoski, M. Activation-induced cell death in T cells. 
Immunol. Rev. 193, 70–81 (2003). 
383. Kunkele, A. et al. Functional Tuning of CARs Reveals Signaling Threshold above 
Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent 
AICD. Cancer Immunol. Res. 3, 368–379 (2015). 
384. Gargett, T. et al. GD2-specific CAR T Cells Undergo Potent Activation and Deletion 
Following Antigen Encounter but can be Protected From Activation-induced Cell Death 
by PD-1 Blockade. Mol. Ther. 24, 1135–1149 (2016). 
385. Lavrsen, K. et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast 
cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj. 
J. 30, 227–36 (2013). 
386. Hillerdal, V., Ramachandran, M., Leja, J. & Essand, M. Systemic treatment with CAR-
engineered T cells against PSCA delays subcutaneous tumor growth and prolongs 
survival of mice. BMC Cancer 14, 30 (2014). 
387. Shuk-Yee Lo, A., Xu, C., Murakami, A. & Marasco, W. A. Regression of established 
renal cell carcinoma in nude mice using lentivirus-transduced human T cells 
expressing a human anti-CAIX chimeric antigen receptor. Mol. Ther. – Oncolytics 1, 
14003 (2014). 
388. Huang, X. et al. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for 
High Risk Sarcomas. PLoS One 10, e0133152 (2015). 
389. Zhou, X. et al. Cellular immunotherapy for carcinoma using genetically modified 
EGFR-specific T lymphocytes. Neoplasia 15, 544–53 (2013). 
390. Parente-Pereira, A. C. et al. Synergistic Chemoimmunotherapy of Epithelial Ovarian 
 291 
Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin. J. Immunol. 191, 
2437–45 (2013). 
391. Klampatsa, A. et al. Intracavitary ???T4 immunotherapy??? of malignant 
mesothelioma using pan-ErbB re-targeted CAR T-cells. Cancer Lett. 393, 52–59 
(2017). 
392. Tasian, S. K. et al. Optimized depletion of chimeric antigen receptor T cells in murine 
xenograft models of human acute myeloid leukemia. Blood 129, (2017). 
393. Chen, K. H. et al. Preclinical targeting of aggressive T-cell malignancies using anti-
CD5 chimeric antigen receptor. Leukemia (2017). doi:10.1038/leu.2017.8 
394. Davila, M. L. et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy 
in B Cell Acute Lymphoblastic Leukemia. 6, (2015). 
395. Grupp, S. a. et al. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid 
Leukemia. N. Engl. J. Med. 368, 1509–1518 (2013). 
396. Cheadle, E. J. et al. Differential role of Th1 and Th2 cytokines in autotoxicity driven by 
CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. 
J. Immunol. 192, 3654–65 (2014). 
397. Tran, E. et al. Immune targeting of fibroblast activation protein triggers recognition of 
multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 210, 1125–35 
(2013). 
398. Kalaitsidou, M., Kueberuwa, G., Schütt, A. & Gilham, D. E. CAR T-cell therapy: toxicity 
and the relevance of preclinical models. Immunotherapy 7, 487–497 (2015). 
399. Song, D.-G. et al. Effective adoptive immunotherapy of triple-negative breast cancer 
by folate receptor-alpha redirected CAR T cells is influenced by surface antigen 
expression level. J. Hematol. Oncol. 9, 56 (2016). 
400. Sun, M. et al. Construction and evaluation of a novel humanized HER2-specific 
chimeric receptor. Breast Cancer Res. 16, R61 (2014). 
401. Cao, Y. et al. Design of Switchable Chimeric Antigen Receptor T Cells Targeting 
Breast Cancer. Angew. Chemie - Int. Ed. (2016). doi:10.1002/anie.201601902 
402. Manning, H. C., Buck, J. R. & Cook, R. S. Mouse Models of Breast Cancer: Platforms 
for Discovering Precision Imaging Diagnostics and Future Cancer Medicine. J. Nucl. 
Med. 57 Suppl 1, 60S–8S (2016). 
403. Close, D. M., Xu, T., Sayler, G. S. & Ripp, S. In vivo bioluminescent imaging (BLI): 
noninvasive visualization and interrogation of biological processes in living animals. 
Sensors (Basel). 11, 180–206 (2011). 
404. Kim, J.-B. et al. Non-Invasive Detection of a Small Number of Bioluminescent Cancer 
Cells In Vivo. PLoS One 5, e9364 (2010). 
405. Zinn, K. R. et al. Non-invasive bioluminescence imaging in small animals. ILAR J. 49, 
103–15 (2008). 
406. Wallace, J. et al. Humane Endpoints and Cancer Research. ILAR J. 41, 87–93 (2000). 
 292 
407. Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. 
Br. J. Cancer 102, 1555–1577 (2010). 
408. Khalil, A. A. et al. The Influence of Hypoxia and pH on Bioluminescence Imaging of 
Luciferase-Transfected Tumor Cells and Xenografts. Int. J. Mol. Imaging 2013, 
287697 (2013). 
409. Black, P. C. et al. Validating bladder cancer xenograft bioluminescence with magnetic 
resonance imaging: the significance of hypoxia and necrosis. AUTHORS. J. Compil. 
BJU Int. Investig. Urol. (2010). doi:10.1111/j.1464-410X.2010.09424.x 
410. Moriyama, E. H. et al. In vitro influence of hypoxia on bioluminescence imaging in 
brain tumor cells. doi:10.1117/12.696720 
411. Jensen, M. M., Jørgensen, J. T., Binderup, T. & Kjær, A. Tumor volume in 
subcutaneous mouse xenografts measured by microCT is more accurate and 
reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med. 
Imaging 8, 16 (2008). 
412. Girit, I. C., Jure-Kunkel, M. & McIntyre, K. W. A structured light-based system for 
scanning subcutaneous tumors in laboratory animals. Comp. Med. 58, 264–70 (2008). 
413. Parente-Pereira, A. C. et al. Trafficking of CAR-Engineered human T cells following 
regional or systemic adoptive transfer in SCID beige mice. J. Clin. Immunol. 31, 710–
718 (2011). 
414. Albelda, S. M. et al. Augmentation of CAR T cell trafficking and antitumor efficacy by 
blocking protein kinase A (PKA) localization. Cancer Immunol. Res. 1–12 (2016). 
doi:10.1158/2326-6066.CIR-15-0263 
415. Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified 
T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–15 (2006). 
416. Carpenito, C. et al. Control of large, established tumor xenografts with genetically 
retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. 
106, 3360–3365 (2009). 
417. Park, J. R. et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T 
lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825–33 (2007). 
418. Song, D.-G. et al. In vivo persistence, tumor localization, and antitumor activity of CAR-
engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). 
Cancer Res. 71, 4617–27 (2011). 
419. Gregoire-Gauthier, J. et al. Use of immunoglobulins in the prevention of GvHD in a 
xenogeneic NOD/SCID/γc− mouse model. Bone Marrow Transplant. 47, 439–450 
(2012). 
420. Ali, N. et al. Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice 
Display a T-Effector Memory Phenotype. PLoS One 7, e44219 (2012). 
421. Rijn, R. S. Van et al. A new xenograft model for graft-versus-host disease by 
intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- yc-/- 
 293 
double-mutant mice. Immunobiology 102, 2522–2531 (2003). 
422. King, M. A. et al. Human peripheral blood leucocyte non-obese diabetic-severe 
combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model 
of xenogeneic graft-versus-host-like disease and the role of host major 
histocompatibility complex. Clin. &amp; Exp. Immunol. 157, 104–118 (2009). 
423. Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy 
generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 
6, 261ra151-261ra151 (2014). 
424. Ross, D. T. et al. Systematic variation in gene expression patterns in human cancer 
cell lines. Nat. Genet. 24, 227–235 (2000). 
425. Spicer, A. P., Parry, G., Patton, S. & Gendler, S. J. Molecular cloning and analysis of 
the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of 
potential o-glycosylation sites, transmembrane, and cytoplasmic domains and a loss 
of minisatellite-like polymorphism. J. Biol. Chem. 266, 15099–15109 (1991). 
426. Wang, L. X. J. et al. Tumor ablation by gene-modified T cells in the absence of 
autoimmunity. Cancer Res. 70, 9591–9598 (2010). 
427. Moon, E. K. et al. Blockade of programmed death 1 augments the ability of human T 
cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer. 
Clin. Cancer Res. 22, 436–447 (2016). 
428. Valitutti, B. S., Müller, S., Salio, M. & Lanzavecchia, A. Degredation of T Cell Receptor 
(TCR)-CD3-Zeta Complexes after Antigenic Stimulation. J. Exp. Med 185, 1859–1864 
(1997). 
429. Agrawal, B. & Krantz, M. Cancer-associated MUC1 mucin inhibits human T-cell 
proliferation, which is reversible by IL-2. Nat. Med. (1998). 
430. Gimmi, C. D. et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis 
of activated human T cells. Nat Med 2, 1367–1370 (1996). 
431. Fisher, J. P. H. et al. Effective combination treatment of GD2-expressing 
neuroblastoma and Ewing’s sarcoma using anti-GD2 ch14.18/CHO antibody with 
Vγ9Vδ2+ γδT cells. Oncoimmunology 5, e1025194 (2016). 
432. Du, S. H. et al. Co-expansion of cytokine-induced killer cells and Vγ9Vδ2 T cells for 
CAR T-cell therapy. PLoS One 11, (2016). 
433. Fisher, J. et al. Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-
Only Chimeric Antigen Receptor. Mol. Ther. 25, 1234–1247 (2017). 
434. Ren, X. et al. Modification of cytokine-induced killer cells with chimeric antigen 
receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor 
(EGFR)-positive malignancies. Cancer Immunol. Immunother. 64, (2015). 
435. Budde, L. E. et al. Combining a CD20 Chimeric Antigen Receptor and an Inducible 
Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive 
Immunotherapy for Lymphoma. PLoS One 8, e82742 (2013). 
 294 
436. Taylor-Papadimitriou, J. et al. MUC1 and the immunobiology of cancer. J. Mammary 
Gland Biol. Neoplasia 7, 209–221 (2002). 
437. Davis, S. J. & van der Merwe, P. A. The kinetic-segregation model: TCR triggering 
and beyond. Nat. Immunol. 7, 803–9 (2006). 
438. Wild, M. K. et al. Dependence of T cell antigen recognition on the dimensions of an 
accessory receptor-ligand complex. J. Exp. Med. 190, 31–41 (1999). 
439. James, J. R. & Vale, R. D. Biophysical mechanism of T-cell receptor triggering in a 
reconstituted system. Nature 487, 64–9 (2012). 
440. Cordoba, S. P. S. et al. The large ectodomains of CD45 and CD148 regulate their 
segregation from and inhibition of ligated T-cell receptor. Blood 121, 4295–4302 
(2013). 
441. Gendler, S., Taylor-Papadimitriou, J., Duhig, T., Rothbard, J. & Burchell, J. A Highly 
Immunogenic Region of a Human Polymorphic Epithelial Mucin Expressed by 
Carcinomas Is Made Up of Tandem Repeats*. J. Biol. Chem. 263, 12820–12823 
(1988). 
 
 
